INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26770, 'Sens light whitening cream 60 gm', 'سينس لايت كريم تفتيح 60جم', '140', '110', 'Whitening topical', 'Bearberry ext.+liquorice ext.+vitamin c+vitamin e', 'Leaders cosmetics > kmt pharma', 'Cream', 'كريم', '60 gm', '1', 'كريم غنى بالفيتامينات ومضادات الاكسدة يعمل على التفتيح ومحاربة التجاعيد', NULL, NULL, NULL, 1930, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26771, 'Sensajoy acne cream 50 gm', 'سينساجوي كريم لحب الشباب 50 جم', '145', '120', 'Skin care', NULL, 'Egyptian co. for cosmetics > orchidia pharmaceutical industries', 'Cream', 'كريم', '50 gm', '1', 'علاج حب الشباب', 'sensajoy is an innovative formula with an intensive blend of skin purifying ingredients that work synergically to solve oily and acne prone skin problems. it regulates sebum secretion for a shine free skin removes dead skin cells and refines wide pores. d', NULL, NULL, 1843, '2023-11-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26772, 'Sensibio cleansing milk (lait) 250 ml', 'سينسيبو ميلك 250مل', '295', NULL, 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '250 ml', '1', NULL, 'the cleansing milk that perfectly cleanses the face and eyes of those with sensitive intolerant skin.ï- a new step forward in the treatment of sensitive intolerant skin sensibio cleansing milk perfectly cleanses the face and eyes with no need to rinse.the', NULL, NULL, 599, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26773, 'Sensibio eye contour gel 15ml', 'سينسيبو جل للعين 15مل', '350', '285', 'Eye contour', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Gel', 'جل', '15ml', '1', NULL, 'daily protective decongesting soothing and moisturising care for the eye contour area of those with sensitive skin. ï- a new step forward in the treatment of sensitive intolerant skin the patented tolï-ridineï- complex instantly and durably acts against i', NULL, NULL, 934, '2023-09-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26774, 'Sensibio forte 40 ml', 'سينسيبو فورت 40مل', '799', '375', 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '40 ml', '1', NULL, 'rapid soothing care for intolerant skin suffering from redness and overheating: redness of mechanical or chemical origin (friction after shave irritation depilation peeling...) overheating after a dermatological operation (post-laser) sunburn. ï- rich in', NULL, NULL, 662, '2025-06-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26775, 'Sensibio h2o 250 ml', 'سينسيبو مياه 250مل', '230', '185', 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '250 ml', '1', NULL, 'the benchmark micelle solution that daily cleanses and removes make-up from sensitive skin. ï- at the cutting edge of innovation bioderma has pioneered micellar solutions. specially formulated for sensitive normal to dry skins the sensibio h2o micelle sol', NULL, NULL, 678, '2023-09-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26776, 'Sensibio h2o 500 ml', 'سينسيبو مياه 100مل', '365', '289', 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '500 ml', '1', NULL, 'the benchmark micelle solution that daily cleanses and removes make-up from sensitive skin. ï- at the cutting edge of innovation bioderma has pioneered micellar solutions. specially formulated for sensitive normal to dry skins the sensibio h2o micelle sol', NULL, NULL, 736, '2023-09-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26777, 'Sensibio light cream 40 ml', 'سينسيبو لايت كريم 40مل', '299', '239', 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Cream', 'كريم', '40 ml', '1', NULL, 'the daily moisturising soothing and protective care for sensitive intolerant skin normal to combination skin. ï- a new step forward in the treatment of sensitive intolerant skin the patented tolï-ridineï-complex instantly and durably acts against inflamma', NULL, NULL, 795, '2023-09-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26778, 'Sensibio mask 75 ml', 'سينسيبو ماسك 75مل', '295', NULL, 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '75 ml', '1', NULL, 'intense hydrating and soothing care for sensitive intolerant skin. ï- a new step forward in the treatment of sensitive intolerant skin the patented tolï-ridineï- complex instantly and durably acts against inflammation. it raises the skinï-s tolerance thre', NULL, NULL, 654, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26779, 'Sensibio rich cream 40 ml', 'سينسيبو كريم 40مل', '299', '239', 'Skin care', NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Cream', 'كريم', '40 ml', '1', NULL, 'daily protective soothing hydrating and intensely nourishing care for dry to very dry sensitive intolerant skin. ï- a new step forward in the treatment of sensitive intolerant skin the patented tolï-ridineï- complex instantly and durably acts against infl', NULL, NULL, 766, '2023-09-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26780, 'Sensicare spray 75 ml', 'سينسيكير سبراي 75 مل', '120', '85', 'Topical care', 'Propolis+panthenol+soya protein+chamomile', 'Leader cosmetics > original pharma group', 'Spray', 'بخاخ', '75 ml', '1', NULL, 'for normal skin structure', NULL, NULL, 900, '2025-01-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26781, 'Sensitelial cleansing gel 200 ml', 'سينسيتيليال غسول منظف 200 مل', '165', NULL, 'Skin acre', NULL, 'Acm dermatological laboratories > biotech egypt', 'Gel', 'جل', '200 ml', '1', 'غسول يومي لتنظيف البشرة شديدة الجفاف. يلطف البشرة بلطف دون إتلاف الغشاء المائي الدهني للبشرة.سهل التشطيف — يحافظ درجة حموضة البشرة.', 'properties sensitelial cleansing gel has been designed for the daily cleansing routine of dry and atopic skin conditions. thanks to its soft cleansing agents and relipidic active ingredients sensitelial cleansing gel very gently cleanses the skin without', NULL, NULL, 928, '2022-06-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26782, 'Sensitelial dermo-cleansing lotion 200 ml', 'سينستيليال لوشن 200مل', '124', NULL, 'Skin acre', NULL, 'Acm dermatological laboratories > biotech egypt', 'Lotion', 'لوشن', '200 ml', '1', NULL, 'properties sensitelial dermo-cleansing lotion has been specially designed for the hygiene of the most sensitive skins. directions for use apply sensitelial dermo-cleansing lotion with a cotton pad to wash the face or remove make-up. it is not necessary to', NULL, NULL, 643, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26783, 'Sensitelial emollient care 200 ml', 'سينستيليال اميولنت كير 200مل', '149', NULL, 'Skin acre', NULL, 'Acm dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '200 ml', '1', NULL, 'properties sensitelial emollient care has been formulated to moisturize dry skin and skin with atopic tendency. thanks to its combination of moisturizing nourishing and soothing active ingredients known for their efficiency and high tolerance sensitelial', NULL, NULL, 734, '2022-08-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26784, 'Sensitelial gel spf 50 - 40 ml', 'سينستيليال جل للحماية من الشمس +50 40مل', '195', NULL, 'Skin care', NULL, 'Acm dermatological laboratories > biotech egypt', 'Gel', 'جل', '40 ml', '1', NULL, 'indications extreme sun conditions. fragile and sun sensitive skins. fair skin or skin subject to sun intolerances. properties its fluid and light texture makes it easy to apply. directions for use apply the product generously 30 minutes before each sun e', NULL, NULL, 701, '2022-08-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26785, 'Sensitelial soothing cream 40 ml', 'سينستيليال كريم 40مل', '105', NULL, 'Skin acre', NULL, 'Acm dermatological laboratories > biotech egypt', 'Cream', 'كريم', '40 ml', '1', NULL, 'properties sensitelial soothing cream has been specially designed to soothe and moisturize sensitive reactive and erythrosic skin. fragrance free. directions for use apply sensitelial soothing cream once or twice a day to clean dry skin.', NULL, NULL, 711, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26786, 'Sensitelial sunscreen spf 100 - 40 ml', 'سينستيليال صن سكرين بمعامل حماية 100 40مل', '195', NULL, 'Sun block', NULL, 'Acm dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '40 ml', '1', NULL, 'indications extreme sun conditions. fragile and sun sensitive skins. fair skin or skin subject to sun intolerances. properties thanks to its association of organic and mineral filters including a micronized extract of pearl the cream protection factor is', NULL, NULL, 638, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26787, 'Sensitelial sunscreen spf 100 tinted 40 ml', 'سينستيليال 40مل', '195', NULL, 'Sun block', NULL, 'Acm dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '40 ml', '1', NULL, 'indications extreme sun conditions. fragile and sun sensitive skins. fair skin or skin subject to sun intolerances. properties thanks to its association of organic and mineral filters including a micronized extract of pearl the cream protection factor is', NULL, NULL, 891, '2022-07-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26788, 'Sensitelial sunscreen spf 50 light tinted 40 ml', 'سينستيليال للحماية من الشمس 40مل', '195', NULL, 'Sun block', NULL, 'Acm dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '40 ml', '1', NULL, 'indications extreme sun conditions. fragile and sun sensitive skins. fair skin or skin subject to sun intolerances. properties its fluid and light texture makes it easy to apply. directions for use apply the product generously 30 minutes before each sun e', NULL, NULL, 632, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26789, 'Senso care oral spray 100ml', 'سنسو كير اورال سبراي 100 مل', '18', NULL, 'Oral care', NULL, 'Hi-care', 'Spray', 'بخاخ', '100ml', '1', NULL, '*antiseptic analgesic and anaesthetic spray for oral cavity', '6223004373954', NULL, 1306, '2022-06-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26790, 'Sensoderm antiseptic soap 80 gm', 'سينسوديرم صابون مطهر 80 جم', '50', '44', 'Soap', NULL, 'Hi-care > novex', 'Soap', 'صابون', '80 gm', '1', NULL, NULL, '769503325255', NULL, 1050, '2025-01-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26791, 'Sensoderm baby soap 80 gm', 'سينسوديرم بيبي صابون 80جم', '50', '44', 'Soap', 'Zinc oxide+titanium dioxide+glycerin+olive oil+chamomile+betaine+paraffin oil+lavender', 'Hi-care > novex', 'Soap', 'صابون', '80 gm', '1', NULL, 'indications : sensitive skin . neonates and babies skin hygiene .', NULL, NULL, 1018, '2025-01-27', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26792, 'Sensoderm cream 50 gm', 'سنسوديرم كريم 50 جرام', '65', '60', 'Soothing topical', 'Panthenol+liquorice+vitamin e+urea+bees wax+calendula+triclosan+dimethicone', 'Hi-care > novex', 'Cream', 'كريم', '50 gm', '1', 'كريم ترطيب وتغذية البشرة غنى بالفيتامينات ومضادات الاكسدة', 'indications : sensitive skin . neonates and babies skin hygiene . contact dermatitis and sweat rash .', '6224000201173', NULL, 2104, '2025-01-31', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26793, 'Sensoderm moisturizing soap 80 gm', 'سينسوديرم صابون 80جم', '50', '44', 'Soap', 'Zinc oxide+glycerin+betaine+paraffin oil+titanium dioxide+olive oil+almond oil', 'Hi-care > novex', 'Soap', 'صابون', '80 gm', '1', NULL, 'indications : sensitive skin . contact dermatitis and sweat rash .', NULL, NULL, 1093, '2025-01-27', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26794, 'Sensoderm soap 80 gm', 'سنسوديرم صابونة 80 جرام', '50', '45', 'Soap', 'Triclosan+boric acid+zinc oxide+glycerin+betaine+paraffin oil+titanium dioxide', 'Hi-care > novex', 'Soap', 'صابون', '80 gm', '1', 'صابون تنظيف لطيفة للبشرة الحساسة، غنية بالمكونات الطبيعية لتهدئة وترطيب البشرة.مناسبة للاستخدام اليومي على الوجه والجسم.', 'indications : sensitive skin . neonates and babies skin hygiene . contact dermatitis and sweat rash .', '769503325101', NULL, 2960, '2025-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26795, 'Sensoderm t.s(transparent) soap 75 gm', 'سنسوديرم صابونة 75 جم', '64', '54', 'Soap', 'Panthenol+chamomile+olive oil+castor oil+glycerin+vitamin e+cetrimide+natural base', 'Hi-care > novex', 'Soap', 'صابون', '75 gm', '1', 'عناية بالجلد.', NULL, NULL, NULL, 3716, '2025-01-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26797, 'Sensorate mouth wash 120ml', 'سينسورات غسول للفم 120 مل', '20', NULL, 'Oral care', NULL, 'Global health', 'Mouth wash', 'غسول للفم', '120ml', '1', 'عناية بالفم.', NULL, NULL, NULL, 2318, '2022-05-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26798, 'Senzo-1 soap 100 gm', 'سينزو-1 صابونة 100 جم', '50', '35', 'Soap', NULL, 'Macro group pharmaceuticals', 'Soap', 'صابون', '100 gm', '1', 'عناية بالجلد الجاف والحساس.', '*medicated soap for dry & sensitive skin daily care. -contains blend of natural anti-oxidants pro-vitamin b5 & natural oils for optimum dry sensitive skin care -senzo-1 soap is used in all dermatological cases of sensitive skin where a mild soap is highly', '6224000437763', NULL, 1300, '2023-08-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26799, 'Senzo-1 soap 75 gm', 'سنزو-1 صابونة 75 جرام', '26', NULL, 'Soap', NULL, 'Macro group pharmaceuticals', 'Soap', 'صابون', '75 gm', '1', NULL, NULL, NULL, NULL, 896, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26800, 'Sepcofruit sachets', 'سيبكوفروت اكياس', '3', NULL, 'Antacid', 'Citric acid+sodium bicarbonte+tartaric acid', 'Sepco pharmaceutical co.', 'Sachet', 'أكياس', NULL, '1', NULL, 'interactions: antacids concurrent use of antacids with citrates may result in systemic alkalosis. concomitant administration of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid st', NULL, NULL, 1149, '2022-07-10', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26801, 'Sepcomouth mouth wash', 'سيبكوماوث غسول للفم', '3', NULL, 'Mouth wash', 'Menthol+methyl salicylate', 'Sepco pharmaceutical co.', 'Mouth wash', 'غسول للفم', NULL, '1', NULL, 'about methyl salicylate salicylates rubefacient counterirritant. mechanism of action of methyl salicylate methyl salicylate is a rubefacient. it produces reddening of the skin by dilatation of the blood vessel and gives a soothing feeling of warmth. it is', NULL, NULL, 766, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26802, 'Septanest n 4 % carp 1.8ml epinephrine 1:200 000', 'سيبتانيست ان 4% كارب 1.8 مل ابينفرين 1:200000', '55', NULL, 'Dental anaesthetic', 'Adrenaline+articaine', 'Septodent saint meur- france > the multinational co. for drugs-egypt', 'Unknown', 'غير محدد', '4 %', '1', NULL, 'abstract 5 articaine preparations including besides 4% articaine with epinephrine 1:100 000 and 1:200 000 4% articaine with epinephrine 1:400 000 2% articaine 1:200 000 and articaine without a vasoconstrictor were investigated on 52 volunteers dental stud', NULL, NULL, 918, '2022-08-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26803, 'Septanest sp 4% 50 carp 1.8ml epinephrine 1:100 000', 'سيبتانيست اس بي %4 50 كارب 1.8مل ابينفرين 1:100000', '975', NULL, 'Dental anaesthetic', 'Adrenaline+articaine', 'Septodent saint meur- france > the multinational co. for drugs-egypt', 'Unknown', 'غير محدد', '4%', '1', NULL, 'abstract 5 articaine preparations including besides 4% articaine with epinephrine 1:100 000 and 1:200 000 4% articaine with epinephrine 1:400 000 2% articaine 1:200 000 and articaine without a vasoconstrictor were investigated on 52 volunteers dental stud', NULL, NULL, 1192, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26804, 'Septazole 400/80mg 20*10 tab.', 'سيبتازول 400/80مجم 20*10 اقراص', '340', '229', 'Antibiotic', 'Sulphamethoxazole+trimethoprim', 'Alexandria', 'Tab', 'أقراص', '80mg', '20', NULL, NULL, '6223000170595', NULL, 1900, '2025-05-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26806, 'Septazole susp. 100 ml', 'سيبتازول معلق 100 مل', '36', '29', 'Antibiotic', 'Sulphamethoxazole+trimethoprim', 'Alexandria', 'Susp', 'معلق', '100 ml', '1', NULL, NULL, '6223000171066', NULL, 1655, '2025-08-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26807, 'Septobar 6 eff. sachet.', 'سيبتوبار 6 اكياس', '5', NULL, 'Urinary.analgesic.antiseptic', 'Halfa bar extract+hexamine', 'Eva pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 934, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26809, 'Septogel oral gel 20 gm', 'سبتوجل جل للفم 20 جم', '10', NULL, 'Oral care', 'Aminoacridine+lidocaine', 'Arab drug company.', 'Gel', 'جل', '20 gm', '2', NULL, 'fast effective releif from common mouth ulcer sore gums and denture rubbing.', '6221060003778', NULL, 876, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26813, 'Seralon-e 30 caps.', 'سيرالون اي 30 كبسول', '26', NULL, 'Liver support supplements', 'Milk thistle+vitamin e', 'Hochster pharmaceutical industries', 'Cap', 'كبسولة', NULL, '3', NULL, 'it is an unique formula designed specially to help liver functions. silymarin: it has direct protective effect on hepatic cells through membrane stabilizing effect protection against harmful and toxic agents. vitamin e: the most effective antioxidant vita', NULL, NULL, 771, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26814, 'Seraval hair serum 120 ml', 'سيرافال سيرم للشعر 120 مل', '250', '165', 'Hair care', NULL, 'Hi-care > revano pharm', 'Serum', 'سيروم', '120 ml', '1', 'سيرم للشعر لترطيبه --الحفاظ علي شكله -- تقليل الهيشان و التقصف', NULL, NULL, NULL, 5044, '2025-01-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26815, 'Sercal foot cream 50 gm', 'سيركال فوت كريم 60جم', '25', NULL, 'Skin care', NULL, 'Egyptian company for cosmetics > excel pharma', 'Cream', 'كريم', '50 gm', '1', NULL, '*foot cracks cream', NULL, NULL, 718, '2022-07-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26816, 'Sercprove 100 mg 20 tab.', 'سيركبروف 100مجم 20 اقراص', '48', NULL, 'Antiplatelet.phosphodiesterase 3 inhibitor', 'Cilostazol', 'Unipharma co.', 'Tab', 'أقراص', '100 mg', '2', NULL, 'description cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. it is manufactured by otsuka pharmaceutical co. under the trade name pletal. although drugs similar', NULL, NULL, 691, '2022-07-15', 0, 'Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).', 'Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.', 'Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26817, 'Sercprove 50 mg 20 tab.', 'سيركبروف 50مجم 20 اقراص', '42', NULL, 'Antiplatelet.phosphodiesterase 3 inhibitor', 'Cilostazol', 'Unipharma co.', 'Tab', 'أقراص', '50 mg', '2', NULL, 'description cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. it is manufactured by otsuka pharmaceutical co. under the trade name pletal. although drugs similar', NULL, NULL, 728, '2022-07-25', 0, 'Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).', 'Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.', 'Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26818, 'Serderm cream 25 gm', 'سيرديرم كريم 25مجم', '20', NULL, 'Moisturizing cream', 'Lanolin+petrolatum+panthenol+cetyl stearyl alcohol+vitamin e+vitamin b6', 'Leader cosmetics > pharmaserve medical', 'Cream', 'كريم', '25 gm', '1', NULL, 'skin moisturizer', NULL, NULL, 685, '2022-08-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26819, 'Serderm cream 50 gm', 'سيرديرم كريم 50 جم', '30', NULL, 'Moisturizing cream', 'Lanolin+petrolatum+panthenol+cetyl stearyl alcohol+vitamin e+vitamin b6', 'Leader cosmetics > pharmaserve medical', 'Cream', 'كريم', '50 gm', '1', NULL, 'skin moisturizer', NULL, NULL, 680, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26820, 'Serdolect 12mg 28 f.c. tab.', 'سيردوليكت 12مجم 14 اقراص', '1,122', '700', 'Psychiatric.antipsychotics', 'Sertindole', 'Lundbeck > multipharma', 'Tab', 'أقراص', '12mg', '2', NULL, NULL, NULL, NULL, 803, '2024-11-17', 0, 'Used in the treatment of schizophrenia.', 'Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ', 'Sertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26821, 'Serdolect 16mg 14 f.c. tab.', 'سيردوليكت 16مجم 14 اقراص', '657', '375', 'Psychiatric.antipsychotics', 'Sertindole', 'Lundbeck > multipharma', 'Tab', 'أقراص', '16mg', '2', NULL, 'indication used in the treatment of schizophrenia. mechanism of action sertindole is an antipsychotic drug with affinity for dopamine d2 serotonin 5-ht2a and 5-ht2c and alpha1-adrenoreceptors. preclinical studies suggest that sertindole acts preferentiall', '5702157141197', NULL, 727, '2024-11-17', 0, 'Used in the treatment of schizophrenia.', 'Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ', 'Sertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26822, 'Serdolect 20mg 14 f.c. tab.', 'سيردوليكت 20مجم 14 اقراص', '657', '375', 'Psychiatric.antipsychotics', 'Sertindole', 'Lundbeck > multipharma', 'Tab', 'أقراص', '20mg', '2', NULL, 'indication used in the treatment of schizophrenia. mechanism of action sertindole is an antipsychotic drug with affinity for dopamine d2 serotonin 5-ht2a and 5-ht2c and alpha1-adrenoreceptors. preclinical studies suggest that sertindole acts preferentiall', '5702157141210', NULL, 703, '2024-11-17', 0, 'Used in the treatment of schizophrenia.', 'Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ', 'Sertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26823, 'Serdolect 4mg 10 f.c. tab.', 'سيردولكت 4مجم 10اقراص', '159', '90', 'Psychiatric.antipsychotics', 'Sertindole', 'Lundbeck > multipharma', 'Tab', 'أقراص', '4mg', '1', NULL, 'indication used in the treatment of schizophrenia. mechanism of action sertindole is an antipsychotic drug with affinity for dopamine d2 serotonin 5-ht2a and 5-ht2c and alpha1-adrenoreceptors. preclinical studies suggest that sertindole acts preferentiall', '5702157141371', NULL, 884, '2024-11-17', 0, 'Used in the treatment of schizophrenia.', 'Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ', 'Sertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26824, 'Serelanocam 20mg 20 f.c. tabs.', 'سيرالانوكام 20مجم 20 اقراص', '13', NULL, 'Nsaid.oxicam', 'Tenoxicam', 'Unipharma co.', 'Tab', 'أقراص', '20mg', '2', NULL, 'mechanism of action of tenoxicam the anti-inflammatory effects of tenoxicam may result from the inhibition of the enzyme cyclooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis (prostaglandins sensitize pain receptors their inhi', NULL, NULL, 762, '2022-07-25', 0, 'For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.', 'The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.', 'Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26825, 'Seretide diskus 100/50mcg 60 doses', 'سيريتايد ديسكس 100/50مكجم 60 جرعة', '244', '187', 'Bronchodilator.glucocorticoid steroid and long-acting b2 agonist', 'Fluticasone+salmeterol', 'Glaxo smithkline > modern pharma', 'Unknown', 'غير محدد', '50mcg', '1', NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', NULL, NULL, 1060, '2024-12-19', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26827, 'Seretide diskus 250/50mcg 60 doses', 'سيريتايد ديسكس 250/50مكجم 60 جرعة', '335', '257', 'Bronchodilator.glucocorticoid steroid and long-acting b2 agonist', 'Fluticasone+salmeterol', 'Glaxo smithkline > modern pharma', 'Unknown', 'غير محدد', '50mcg', '1', NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', NULL, NULL, 8937, '2024-12-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26829, 'Seretide evohaler 125/25mcg 120 metered actuations', 'سيريتايد ايفوهيلر 125/25مكجم 120 جرعة', '228', '198', 'Bronchodilator.glucocorticoid steroid and long-acting b2 agonist', 'Fluticasone+salmeterol', 'Glaxo smithkline > modern pharma', 'Unknown', 'غير محدد', '25mcg', '1', 'موسع للشعب الهوائية -- حالات الازمات التنفسية', 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', NULL, NULL, 5433, '2024-10-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26832, 'Serigabtin 150mg 20 caps.', 'سيريجابتين 150مجم 20 كبسولة', '63', NULL, 'Anti-epileptic.gaba analogs', 'Pregabalin', 'Sedico > serio pharm-egypt', 'Cap', 'كبسولة', '150mg', '2', NULL, 'about pregabalin a gaba agonist anticonvulsant. mechanism of action of pregabalin pregabalin is a gaba neurotransmitter analog. it produces its action by modulating calcium channels and also reduces the release of neurotransmitters such as glutamate norep', '6225000092129', NULL, 715, '2022-12-08', 0, 'Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]', 'Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.[L7066]  



By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.[A31163] In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.[A36628] 



Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[A31165]  ', 'Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.[A31163,A187190] Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.[A31163,A187190] Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.[A187190] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26834, 'Serinosprevir 400mg 28 tablets', 'سيرينوسبريفر 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Future pharmaceutical industries (fpi) > inspire pharmaceutical company', 'Tablet', 'أقراص', '400mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 711, '2022-08-03', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26836, 'Serious mass weight gain protein 5.44 kg', 'سيريوس ماس بروتين لزيادة الوزن 5.44 كجم', '3,800', NULL, 'Supplement', 'Multivitamin+minerals+protein', 'Coming soon ..', 'Unknown', 'غير محدد', NULL, '1', NULL, 'serious mass is the ultimate in weight gain formulas. with 1 250 calories per serving and 50 grams of protein for muscle recovery support this instantized powder makes the ideal post-workout and between meals shake for sizing up your goals. serious mass p', NULL, NULL, 752, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26837, 'Serlift 100mg 10 f.c. tab.', 'سيرليفت 100 مجم 10 اقراص', '74', '56', 'Psychiatric.antidepressants', 'Sertraline', 'Global napi pharmaceuticals > rexcel', 'Tab', 'أقراص', '100mg', '1', 'علاج الامراض النفسية -- مضاد للاكتئاب -- يؤخذ تحت اشراف طبي', 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', NULL, NULL, 2705, '2024-11-11', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26838, 'Sermohair hair serum 120 ml', 'سيرموهير سيروم للشعر 120مل', '185', NULL, 'Hair care', 'Snake oil+aloe vera extract+almond oil+olive oil+silicon oil+cyclopentasiloxane+phenyltrimethicone', 'Egyptian company for comsetics > emaj pharma', 'Serum', 'سيروم', '120 ml', '1', NULL, '**hair nourishing. highly effective blend of active ingredients that makes the hair shinier healthier and causes less tangles & control hair falling. **indications: damaged or split ended hair broken hair & frizzy hair **application: rub 2-3 drops on the', NULL, NULL, 907, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26839, 'Seroflo 100/50mcg pd. for inh. 30 blisters', 'سيروفلو 100/50مكجم باودر للاستنشاق 30 بليستر', '53', NULL, 'Bronchodilator.short-acting b2 agonist', 'Fluticasone+salmeterol', 'Cipla ltd. - india > star international company', 'Unknown', 'غير محدد', '50mcg', '1', NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', '8901117194403', NULL, 803, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26841, 'Seroflo 250/50mcg pd. for inh. 30 blisters', 'سيروفلو 250/50 ميكروجرام استنشاق 30 لاصقة', '63', NULL, 'Bronchodilator.short-acting b2 agonist', 'Fluticasone+salmeterol', 'Cipla ltd. - india > star international company', 'Unknown', 'غير محدد', '50mcg', '1', NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', NULL, NULL, 851, '2022-08-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26842, 'Seroflo 500/50mcg pd. for inh. 30 blisters', 'سيروفلو 500/50مكجم باودر للاستنشاق 30 بليستر', '77', NULL, 'Bronchodilator.short-acting b2 agonist', 'Fluticasone+salmeterol', 'Cipla ltd. - india > star international company', 'Unknown', 'غير محدد', '50mcg', '1', NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', '8901117451063', NULL, 919, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26843, 'Serolact 10 sachet', 'سيرولاكت 10 اكياس', '80', '65', 'Immunity booster', 'L-lysine 100 mg+probiotic+multivitamin', 'Dutch united > luxor pharma gl united group', 'Sachet', 'أكياس', NULL, '1', 'مكمل غذائى ومعزز للمناعة وفاتح للشهية للكبار والاطفال', 'appetizer and improve immunity and git disorders', NULL, NULL, 4087, '2025-05-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26844, 'Serolact 20 sachet', 'سيرولاكت 20 كيس', '80', NULL, 'Immunity booster', 'L-lysine 100 mg+probiotic+multivitamin', 'Dutch united > luxor pharma gl united group', 'Sachet', 'أكياس', NULL, '1', NULL, 'appetizer and improve immunity and git disorders', NULL, NULL, 998, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26845, 'Serolact 30 sachet', 'سيرولاكت 30 كيس', '110', NULL, 'Immunity booster', 'L-lysine 100 mg+probiotic+multivitamin', 'Dutch united > luxor pharma gl united group', 'Sachet', 'أكياس', NULL, '1', NULL, 'appetizer and improve immunity and git disorders', NULL, NULL, 1237, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26846, 'Seroleze hair serum 120 ml', 'سيروليز سيروم للشعر 120 مل', '300', '250', 'Hair care', 'Dimethicone+dimethiconol+soy beans oil+olive oil+argan oil+almond oil+vitamin e+cyclopentasiloxan', 'Macro group pharmaceuticals', 'Serum', 'سيروم', '120 ml', '1', NULL, 'frizz control', '6224000437824', NULL, 1099, '2025-03-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26847, 'Seronorm 100 mg 10 tab', 'سيرونورم 100مجم 10 اقراص', '27', '19.2', 'Psychiatric.antidepressants', 'Sertraline', 'Unipharma co.', 'Tab', 'أقراص', '100 mg', '1', 'مضاد اكتئاب -- امراض نفسية', NULL, NULL, NULL, 2019, '2025-07-07', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26848, 'Seronorm 25 mg 10 tab.', 'سيرونورم 25 مجم 10 اقراص', '10', NULL, 'Psychiatric.antidepressants', 'Sertraline', 'Unipharma co.', 'Tab', 'أقراص', '25 mg', '1', 'مضاد اكتئاب -- امراض نفسية -- منع الغثيان والقئ الناتج عن العمليات الجراحية والعلاج الكميائي', 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', NULL, NULL, 1364, '2022-05-29', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26849, 'Seropar 10 mg 10 tab.', 'سيروبار 10مجم 10 اقراص', '11', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Buspirone', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '10 mg', '1', NULL, 'about buspirone psychotropic drug serotonin 5-ht1a receptor partial agonist weak dopamine (d2) antagonist azaspirodecanediones derivative sedative anxiolytic agent. mechanism of action of buspirone buspirone has a partial agonistic action on 5ht1a recepto', NULL, NULL, 982, '2022-07-11', 0, 'Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.[L4478]', 'The therapeutic action of buspirone in generalized anxiety disorders is thought to be mainly derived from its interaction with two major 5-HT<sub>1A</sub> receptor subtypes that are involved in the brain''s anxiety and fear circuitry to enhance the serotonergic activity in these brain areas.[L7375] Buspirone acts as a full agonist at presynaptic 5-HT<sub>1A</sub> receptors, or 5-HT<sub>1A</sub> autoreceptors, expressed at dorsal raphe while acting as a partial agonist at the postsynaptic 5-HT<sub>1A</sub> receptors expressed on hippocampus and cortex.[A182315,A182420] 5-HT<sub>1A</sub> receptors function as inhibitory autoreceptors by being expressed on the soma or dendrites of serotonergic neurons or mediate postsynaptic actions of 5-HT by being highly expressed on the corticolimbic circuits.[T28] They are inhibitory G-protein coupled receptors that couple to Gi/Go proteins. When activated, presynaptic 5-HT<sub>1A</sub> autoreceptors causes neuron hyperpolarization and reduces the firing rate of the serotonergic neuron, thereby decreasing extracellular 5-HT levels in the neuron''s projection areas. Activated postsynaptic 5-HT<sub>1A</sub> receptors promote hyperpolarization to released 5-HT on pyramidal neurons.[A182420] 



The anxiolytic action of buspirone is mainly thought to arise from the interaction at presynaptic 5-HT<sub>1A</sub> autoreceptors. Acting as a potent agonist in these receptors, buspirone initially causes activation of these autoreceptors and inhibition of 5-HT release. It is proposed that buspirone induces desensitization of somatodendritic autoreceptors over time, which may explain the delayed onset of action of the drug. Desensitization of the autoreceptors ultimately results in heightened excitation of serotonergic neurons and enhanced 5-HT release.[T28] Buspirone also displays a weak affinity for serotonin 5HT2 receptors and acts as a weak antagonist on dopamine D2 autoreceptors,[L7375] although there is not much evidence that the action at these receptors contribute to the anxiolytic effect of buspirone.[A182312] It acts as an antagonist at presynaptic dopamine D3 and D4 receptors and may bind to alpha-1 adrenergic receptors as a partial agonist.[A181751]', 'The clinical effect of buspirone in alleviating the symptoms of generalized anxiety disorders typically takes 2 to 4 weeks to achieve.[L7375] The delayed onset of action of buspirone suggests that the therapeutic effectiveness in generalized anxiety may involved more than its molecular mechanism of action at the 5-HT<sub>1A</sub> receptors,[T28] or buspirone may induce adaptations of 5-HT<sub>1A</sub> receptors.[L7375] Buspirone was not shown to alter the psychomotor or cognitive function in healthy volunteers, and the risk of developing sedation is relatively low compared to other anxiolytics, such as benzodiazepines.[A180985] Unlike benzodiazepines and barbiturates used in anxiety disorders, buspirone is not associated with a risk for developing physical dependence or withdrawal, or any significant interaction with central nervous system depressants such as ethanol. This is due to the lack of effects on GABA receptors.[A180985,L7375] Buspirone also does not exhibit any anticonvulsant or muscle-relaxing properties,[A182309] but may interfere with arousal reactions due to its inhibitory action on the aactivity of noradrenergic locus coerulus neurons.[T28]



Despite its clinical effectiveness in generalized anxiety, buspirone demonstrated limited clinical effectiveness on panic disorders, severe anxiety, phobias, and obsessive compulsive disorders.[A181751,T28] The clinical effectiveness of the long-term use of buspirone, for more than 3 to 4 weeks, has not demonstrated in controlled trials but there were no observable significant adverse events in patients receiving buspirone for a year in a study of long-term use.[L4478]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26850, 'Seropipe hair mask 225 ml', 'سيروبايب ماسك للشعر 225 مل', '310', '285', 'Hair care', 'Kamigen e+kamigen k+biotin+keratin+argan oil+coffee arabica fruit ext.+vitamin e', 'Egyptian co. for cosmetics > parkville pharmaceuticals', 'Unknown', 'غير محدد', '225 ml', '1', NULL, 'for silky smooth hair. safe for treated hair.', NULL, NULL, 841, '2025-10-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26851, 'Seropipe hair serum 120 ml', 'سيروبايب سيروم للشعر 120مل', '295', '255', 'Hair care', 'Kamigen e+kamigen k+hydrolyzed lupin protein+hordeum vulgare+urtica dioica germ oil+coffee arabica fruit ext.', 'Egyptian co. for cosmetics > parkville pharmaceuticals', 'Serum', 'سيروم', '120 ml', '1', NULL, '** multiple action serum: - hair growth accelerator - smooth intense - extra strength extra shine **how to use: apply a suitable amount on your hand and rub well on scalp and hair. ** ingredients: isodon trichocarpus extract (kamigen e) + sophora angustif', '6223012633972', NULL, 968, '2025-10-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26852, 'Seropipe hair shampoo 300 ml', 'سيروبايب شامبو للشعر 300مل', '210', '190', 'Hair care', 'Kamigen e+kamigen k+biotin+keratin+argan oil+coffee arabica fruit ext.+vitamin e', 'Egyptian co. for cosmetics > parkville pharmaceuticals', 'Amp', 'أمبول', '300 ml', '1', NULL, 'for silky smooth hair. safe for treated hair. **how to use: apply to wet hair and gently massage the scalp and roots with fingertips for 1-2 minutes then rinse. ** ingredients: isodon trichocarpus extract (kamigen e) + sophora angustifolia extract (kamige', '6224008073598', NULL, 831, '2024-04-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26853, 'Seropipe hair spray 200 ml', 'سيروبايب سبراي للشعر 200مل', '265', '220', 'Hair care', 'Kamigen e+kamigen k+hydrolyzed lupin protein+hordeum vulgare+urtica dioica germ oil+coffee arabica fruit ext.', 'Egyptian co. for cosmetics > parkville pharmaceuticals', 'Spray', 'بخاخ', '200 ml', '1', NULL, '** multiple action serum: - hair growth accelerator - smooth intense - extra strength extra shine **how to use: apply a suitable amount on your hand and rub well on scalp and hair. ** ingredients: isodon trichocarpus extract (kamigen e) + sophora angustif', NULL, NULL, 1034, '2025-08-19', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26856, 'Seroquel 200mg 10 tab', 'سيروكويل 200مجم 10 قرص', '143', '125', 'Psychiatric.antipsychotics', 'Quetiapine', 'Astra zeneca', 'Tab', 'أقراص', '200mg', '1', NULL, NULL, NULL, NULL, 972, '2024-11-25', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26859, 'Seroquel xr 200mg 10 tab', 'سيروكويل اكس ار 200مجم 10 اقراص', '135', NULL, 'Psychiatric.antipsychotics', 'Quetiapine', 'Astra zeneca', 'Tab', 'أقراص', '200mg', '1', NULL, NULL, NULL, NULL, 857, '2022-07-08', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26861, 'Seroquel xr 400mg 30 tab', 'سيروكويل اكس ار 400مجم 30 قرص', '915', '630', 'Psychiatric.antipsychotics', 'Quetiapine', 'Astra zeneca', 'Tab', 'أقراص', '400mg', '3', NULL, NULL, NULL, NULL, 1228, '2024-04-20', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26862, 'Seroquel xr 50 mg 10 tab', 'سيروكويل اكس ار 50مجم 10 قرص', '67', '45', 'Psychiatric.antipsychotics', 'Quetiapine', 'Astra zeneca', 'Tab', 'أقراص', '50 mg', '1', NULL, NULL, NULL, NULL, 1246, '2024-04-20', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26866, 'Serpass 100mg 20 f.c. tab.', 'سيرباس 100مجم 20 قرص', '135', '118', 'Psychiatric.antidepressants', 'Sertraline', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '100mg', '2', NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6223002141647', NULL, 4783, '2025-08-03', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26867, 'Serpass 50mg 30 f.c.tab.', 'سيرباس 50مجم 30 قرص', '102', '76.5', 'Psychiatric.antidepressants', 'Sertraline', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '50mg', '3', NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6223002142583', NULL, 3735, '2024-08-17', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26869, 'Sertraline 20mg/ml oral concentrate 60 ml', 'سيرترالين 20مجم/مل 60مل', '30', NULL, 'Psychiatric.antidepressants', 'Sertraline', 'Sigma', 'Unknown', 'غير محدد', '20mg', '1', NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', NULL, NULL, 998, '2022-07-27', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26871, 'Servect hair oil with serum 200 ml', 'سيرفيكت هير اويل مع سيرم 200 مل', '200', '130', 'Hair care', 'Snake oil +vitamin e +tea tree oil +wheat germ oil +castor oi l+bht +almond oil +olive oil+ jasmine oil +safflower oil+ perfume +liquid paraffin oil', 'Egyptian co. for cosmetics > servect pharm', 'Hair oil', 'زيت شعر', '200 ml', '1', 'الحفاظ علي الشعر -- نظافة الشعر -- الحفاظ علي لمعان و تقوية الشعر', NULL, NULL, NULL, 4694, '2024-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26872, 'Servicare liquid intimate feminine wash 250 ml', 'سيرفيكير غسول 250مل', '26', NULL, 'Vaginal wash', 'Chlorhexidine+cetrimide+thymol+menthol+rosa oil+tego betain', 'Hi-care > castle care', 'Unknown', 'غير محدد', '250 ml', '1', NULL, NULL, NULL, NULL, 851, '2022-07-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26873, 'Serviclazid 80mg 10 tab.', 'سيرفيكلازيد 80مجم 10 اقراص', '6', NULL, 'Anti-diabetic.secretagogues.sulfonylurea', 'Gliclazide', 'Novartis', 'Tab', 'أقراص', '80mg', '1', NULL, 'about gliclazide first generation sulfonylurea oral antidiabetic agent. mechanism of action of gliclazide it is an antidiabetic drug which exerts it`s action by increasing insulin release from the pancreas and by improving glucose tolerance. it acts on th', '6223002641376', NULL, 983, '2022-08-02', 0, 'For the treatment of NIDDM in conjunction with diet and exercise. ', 'Gliclazide binds to the &beta; cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the &beta; cells. This opens voltage-dependent calcium channels in the &beta; cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.', 'Based on the pharmacological properties, gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates &beta; cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26877, 'Servipep 20mg 14 f.c. tab.', 'سيرفيبيب 20مجم 14 قرص', '10', NULL, 'Peptic ulcer.anti-histamine.h2 antagonist', 'Famotidine', 'Novartis', 'Tab', 'أقراص', '20mg', '2', NULL, NULL, '6223002640157', NULL, 791, '2022-12-08', 0, 'Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.[L11139]



It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.[L11139]



The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.[L11142]



Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.[L11166,L11172]', 'Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK<sub>2</sub> receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H<sub>2</sub> receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. [T28] In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H<sub>2</sub> receptors and blocks the actions of histamine.[L11166]', 'Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin.[L11139,L11142]



Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.[A189459]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26879, 'Servivit plus 14 caps.', 'سيرفيفيت بلس 14 كبسول', '13', NULL, 'Vitamins', 'Vitamins', 'Novartis', 'Cap', 'كبسولة', NULL, '2', NULL, 'about vitamins vitamins are substances that are found in foods we eat. the term vitamin is derived from the words vital and amine because vitamins are required for life and were originally thought to be amines. all vitamins are not amines. vitamins are di', '6223002640409', NULL, 1266, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26881, 'Seta cream 50 gm', 'سيتا كريم 50 جم', '25', NULL, 'Moisturizing topicals', 'Urea+lactic acid+salicylic acid+sorbitol+moisturizing cream base', 'Macro group pharmaceuticals', 'Cream', 'كريم', '50 gm', '1', NULL, '-specially designed moisturizing cream to counteract skin dryness (xerosis) flaking scaling & cracking especially in winter season or in hot summer intervals due to over exposure to sun rays. -provides extra emollient effect for dry hands elbows knees & h', NULL, NULL, 1308, '2022-06-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26882, 'Setano skin cleanser gel 120ml', 'سيتانو جل 120مل', '35', NULL, 'Skin care', 'Thyme extract+menthol+cocamide dea', 'Hi-care > smart marketing', 'Gel', 'جل', '120ml', '1', NULL, 'for all skin types **application: apply suitable amount of the gel on your skin & rub gently then wash with water.', NULL, NULL, 895, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26885, 'Sevelam 800 mg 15 f.c. tabs.', 'سيفيلام 800مجم 15 قرص', '80', NULL, 'Phosphate binder', 'Sevelamer', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '800 mg', '3', 'تقليل مستوي الفوسفات في مرضي الفشل الكلوي -- الحفاظ علي مستوي الكالسيوم في الدم', 'about sevelamer phosphate binder management of hyperphosphataemia urinary alkalinizer. mechanism of action of sevelamer sevelamer is a phosphate binder. it is used to reduce the level of phosphorus in chronic renal disease. it binds with phosphate in the', NULL, NULL, 2886, '2022-05-21', 0, 'For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.', 'Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.', 'Patients with end-stage renal disease (ESRD) retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. When the product of serum calcium and phosphorus concentrations (Ca x P) exceeds 55 mg<sup>2</sup>/dL<sup>2</sup>, there is an increased risk that ectopic calcification will occur. Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency. An increase in parathyroid hormone (PTH) levels is characteristic of patients with chronic renal failure. Increased levels of PTH can lead to osteitis fibrosa, a bone disease. A decrease in serum phosphorus may decrease serum PTH levels. Treatment of hyperphosphatemia includes reduction in dietary intake of phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and removal of phosphate with dialysis. Sevelamer taken with meals has been shown to decrease serum phosphorus concentrations in patients with ESRD who are on hemodialysis. <i>In vitro</i> studies have shown that the capsule and tablet formulations bind phosphate to a similar extent. Sevelamer treatment also results in a lowering of low-density lipoprotein (LDL) and total serum cholesterol levels.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26886, 'Sevoflurane 100% liquid for inhalation 250 ml', 'سيفوفلوران 100% سائل الاستنشاق 250 مل', '3,715', '1250', 'General anaesthesia', 'Sevoflurane', 'Arab caps > acdima international trading', 'Unknown', 'غير محدد', '100%', '1', NULL, 'about sevoflurane volatile halogenated anaesthetics sweet-smelling non-flammable highly fluorinated methyl isopropyl ether mechanism of action of sevoflurane sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel open', NULL, NULL, 2298, '2024-10-23', 0, 'Sevoflurane is used for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.[L42340]', 'The precise mechanism of action of sevoflurane has not been fully elucidated. Like other halogenated inhalational anesthetics, sevoflurane induces anesthesia by binding to ligand-gated ion channels and blocking CNS neurotransmission. It has been suggested that inhaled anesthetics enhance inhibitory postsynaptic channel activity by binding GABA<sub>A</sub> and glycine receptors, and inhibit excitatory synaptic channel activity by binding nicotinic acetylcholine, serotonin, and glutamate receptors.[A249890] Sevoflurane has an effect on several ionic currents, including the hyperpolarisation-activated cation current (I<sub>f</sub>), the T-type and L-type Ca<sup>2+</sup> currents (I<sub>Ca, T</sub> and I<sub>Ca, L</sub>), the slowly activating delayed rectifier K<sup>+</sup> currents (I<sub>Ks</sub>), and the Na<sup>+</sup>/Ca<sup>2+</sup> exchange current (I<sub>NCX</sub>).[A249895] This ability to modulate ion channel activity can also regulate cardiac excitability and contractility.[A249895]', 'Sevoflurane induces muscle relaxation and reduces sensitivity by altering tissue excitability with a fast onset of action. It does so by decreasing the extent of gap junction-mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.[A249905] Compared to [halothane] and [isoflurane], sevoflurane has a shorter emergence time, as well as a shorter time to first analgesia.[L42340] To reach an equilibrium between alveolar and arterial partial pressure, only a minimal amount of sevoflurane needs to be dissolved in blood.[L42340] 



The use of sevoflurane can increase the risk of renal injury, respiratory depression, and QT prolongation. Also, it can lead to malignant hyperthermia, perioperative hyperkalemia, and pediatric neurotoxicity. Episodes of severe bradycardia and cardiac arrest have been reported in pediatric patients with Down Syndrome given sevoflurane. Sevoflurane anesthesia may impair the performance of activities requiring mental alertness, such as driving or operating machinery.[L42340]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26887, 'Sevoflurane baxter 100% liquid for inhalation 250 ml', 'سيفوفلوران باكستر 100% سائل للاستنشاق 250 مل', '2,428', '1437', 'General anaesthesia', 'Sevoflurane', 'Baxter ag > multipharma', 'Unknown', 'غير محدد', '100%', '1', NULL, 'about sevoflurane volatile halogenated anaesthetics sweet-smelling non-flammable highly fluorinated methyl isopropyl ether mechanism of action of sevoflurane sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel open', NULL, NULL, 1291, '2025-08-16', 0, 'Sevoflurane is used for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.[L42340]', 'The precise mechanism of action of sevoflurane has not been fully elucidated. Like other halogenated inhalational anesthetics, sevoflurane induces anesthesia by binding to ligand-gated ion channels and blocking CNS neurotransmission. It has been suggested that inhaled anesthetics enhance inhibitory postsynaptic channel activity by binding GABA<sub>A</sub> and glycine receptors, and inhibit excitatory synaptic channel activity by binding nicotinic acetylcholine, serotonin, and glutamate receptors.[A249890] Sevoflurane has an effect on several ionic currents, including the hyperpolarisation-activated cation current (I<sub>f</sub>), the T-type and L-type Ca<sup>2+</sup> currents (I<sub>Ca, T</sub> and I<sub>Ca, L</sub>), the slowly activating delayed rectifier K<sup>+</sup> currents (I<sub>Ks</sub>), and the Na<sup>+</sup>/Ca<sup>2+</sup> exchange current (I<sub>NCX</sub>).[A249895] This ability to modulate ion channel activity can also regulate cardiac excitability and contractility.[A249895]', 'Sevoflurane induces muscle relaxation and reduces sensitivity by altering tissue excitability with a fast onset of action. It does so by decreasing the extent of gap junction-mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.[A249905] Compared to [halothane] and [isoflurane], sevoflurane has a shorter emergence time, as well as a shorter time to first analgesia.[L42340] To reach an equilibrium between alveolar and arterial partial pressure, only a minimal amount of sevoflurane needs to be dissolved in blood.[L42340] 



The use of sevoflurane can increase the risk of renal injury, respiratory depression, and QT prolongation. Also, it can lead to malignant hyperthermia, perioperative hyperkalemia, and pediatric neurotoxicity. Episodes of severe bradycardia and cardiac arrest have been reported in pediatric patients with Down Syndrome given sevoflurane. Sevoflurane anesthesia may impair the performance of activities requiring mental alertness, such as driving or operating machinery.[L42340]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26888, 'Sfira hair lotion 120 ml', 'سفيرا لوسيون للشعر 120 مل', '250', '145', 'Hair care', 'Aloe vera+olive oil+saw palmetto+caffeine+sodium hylauronate+panthenol', 'El-helou perfumes & cosmetics > biotrade pharmaceutical', 'Lotion', 'لوشن', '120 ml', '1', NULL, NULL, NULL, NULL, 1976, '2025-04-18', 0, 'Indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions, including contact or atopic dermatitis, eczema, dermatitis and acne urticata, first- and second-degree burns, radiation dermatitis, and sunburn. ', 'It is suggested that aloe polysaccharides mediate skin-protectant effects in damaged skin, induced by internal or other external factors such as radiation, via inhibiting apoptosis of normal cell lines _in vitro_ and thrombocytes _in vivo_ [A32473]. Following irradiation, aloe polysaccharides block the upregulation of pro-apoptotic p53, Bax, and Bad while blocking downregulating anti-apoptotic Bcl-2 [A32473]. _In vivo_, aloe polysaccharides may act as a scavenger for oxygen free radicals including DPPH, alkyl radicals, superoxides, and singlet oxygen and hydroxyl radicals that may also be generated by superoxides [A32470, A32476]. Hydrogen peroxide, which is a weak initiate lipid peroxidation, may also be effectively scavenged by aloe polysaccharides [A32476]. In a Fenton reaction system, aloe polysaccharides demonstrated a concentration-dependent scavenging activity against hydroxyl radical that were generated during the reaction [A32476]. Aloe polysaccharides may also compete with oxygen to react with nitric oxide (NO), thereby inhibiting the generation of nitrite and peroxynitrite anions that act as free radicals [A32476]. 



Findings from a study investigating the effects of aloe polysaccharides on doxorubicin-induced oxidative stress suggest that aloe polysaccharides mediate potent antioxidant actions _in vivo_ [A32476]. Doxorubicin, known to generate reactive oxygen species such as superoxide and hydroxy radicals, was administered to albino rats. This led to myocardial oxidative stress and cardiac injury accompanied by leakage of LDH and CPK from cardiac myocytes and to serum due to lipid peroxidation of cardiac membranes, reduced levels of antioxidant coenzyme GSH, and increased levels of SOD from a compensatory and combative mechanism of oxidative stress [A32476]. Treatment with aloe polysaccharides resulted in a significant decrease in serum LDH and CPK levels, indicating that aloe polysaccharides are capable in stabilizing cardiac membranes from peroxidative damage. Restored levels of endogenous GSH and SOD in a dose-dependent manner were also observed with the treatment of aloe polysaccharides, suggesting that aloe polysaccharides exhibit potent antioxidant properties [A32476].



In a study of rats with open cutaneous back wounds, treatment with aloe polysaccharides decreased the levels of matrix metalloproteinase-3 (MMP-3) and induced tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) during the early stage of wound repair, resulting in decreased collagen breakdown and increased preservation of collagen content in the injured area [A32471]. A study proposes that acemannan, a common aloe polysaccharide, stimulates BMSC proliferation, ALPase activity, expression of VEGF, BMP-2, OPN, BSP, and mineralization leading to osteoblast differentiation and bone formation during socket healing [A32475]. ', 'Aloe polysaccharides mediate antioxidant and anti-inflammatory actions, as well as immunoregulatory activities. Various studies indicate that aloe polysaccharides possess effective free radical scavenging activity _in vitro_, and produce potent antioxidant potential during oxidative stress _in vivo_ [A32476]. According to the findings of studies _in vitro_ and _in vivo_, aloe polysaccharides exhibit radioprotective activity. Treatment with acemmanan, which is a common aloe polysaccharide, on CH3 mice with radiation-induced skin reactions resulted in reduced signs of those reactions [A32473]. Studies suggest that aloe polysaccharides may evidently attenuate tumor growth in mice [A32473]. Treatment of aloe polysaccharides in Vero cells as well as in the in vivo zebrafish model led to protective effects against AAPH-indued oxidative stress resulting from accumulation of free radical species and improved cell viability [A32470]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26889, 'Sfira moisturizing cream 60 gm', 'سفيرا كريم مرطب 60 جم', '69', NULL, 'Moisturizing cream', 'Aloe vrea+jojoba oil+panthenol+shea butter+olive oil+caffeine+glycerin+vitamin e', 'El-helou perfumes & cosmetics > biotrade pharmaceutical', 'Cream', 'كريم', '60 gm', '1', 'كريم مرطب للجلد __ يعمل علي تنعيم وترطيب الجلد', NULL, NULL, NULL, 2637, '2022-04-24', 0, 'Indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions, including contact or atopic dermatitis, eczema, dermatitis and acne urticata, first- and second-degree burns, radiation dermatitis, and sunburn. ', 'It is suggested that aloe polysaccharides mediate skin-protectant effects in damaged skin, induced by internal or other external factors such as radiation, via inhibiting apoptosis of normal cell lines _in vitro_ and thrombocytes _in vivo_ [A32473]. Following irradiation, aloe polysaccharides block the upregulation of pro-apoptotic p53, Bax, and Bad while blocking downregulating anti-apoptotic Bcl-2 [A32473]. _In vivo_, aloe polysaccharides may act as a scavenger for oxygen free radicals including DPPH, alkyl radicals, superoxides, and singlet oxygen and hydroxyl radicals that may also be generated by superoxides [A32470, A32476]. Hydrogen peroxide, which is a weak initiate lipid peroxidation, may also be effectively scavenged by aloe polysaccharides [A32476]. In a Fenton reaction system, aloe polysaccharides demonstrated a concentration-dependent scavenging activity against hydroxyl radical that were generated during the reaction [A32476]. Aloe polysaccharides may also compete with oxygen to react with nitric oxide (NO), thereby inhibiting the generation of nitrite and peroxynitrite anions that act as free radicals [A32476]. 



Findings from a study investigating the effects of aloe polysaccharides on doxorubicin-induced oxidative stress suggest that aloe polysaccharides mediate potent antioxidant actions _in vivo_ [A32476]. Doxorubicin, known to generate reactive oxygen species such as superoxide and hydroxy radicals, was administered to albino rats. This led to myocardial oxidative stress and cardiac injury accompanied by leakage of LDH and CPK from cardiac myocytes and to serum due to lipid peroxidation of cardiac membranes, reduced levels of antioxidant coenzyme GSH, and increased levels of SOD from a compensatory and combative mechanism of oxidative stress [A32476]. Treatment with aloe polysaccharides resulted in a significant decrease in serum LDH and CPK levels, indicating that aloe polysaccharides are capable in stabilizing cardiac membranes from peroxidative damage. Restored levels of endogenous GSH and SOD in a dose-dependent manner were also observed with the treatment of aloe polysaccharides, suggesting that aloe polysaccharides exhibit potent antioxidant properties [A32476].



In a study of rats with open cutaneous back wounds, treatment with aloe polysaccharides decreased the levels of matrix metalloproteinase-3 (MMP-3) and induced tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) during the early stage of wound repair, resulting in decreased collagen breakdown and increased preservation of collagen content in the injured area [A32471]. A study proposes that acemannan, a common aloe polysaccharide, stimulates BMSC proliferation, ALPase activity, expression of VEGF, BMP-2, OPN, BSP, and mineralization leading to osteoblast differentiation and bone formation during socket healing [A32475]. ', 'Aloe polysaccharides mediate antioxidant and anti-inflammatory actions, as well as immunoregulatory activities. Various studies indicate that aloe polysaccharides possess effective free radical scavenging activity _in vitro_, and produce potent antioxidant potential during oxidative stress _in vivo_ [A32476]. According to the findings of studies _in vitro_ and _in vivo_, aloe polysaccharides exhibit radioprotective activity. Treatment with acemmanan, which is a common aloe polysaccharide, on CH3 mice with radiation-induced skin reactions resulted in reduced signs of those reactions [A32473]. Studies suggest that aloe polysaccharides may evidently attenuate tumor growth in mice [A32473]. Treatment of aloe polysaccharides in Vero cells as well as in the in vivo zebrafish model led to protective effects against AAPH-indued oxidative stress resulting from accumulation of free radical species and improved cell viability [A32470]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26890, 'Sfira whitening cream 50 gm', 'سفيرا كريم تفتيح 50جم', '89', NULL, 'Whitening topical', 'Vitamin c+vitamin e+kohic acid+liquorice ext.+alpha arbutin', 'El-helou perfumes & cosmetics > biotrade pharmaceutical', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 887, '2022-08-04', 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26891, 'Sfn-10 nail mycosis solution 3.3 ml', 'اس اف ان 10 للاظافر محلول 3.3 مل', '298', NULL, 'Antifungal', 'Ethyl lactate+aqua+acetic acid+undecylenic acid+methylisothiazolinone', 'Crab sinergy > rotabiogen for pharmaceutical invest.', 'Solution', 'محلول', '3.3 ml', '1', NULL, NULL, NULL, NULL, 1235, '2023-06-29', 0, 'Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.', 'CTI-01 inhibits the systemic release of cytokines, such as TNF-alpha and HMGB1, which promote the body''s inflammatory response. The over-expression of these cytokines has been linked to diseases that occur in critical care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and post-operative ileus following abdominal surgery.', NULL, 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26892, 'Shaan rejuvenition cream 120 gm', 'شان كريم 120 جم', '150', '125', 'Skin care', NULL, 'Egyptian company for cosmetics > parkville pharmaceuticals', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, '6224008073024', NULL, 883, '2024-05-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26893, 'Shaan facial cleanser 250 ml', 'شان غسول للوجه 220 مل', '175', '150', 'Skin care', 'Panthenol+carbomer 40+triethanolamine+aloe vera+chamomile+hydrogenated castor oil+methyl paraben+propyl paraben', 'Parkville', 'Cleanser', 'منظف', '250 ml', '1', NULL, 'gentle cleanser for dry and sensitive skin perfectly cleanses and purifies the skin from dirt impurities and dead cells without leaving skin irritant or dry shaan contains moisturizing ingredients which hydrate and soothes the skin (soap free). for dry sk', '6224008073383', NULL, 961, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26894, 'Shaan intimate feminine cleanser 220 ml', 'شان منظف للعناية الشخصية بالسيدات 220 مل', '110', NULL, 'Vaginal wash', NULL, 'Egyptian company for cosmetics > parkville pharmaceuticals', 'Cleanser', 'منظف', '220 ml', '1', NULL, 'intimate cleanser provides daily freshness for females with soothing and anti-bacterial action which contains natural ingredients: almond oil aloe vera tea tree oil and olive oil free of sulfates and shaan preserves ph-balanced.', '6221009004064', NULL, 697, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26895, 'Shaan lip balm 5 gm', 'شان مرطب للشفاه 10 جرام', '90', '80', 'Skin care', NULL, 'Egyptian company for cosmetics > parkville pharmaceuticals', 'Unknown', 'غير محدد', '5 gm', '1', 'مرطب شفاه', NULL, '6224008073956', NULL, 1235, '2024-06-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26896, 'Shaan soothing gel 120 gm', 'شان جل ملطف ومرطب للجلد 120 جرام', '170', '150', 'Soothing topical', 'Panthenol+carbomer 40+triethanolamine+aloe vera+chamomile+hydrogenated castor oil+methyl paraben+propyl paraben', 'Egyptian company for cosmetics > parkville pharmaceuticals', 'Gel', 'جل', '120 gm', '1', 'جل مرطب للجلد -- تنعيم الجلد وتفنيحه', 'non-greasy moisturizing gel with high absorption provides immediate soothing action moisturizes hydrates restore dry skin barrier and prevents itching and inflammation symptoms. used post-laser apply 2-3 times daily.', '6224008073390', NULL, 1641, '2024-02-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26897, 'Shaddock eye contour cream 120 gm', 'شادوك كريم للعين 120جم', '220', NULL, 'Eye contour', NULL, 'Egyptian company for cosmetics > care mid-east pharma', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, NULL, NULL, 641, '2022-07-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26898, 'Shaddock eye contour cream 20 gm', 'شادوك كريم 20جم', '59', NULL, 'Eye contour', NULL, 'Egyptian company for cosmetics > care mid-east pharma', 'Cream', 'كريم', '20 gm', '1', NULL, NULL, NULL, NULL, 689, '2022-07-17', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26899, 'Shade out cream 15 gm', 'شيد اوت كريم 15 جم', '100', '91', 'Eye contour', 'Aqua+vitamin c+vitamin e+panthenol+eutanol g+octyl methoxycinnamate+titanium dioxide+allantoin+glyce', 'Mash premiere', 'Cream', 'كريم', '15 gm', '1', 'حالات الهالات السوداء تحت العين', 'eye contour cream that nourishes the skin around the eyes', '6222001405071', NULL, 785, '2024-04-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26900, 'Shalgaten 100mg 20 caps.', 'شالجاتين 100مجم 20 كبسولة', '18', NULL, 'Anti-epileptic.gaba analogs', 'Gabapentin', 'Egpi > sea pharm for pharmaceuticals', 'Cap', 'كبسولة', '100mg', '2', 'علاج الصرع -- تقليل نوبات التشنجات -- تنظيم وظائف المخ والعضلات', 'about gabapentin a gaba analogue anticonvulsant mood stabilizer. mechanism of action of gabapentin gabapentin is a gaba derivative and it bounds to lipophilic molecule. the mechanism of action of gabapentin is not exactly known. it crosses blood brain bar', NULL, NULL, 990, '2022-04-14', 0, 'In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]', 'The precise mechanism through which gabapentin exerts its therapeutic effects is unclear.[L8717,L8720] The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported).[A186179,A14097,A186277] The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons.[A186179] There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia.[A14097] Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters.[A186179] It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.[A186277]



There is some evidence that gabapentin also acts on adenosine receptors[A11009, A186209] and voltage-gated potassium channels,[A186212] though the clinical relevance of its action at these sites is unclear.', 'Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.[L8717,L8732] It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.[L8765]



Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.[L8717,L8720,L8732]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26901, 'Shalgaten 300mg 20 capsules', 'شالجاتن 300مجم 20 كبسولة', '61', NULL, 'Anti-epileptic.gaba analogs', 'Gabapentin', 'Egpi > sea pharm for pharmaceuticals', 'Capsule', 'كبسولة', '300mg', '2', 'مهديء عصبي - مضاد للتشنجات', NULL, NULL, NULL, 4689, '2023-02-05', 0, 'In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]', 'The precise mechanism through which gabapentin exerts its therapeutic effects is unclear.[L8717,L8720] The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported).[A186179,A14097,A186277] The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons.[A186179] There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia.[A14097] Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters.[A186179] It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.[A186277]



There is some evidence that gabapentin also acts on adenosine receptors[A11009, A186209] and voltage-gated potassium channels,[A186212] though the clinical relevance of its action at these sites is unclear.', 'Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.[L8717,L8732] It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.[L8765]



Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.[L8717,L8720,L8732]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26902, 'Shalgaten 400mg 20 capsules', 'شالجاتين 400مجم 20 كبسولة', '62', NULL, 'Anti-epileptic.gaba analogs', 'Gabapentin', 'Egpi > sea pharm for pharmaceuticals', 'Capsule', 'كبسولة', '400mg', '2', 'مهديء عصبي مضاد للتشنجات والصرع', NULL, '6224001937019', NULL, 12338, '2023-05-07', 0, 'In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]', 'The precise mechanism through which gabapentin exerts its therapeutic effects is unclear.[L8717,L8720] The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported).[A186179,A14097,A186277] The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons.[A186179] There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia.[A14097] Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters.[A186179] It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.[A186277]



There is some evidence that gabapentin also acts on adenosine receptors[A11009, A186209] and voltage-gated potassium channels,[A186212] though the clinical relevance of its action at these sites is unclear.', 'Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.[L8717,L8732] It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.[L8765]



Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.[L8717,L8720,L8732]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26903, 'Sham 300mg 24 caps.', 'شام 300مجم 24 كبسول', '18', NULL, 'Urolithiac', 'Salicylhydroxamic acid', 'El nasr', 'Cap', 'كبسولة', '300mg', '2', NULL, 'it exerts a dual urolithiac activity. it inhibits both the urease enzyme activity and sulphation of mucopolysaccharides which are responsible for renal stone formation. sham is metabolized in the body to salicylamide which exerts analgesic anti-pyretic as', '6221067003467', NULL, 747, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26904, 'Shamo hair serum 150 ml', 'شامو سيروم 150مل', '59', NULL, 'Hair care', NULL, 'El-masria for cosmetics > admin pharma', 'Serum', 'سيروم', '150 ml', '1', NULL, 'nutritive for hair', NULL, NULL, 718, '2022-07-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26905, 'Shamsomox 400 mg 5 f.c. tabs', 'شامسوموكس 400مجم 5 اقراص', '89', '81', 'Antibiotic.quinolone', 'Moxifloxacin', 'El shams trading', 'Tab', 'أقراص', '400 mg', '1', NULL, NULL, '225000352124', NULL, 1523, '2025-01-07', 0, 'For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).', 'The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.', 'Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: _Corynebacterium_ species, _Micrococcus luteus_, _Staphylococcus aureus_, _Staphylococcus epidermidis_, _Staphylococcus haemolyticus_, _Staphylococcus hominis_, _Staphylococcus warneri_, _Streptococcus pneumoniae_, and _Streptococcus viridans_ group. Aerobic Gram-negative microorganisms: _Acinetobacter lwoffii_, _Haemophilus influenzae_, and _Haemophilus parainfluenzae_. Other microorganisms: _Chlamydia trachomatis_. Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26906, 'Shancita 100mg/ml 30 ml oral sol.', 'شانسيتا 100مجم/مل 30مل محلول بالفم', '76', '47.5', 'Cerebral circulatory inhancer', 'Citicholine', 'Amriya', 'Sol', 'محلول', '100mg', '1', 'حالات الزهايمر', 'citicoline is a brain chemical that occurs naturally in the body. as a medicine it is taken by mouth as a supplement or given by iv or as a shot. citicoline is used for alzheimer s disease and other types of dementia head trauma cerebrovascular disease su', '6221075051153', NULL, 2288, '2023-11-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26907, 'Shancita 500mg/3ml 5 amp for iv/im inj.', 'شانسيتا حقن 500مجم / 3مل 5 امبولات', '145', '95', 'Cerebral circulatory inhancer', 'Citicholine', 'Amriya', 'Inj', 'حقن', '500mg', '5', 'علاج مساعد في حالات السكتة الدماغية -- علاج نقص نمو المخ عند الاطفال -- علاج الامراض العصبية -- علاج مساعد للزهايمر', 'citicoline is a brain chemical that occurs naturally in the body. as a medicine it is taken by mouth as a supplement or given by iv or as a shot. citicoline is used for alzheimer s disease and other types of dementia head trauma cerebrovascular disease su', NULL, NULL, 2570, '2025-09-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26908, 'Baby ran lotion 120 ml', 'بيبي ران لوشن 120 مل', '50', NULL, 'Skin care.soothing', 'Zinc oxide + shea butter + jojoba oil + macadamia oil + panthenol + petroleum jelly + chamomile + cucumber + green tea + aloe vera + cod liver oil + wheat germ oil', 'Prime pharma', 'Lotion', 'لوشن', '120 ml', '1', NULL, NULL, NULL, NULL, 717, '2022-12-02', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26910, 'Sharkilage 30 caps.', 'شاركيلاج 30 كبسولة', '135', '70.5', 'Antirheumatic.osteoarthritis.anabolic agents', 'Chondroitin+glucosamine', 'Arab caps > multicare', 'Cap', 'كبسولة', NULL, '3', NULL, 'about chondroitin sulphate a sulfated glycosaminoglycan (mucopolysaccharides dietary supplement anti-rheumatic and anti-inflammatory. mechanism of action of chondroitin sulphate chondroitin sulfate is part of a large protein molecule (proteoglycan) that g', '6224007326046', NULL, 1738, '2024-02-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26911, 'Sharkilage plus 30 caps.', 'شاركيلاج بلس 30 كبسولة', '150', '78', 'Anti-rheumatic.osteoarthritis.anabolic agents', 'Chondroitin+glucosamine+methyl sulphonyl methane', 'Arab caps > pharmacare', 'Cap', 'كبسولة', NULL, '3', 'علاج حالات التهاب المفاصل والغضاريف -- بناء انسجة المفاصل والغضاريف -- مضاد لالتهاب المفاصل والعظام -- مضاد للروماتيزم -- تقليل الام المفاصل والركبة -- زيادة لزوجة السائل الغضروفي -- تقليل التورم الناتج من الالتهاب.', NULL, '6224007326312', NULL, 19533, '2024-02-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26912, 'Shatbiotic 400 mg 10 caps.', 'شاتبيوتك 400مجم 10 كبسول', '84', NULL, 'Antibiotic.cephalosporin.third-generation', 'Ceftibuten', 'Biomed pharmaceuticals', 'Cap', 'كبسولة', '400 mg', '1', NULL, 'ceftibuten is a third-generation cephalosporin antibiotic. it is an orally administered agent with two dosage forms capsule or oral suspension. indications ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (abecb) acute bacte', NULL, NULL, 623, '2022-08-03', 0, 'Indicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.', 'Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.', 'Ceftibuten is an antibiotic with bactericidal actions. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26913, 'Shatbiotic 90mg/5ml pd for oral susp. 60 ml', 'شاتبيوتك 90مجم/5مل شراب معلق 60مل', '36', NULL, 'Antibiotic.cephalosporin.third-generation', 'Ceftibuten', 'Biomed pharmaceuticals', 'Susp', 'معلق', '90mg', '1', NULL, 'ceftibuten is a third-generation cephalosporin antibiotic. it is an orally administered agent with two dosage forms capsule or oral suspension. indications ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (abecb) acute bacte', NULL, NULL, 660, '2022-08-02', 0, 'Indicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.', 'Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.', 'Ceftibuten is an antibiotic with bactericidal actions. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26914, 'Shatoo 50/200mg 7 c.r. f.c. tabs.', 'شاتو 50/200مجم 7 اقراص', '52', '38', 'Parkinson s disease.dopamine agonist', 'Carbidopa+levodopa', 'Egyphar', 'Tab', 'أقراص', '200mg', '1', NULL, 'about carbidopa a noncompetitive dopa decarboxylase inhibitor antidyskinetics anti-parkinson`s agent. mechanism of action of carbidopa carbidopa inhibits the peripheral decarboxylation of levodopa and thus slowing its conversion to dopamine in extra cereb', '6224001026669', NULL, 1765, '2024-11-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26915, 'Sherimaint soln for i.v. inf. 250 ml', 'شيريماينت محلول 250مل', '5', NULL, 'Sterile solution', 'Calcium gluconate+glucose (dextrose)+potassium chloride+sodium chloride', 'Al mottahedoon pharma', 'Sol', 'محلول', '250 ml', '1', NULL, 'about calcium gluconate nutritional medicines salt of calcium and gluconic acid mechanism of action of calcium gluconate calcium gluconate is used to prevent or treat negative calcium balance. it also helps facilitate nerve and muscle performance as well', '8690973375216', NULL, 795, '2022-07-14', 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26916, 'Shiny 10 sachets', 'شايني 10 اكياس', '180', '145', NULL, NULL, '> drug pharma egypt', 'Sachet', 'أكياس', NULL, '1', 'منع تساقط الشعر -- تقوية الشعر -- زيادة لمعانه', NULL, '8690973050571', NULL, 1106, '2024-04-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26917, 'Shire 25 gummies', 'شاير 25 قطعة', '110', '95', 'Omega-3', 'Omega-3', 'Medcare > medicina medical ltd.', 'Unknown', 'غير محدد', NULL, '1', 'مصدر للاوميجا 3 -- مصدر للطاقة -- مضاد للاكسدة', 'dose: 1-2 gummies per day.', '6225000257962', NULL, 4123, '2025-07-15', 0, 'Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia. ', 'Omega-3 fatty acids mediate anti-inflammatory effects and increased levels of EPA or DHA has shown to decrease the levels of PGE2 and 4 series-LT. 

Eicosapentaenoic acids compete with constitutive levels of arachidonic acid in cell membranes for the same desaturation enzymes and produce 3-series prostaglandins and thromboxanes, and 5-series leukotrienes which have low pro-inflammatory potential. The alteration in leukotriene biosynthesis due to higher concentration of omega-3 fatty acids compared to arachidonic acid underlies the anti-inflammatory effects. 

EPA and DHA also give rise to resolvins and related lipid signalling molecules such as protectins via cyclooxygenase and lipoxygenase pathways, which have anti-inflammatory effects. They inhibit transendothelial migration of neutrophils and inhibit TNF and IL-1β production. Omega-3 fatty acids also decrease adhesion molecule expression on leukocytes and on endothelial cells and decrease intercellular adhesive interactions.

Omega-3 (or n-3) polyunsaturated fatty acids (PUFAs) and their metabolites are natural ligands for peroxisome proliferator-activated receptor (PPAR) gamma that regulates inflammatory gene expression and NFκB activation. PPAR alpha activation is also associated with induction of COX-2 expression. 

The role of EPA and DHA in reducing triglyceride levels include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal-beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. They also may reduce triglyceride synthesis because they are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids. ', 'Omega-3 fatty acids are triglycerides that get broken down into smaller fatty acid units. They act to reduce plasma triglyceride levels however increase the cholesterol levels and are thought to possess potent antiarrythmic effects. Polyunsaturated fatty acids including eicosapentaenoic and docosahexaenoic acid mediate important cellular function such as inhibition of platelet function, prolongation of bleeding time, anti-inflammatory effects and reduction of plasma fibrinogen. Polyunsaturated fatty acids are components of the phospholipids that form the structures of the cell membranes and also serve as energy source. They form eicosanoids which are important signalling molecules with wide-ranging functions in the body''s cardiovascular, pulmonary, immune and endocrine systems. DHA tends to exist in high concentrations in the retina, brain (via uptake by Mfsd2a as a transporter), and sperm.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26918, 'Shire 50 gummies', 'شاير 50 قطعة', '180', '150', 'Omega-3', 'Omega-3', 'Medcare > medicina medical ltd.', 'Unknown', 'غير محدد', NULL, '1', 'مصدر لاوميجا التي تساعد علي تحسين الذاكرة -- يساعد علي تحسين عمل المخ -- تحسن عمل المفاصل و العظام', 'dose: 1-2 gummies per day.', '6225000257962', NULL, 3093, '2025-08-16', 0, 'Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia. ', 'Omega-3 fatty acids mediate anti-inflammatory effects and increased levels of EPA or DHA has shown to decrease the levels of PGE2 and 4 series-LT. 

Eicosapentaenoic acids compete with constitutive levels of arachidonic acid in cell membranes for the same desaturation enzymes and produce 3-series prostaglandins and thromboxanes, and 5-series leukotrienes which have low pro-inflammatory potential. The alteration in leukotriene biosynthesis due to higher concentration of omega-3 fatty acids compared to arachidonic acid underlies the anti-inflammatory effects. 

EPA and DHA also give rise to resolvins and related lipid signalling molecules such as protectins via cyclooxygenase and lipoxygenase pathways, which have anti-inflammatory effects. They inhibit transendothelial migration of neutrophils and inhibit TNF and IL-1β production. Omega-3 fatty acids also decrease adhesion molecule expression on leukocytes and on endothelial cells and decrease intercellular adhesive interactions.

Omega-3 (or n-3) polyunsaturated fatty acids (PUFAs) and their metabolites are natural ligands for peroxisome proliferator-activated receptor (PPAR) gamma that regulates inflammatory gene expression and NFκB activation. PPAR alpha activation is also associated with induction of COX-2 expression. 

The role of EPA and DHA in reducing triglyceride levels include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal-beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. They also may reduce triglyceride synthesis because they are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids. ', 'Omega-3 fatty acids are triglycerides that get broken down into smaller fatty acid units. They act to reduce plasma triglyceride levels however increase the cholesterol levels and are thought to possess potent antiarrythmic effects. Polyunsaturated fatty acids including eicosapentaenoic and docosahexaenoic acid mediate important cellular function such as inhibition of platelet function, prolongation of bleeding time, anti-inflammatory effects and reduction of plasma fibrinogen. Polyunsaturated fatty acids are components of the phospholipids that form the structures of the cell membranes and also serve as energy source. They form eicosanoids which are important signalling molecules with wide-ranging functions in the body''s cardiovascular, pulmonary, immune and endocrine systems. DHA tends to exist in high concentrations in the retina, brain (via uptake by Mfsd2a as a transporter), and sperm.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26919, 'Shoma cream 60 gm', 'شوما كريم 60 جرام', '130', '80', 'Moisturizing topicals', 'Glycerin+paraffin oil+salicylic acid+lactic acid+panthenol+urea+bees wax', 'Al helou for perfume & cosmetics > safe life', 'Cream', 'كريم', '60 gm', '1', 'تفتيح الأماكن الداكنة مثل الكوع والركبة.', 'cream for cracked heels', NULL, NULL, 8578, '2024-05-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26920, 'Shorsalin 150 mg 30 f.c. tabs.', 'شورسالين 150مجم 30 قرص', '35', NULL, 'Anti-epileptic.carboxamides', 'Oxcarbazepine', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '150 mg', '3', 'يقلل من النبضات العصبية التي تسبب النوبات والألم. يستخدم لعلاج أنواع معينة من النوبات في مرضى الصرع.', 'about oxcarbazepine carboxamide derivative iminostilbenes anticonvulsant mood stabilizing agent. mechanism of action of oxcarbazepine oxcarbazepine prolongs the inactivated state of voltage sensitive neuronal sodium ion channel either by increasing the ef', '6223002142798', NULL, 1154, '2022-07-18', 0, 'In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.[L8627] 



In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]', 'The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]



Increased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine''s activity[A34516], but this effect could not be replicated _in vivo_.[A186104]', 'Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsy by inhibiting abnormal electrical activity in the brain.[L8627,L8630,L8633]



There have been rare reports of oxcarbazepine resulting in the development of hematologic abnormalities, including agranulocytosis and aplastic anemia. Patients should be undergo frequent laboratory testing and should be monitored closely for signs and symptoms of blood dyscrasias. Oxcarbazepine has also been associated with the development of dermatologic reactions which can progress from a simple rash to potentially fatal reactions such as toxic epidermal necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). Patients with the HLA-A 3101 and/or HLA-B 1502 alleles may be at higher risk of this reaction. Oxcarbazepine should be discontinued at the first sign of a drug-induced skin reaction.[L8627,L8630,L8633]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26921, 'Shorsalin 300mg 30 f.c.tab', 'شورسالين 300مجم 30 قرص', '56', NULL, 'Anti-epileptic.carboxamides', 'Oxcarbazepine', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '300mg', '3', NULL, NULL, NULL, NULL, 1427, '2022-07-18', 0, 'In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.[L8627] 



In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]', 'The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]



Increased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine''s activity[A34516], but this effect could not be replicated _in vivo_.[A186104]', 'Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsy by inhibiting abnormal electrical activity in the brain.[L8627,L8630,L8633]



There have been rare reports of oxcarbazepine resulting in the development of hematologic abnormalities, including agranulocytosis and aplastic anemia. Patients should be undergo frequent laboratory testing and should be monitored closely for signs and symptoms of blood dyscrasias. Oxcarbazepine has also been associated with the development of dermatologic reactions which can progress from a simple rash to potentially fatal reactions such as toxic epidermal necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). Patients with the HLA-A 3101 and/or HLA-B 1502 alleles may be at higher risk of this reaction. Oxcarbazepine should be discontinued at the first sign of a drug-induced skin reaction.[L8627,L8630,L8633]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26922, 'Shorsalin 600 mg 30 f.c. tabs.', 'شورسالين 600مجم 30 قرص', '92', NULL, 'Anti-epileptic.carboxamides', 'Oxcarbazepine', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '600 mg', '3', NULL, 'about oxcarbazepine carboxamide derivative iminostilbenes anticonvulsant mood stabilizing agent. mechanism of action of oxcarbazepine oxcarbazepine prolongs the inactivated state of voltage sensitive neuronal sodium ion channel either by increasing the ef', NULL, NULL, 1540, '2022-07-18', 0, 'In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.[L8627] 



In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]', 'The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]



Increased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine''s activity[A34516], but this effect could not be replicated _in vivo_.[A186104]', 'Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsy by inhibiting abnormal electrical activity in the brain.[L8627,L8630,L8633]



There have been rare reports of oxcarbazepine resulting in the development of hematologic abnormalities, including agranulocytosis and aplastic anemia. Patients should be undergo frequent laboratory testing and should be monitored closely for signs and symptoms of blood dyscrasias. Oxcarbazepine has also been associated with the development of dermatologic reactions which can progress from a simple rash to potentially fatal reactions such as toxic epidermal necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). Patients with the HLA-A 3101 and/or HLA-B 1502 alleles may be at higher risk of this reaction. Oxcarbazepine should be discontinued at the first sign of a drug-induced skin reaction.[L8627,L8630,L8633]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26923, 'Siboline hair shampoo 60 ml', 'سيبولاين شامبو للشعر 60 مل', '24', '8', 'Anti-lice', NULL, 'Mash premiere', 'Amp', 'أمبول', '60 ml', '1', NULL, NULL, NULL, NULL, 662, '2024-02-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26924, 'Sideral active 15 orodispersible sticks', 'سيدرال اكتيف 15 ستيكس', '150', '120', 'Multivitamins', 'Iron+vitamin c+vitamin b6+folic acid+vitamin b12', '> al esraa pharmaceutical optima', 'Unknown', 'غير محدد', NULL, '1', 'فيتامينات متعددة+حديد', 'iron ... 14 mg vitamin c ... 48 mg vitamin b6 ... 1 mg folic acid ... 150 mg vitamin b12 ... 2 mg method of administration: - one sachet a day the contents of which dissolve directly in the mouth.', '6224011605045', NULL, 8021, '2025-07-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26925, 'Sienta shampoo 100 ml', 'سيانتا شامبو 100 مل', '35', NULL, 'Hair care', 'Piroctone olamine+cetarol+cetrimonium chloride+citric acid+coconut+aloe vera gel+d-panthenol+laurel', 'Egpi > egd', 'Amp', 'أمبول', '100 ml', '1', NULL, 'composition: piroctone olamine+cetarol+cetrimonium chloride+citric acid+coconut+aloe vera gel+d-panthenol+laurel ether+propylene glycol anti-dandruff shampoo', NULL, NULL, 374, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26926, 'Sienta shampoo 200 ml', 'سيانتا شامبو 200 مل', '60', NULL, 'Hair care', 'Piroctone olamine+cetarol+cetrimonium chloride+citric acid+coconut+aloe vera gel+d-panthenol+laurel', 'Egpi > egd', 'Amp', 'أمبول', '200 ml', '1', NULL, 'composition: piroctone olamine+cetarol+cetrimonium chloride+citric acid+coconut+aloe vera gel+d-panthenol+laurel ether+propylene glycol anti-dandruff shampoo', NULL, NULL, 408, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26927, 'Siesta 10mg 14 caps.', 'سيستا 10مجم 14 كبسولة', '12', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Zaleplon', 'Sigma > andalous pharma', 'Cap', 'كبسولة', '10mg', '1', NULL, 'about zaleplon pyrazolopyrimidine derivative( a nonbenzodiazepine sedative-hypnotic. mechanism of action of zaleplon zaleplon is a non benzodiazepine sedative-hypnotic drug. it binds to the benzodiazepine binding site on gaba-a receptors containing the al', '6224000396022', NULL, 925, '2023-05-04', 0, 'For the treatment of short-term treatment of insomnia in adults.', 'Zaleplon exerts its action through subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.', 'Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABA<sub>A</sub>-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26928, 'Sifrol 0.18mg 30 tab.', 'سيفرول 0.18مجم 30 اقراص', '150', NULL, 'Parkinson s disease.dopamine agonist', 'Pramipexol', 'Boehringer ingelheim', 'Tab', 'أقراص', '0.18mg', '3', 'لمرضى الباركنسون والشلل الرعاش', 'about pramipexole a nonergot dopamine agonist antiparkinsonism. mechanism of action of pramipexole pramipexole is a non-ergot dopamine agonist. it stimulates dopamine receptor in the striatum. it binds with high affinity to d3 receptors than d2 or d4 rece', '4048846000583', NULL, 1246, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26929, 'Sifrol 0.7mg 30 tab', 'سيفرول 0.7مجم 30 قرص', '645', NULL, 'Parkinson s disease.dopamine agonist', 'Pramipexol', 'Boehringer ingelheim', 'Tab', 'أقراص', '0.7mg', '3', 'لمرضى الباركنسون والشلل الرعاش', NULL, NULL, NULL, 1827, '2022-02-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26931, 'Sigdutaster 0.5mg 10 capsule', 'سيجدوتاستر 0.5مجم 10 كبسولات', '28', NULL, '8 alpha-reductase inhibitor', 'Dutasteride', 'Sigma', 'Capsule', 'كبسولة', '0.5mg', '1', NULL, 'about dutasteride a 5-alpha-reductase inhibitor in benign prostatic hyperplasia(bph) male baldness. mechanism of action of dutasteride this is a selective inhibitor of both type 1 and type 2 isoforms of steroid 5alpha-reductase (an intracellular enzyme th', NULL, NULL, 1092, '2022-07-07', 0, 'Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].[L10568]', 'The 5α-reductase is a nuclear-bound steroid intracellular enzyme primarily located in the prostatic stromal cell that converts the androgen testosterone into the more active metabolite, 5α-dihydrotestosterone (DHT).[A2132] DHT is considered to be the primary androgen playing a role in the initial development and subsequent enlargement of the prostate gland. It serves as the hormonal mediator for the hyperplasia upon accumulation within the prostate gland.[A178270] DHT displays a higher affinity towards androgen receptors in the prostate gland compared to testosterone[T28] and by acting on the androgen receptors, DHT modulates genes that are responsible for cell proliferation.[A178279] Responsible for the synthesis of approximately one-third of circulating DHT, type I 5α-reductase is predominant in the sebaceous glands of most regions of skin, including the scalp, and liver. The type II 5a-reductase isozyme is primarily found in the prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.[L10568] Due to its dual inhibition of both isoenzymes of 5α-reductase, dutasteride causes a near-complete suppression of DHT.[A178348] Compared to a 70% reduction of serum DHT levels caused by [finasteride], a near-complete suppression of serum DHT-more than 90% is seen with dutasteride.[A178378]



By forming a stable complex with both type II and type II 5α-reductase, dutasteride inhibits its enzymatic action of converting testosterone to 5α-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. It is proposed that DHT is the principal androgen responsible for prostatic growth in later life-normal masculinization of the external genitalia and maturation of the prostate gland during development-thus reducing the serum DHT levels results in reduced prostatic volume and increased epithelial apoptosis.[A178375] Dutasteride is a competitive and specific inhibitor of both Type I and Type II 5α-reductase isoenzymes and when evaluated under _in vitro_ and _in vivo_ conditions, the dissociation of the drug from the drug-enzyme complex is reported to be extremely slow.[L10568] Dutasteride does not bind to the human androgen receptor.[L10568]', 'Dutasteride is a synthetic 4-azasteroid compound that selectively inhibits both the type I and type II isoforms of steroid 5α-reductase, an intracellular enzyme that converts testosterone to 5α-dihydrotestosterone (DHT). Dutasteride works by reducing the levels of circulating DHT. It was also shown to reduce the size of the prostate gland, improve urinary flow, and symptoms of benign prostatic hyperplasia alone or in combination with tamsulosin.[L6256] The effect of the reduction of DHT by dutasteride is dose-dependent, with the maximum effect observed within 1-2 weeks following initial administration.[L10568] 



After 1 and 2 weeks of daily dosing with dutasteride 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively.[L10568] The serum concentrations of DHT were maintained to be decreased by more than 90% in 85% of patients following 1 years'' administration of oral dutasteride 0.5 mg/day.[A178345] As evident from the clinical studies, dutasteride may also cause decreases in serum PSA in the presence of prostate cancer.[L10568] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26933, 'Sigmacyn 1500mg vial i.m. i.v.', 'سيجماسين 1500مجم فيال', '17', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Ampicillin+sulbactam', 'Sigma', 'Vial', 'فيال', '1500mg', '1', NULL, 'other indications & uses beta-lactamase-producing: s. aureus e. coli klebsiella spp p. mirabilis bacteroides fragilis enterobacter spp acinetobacter calcoaceticus systemic adverse reactions systemic reactions reported in less than 1% of the patients were:', NULL, NULL, 763, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26934, 'Sigmacyn 250mg/5ml susp. 60ml', 'سيجماسين 250مجم/5مل شراب معلق 60مل', '38', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Ampicillin+sulbactam', 'Sigma', 'Susp', 'معلق', '250mg', '1', NULL, NULL, '6221172002263', NULL, 837, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26936, 'Sigmacyn 750mg vial i.m. i.v.', 'سيجماسين 750مجم فيال', '12', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Ampicillin+sulbactam', 'Sigma', 'Vial', 'فيال', '750mg', '1', NULL, 'other indications & uses beta-lactamase-producing: s. aureus e. coli klebsiella spp p. mirabilis bacteroides fragilis enterobacter spp acinetobacter calcoaceticus systemic adverse reactions systemic reactions reported in less than 1% of the patients were:', NULL, NULL, 860, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26939, 'Sigmagrel 75mg 20 f.c. tab', 'سيجماجريل 75مجم 20 قرص', '60', NULL, 'Antiplatelet.adp receptor blocker', 'Clopidogrel', 'Sigma', 'Tab', 'أقراص', '75mg', '2', 'مضاد للتجلط -- الحفاظ علي صحة القلب -- علاج الجلطات التي تتكون في الجسم -- الحفاظ علي سيولة الدورة الدموية', NULL, '6221051012079', NULL, 857, '2022-12-08', 0, 'Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]', 'Clopidogrel is activated via a 2 steps reaction to an active thiol-containing metabolite.[A180508] This active form is a platelet inhibitor that irreversibly binds to P2Y<sub>12</sub> ADP receptors on platelets.[L7213] This binding prevents ADP binding to P2Y<sub>12</sub> receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation.[L7213]', 'Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] It has a long duration of action as it is taken once daily and a large therapeutic window as it is given in doses of 75-300mg daily.[L7213]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26940, 'Sigmalip 20 mg 10 f.c.tab.', 'سيجماليب 20مجم 10 اقراص', '24', NULL, 'Antihyperlipidemic.statins', 'Atorvastatin', 'Sigma', 'Tab', 'أقراص', '20 mg', '1', NULL, 'description : is a member of the drug class known as statins. dose: adult po- initial- the recommended dose is 10 mg daily. maximum: 80 mg/day. indication : may be used as primary prevention in individuals with multiple risk factors for coronary heart dis', '6221051013458', NULL, 1003, '2022-12-08', 0, 'Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]



Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] 



Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]



Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]



Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). 



_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]', 'Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925] 



Elevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.[A181087] Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.[A177415] In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.[A177397] It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.[A177388]



**Myopathy/Rhabdomyolysis**



Atorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (> 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.[F4670,F4673]



**Endocrine Effects**



Statins are associated with a risk of increased serum HbA1c and glucose levels. An _in vitro_ study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet β cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.[F4673]



**Cardiovascular**



Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4673]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.[F4673] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26941, 'Sigmalip 40mg 10 f.c.tab.', 'سيجماليب 40مجم 10 اقراص', '32', NULL, 'Antihyperlipidemic.statins', 'Atorvastatin', 'Sigma', 'Tab', 'أقراص', '40mg', '1', NULL, 'description : is a member of the drug class known as statins. dose: adult po- initial- the recommended dose is 10 mg daily. maximum: 80 mg/day. indication : may be used as primary prevention in individuals with multiple risk factors for coronary heart dis', NULL, NULL, 720, '2022-07-17', 0, 'Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]



Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] 



Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]



Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]



Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). 



_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]', 'Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925] 



Elevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.[A181087] Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.[A177415] In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.[A177397] It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.[A177388]



**Myopathy/Rhabdomyolysis**



Atorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (> 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.[F4670,F4673]



**Endocrine Effects**



Statins are associated with a risk of increased serum HbA1c and glucose levels. An _in vitro_ study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet β cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.[F4673]



**Cardiovascular**



Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4673]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.[F4673] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26942, 'Sigmaprofen 0.03% ophth. soln. 5 ml', 'سيجمابروفين 0.03% قطرة للعين 5مل', '12', NULL, 'Nsaid.propionic acid derivatives', 'Flurbiprofen', 'Sigma tec', 'Sol', 'محلول', '0.03%', '1', NULL, NULL, '6221172002034', NULL, 978, '2022-07-26', 0, 'Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis. ', 'Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.', 'Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26943, 'Sigmastinal 20mg/ml 1 amp.', 'سيجماستينال 20مجم/مل 1 امبول', '3', NULL, 'Antispasmodic', 'Hyoscin-n-butylbromid', 'Sigma tec', 'Amp', 'أمبول', '20mg', '1', NULL, 'hyoscine-n-butylbromide is an antispasmodic drug used to treat conditions associated with spasms of the gastrointestinal tract such as cramping. how does it work? this medication relieves gastrointestinal cramping by relieving smooth muscle contractions.', NULL, NULL, 767, '2022-07-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26945, 'Digest 365 daily use 30 caps. (adrien gagnon)', 'دايجست 365 مستخدم يومي 30 كبسولة', '690', '590', 'Digestive enzymes', 'Vegetable digestive enzyme complex (digezyme)', 'Egypharma', 'Cap', 'كبسولة', NULL, '3', NULL, NULL, NULL, NULL, 1501, '2024-07-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26948, 'Signifor 0.3mg/ml 30 amp.', 'سيجنيفور 0.3مجم/مل 30 امبول', '13,938', NULL, 'Hypothalmic hormones.somatostatin analogues', 'Pasireotide', 'Novartis > novartis scientific office', 'Amp', 'أمبول', '0.3mg', '30', NULL, 'indication for the treatment of cushingï-s disease specifically for those patients whom pituitary surgery has not been curative or is not an option. mechanism of action pasireotide activates a broad spectrum of somatostatin receptors exhbiting a much high', NULL, NULL, 824, '2022-08-04', 0, 'For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.', 'Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing''s disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. ', 'Signifor® is an analogue of somatostatin that promotes  reduced levels of cortisol secretion in Cushing''s disease patients.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26949, 'Signifor 0.6mg/ml 30 amp.', 'سيجنيفور 0.6مجم/مل 30 امبول', '16,215', NULL, 'Hypothalmic hormones.somatostatin analogues', 'Pasireotide', 'Novartis > novartis scientific office', 'Amp', 'أمبول', '0.6mg', '30', NULL, 'indication for the treatment of cushingï-s disease specifically for those patients whom pituitary surgery has not been curative or is not an option. mechanism of action pasireotide activates a broad spectrum of somatostatin receptors exhbiting a much high', NULL, NULL, 897, '2022-07-24', 0, 'For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.', 'Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing''s disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. ', 'Signifor® is an analogue of somatostatin that promotes  reduced levels of cortisol secretion in Cushing''s disease patients.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26950, 'Signifor 0.9mg/ml 30 amp.', 'سيجنيفور 0.9مجم/مل 30 امبول', '18,699', NULL, 'Hypothalmic hormones.somatostatin analogues', 'Pasireotide', 'Novartis > novartis scientific office', 'Amp', 'أمبول', '0.9mg', '30', NULL, 'indication for the treatment of cushingï-s disease specifically for those patients whom pituitary surgery has not been curative or is not an option. mechanism of action pasireotide activates a broad spectrum of somatostatin receptors exhbiting a much high', NULL, NULL, 700, '2022-07-25', 0, 'For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.', 'Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing''s disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. ', 'Signifor® is an analogue of somatostatin that promotes  reduced levels of cortisol secretion in Cushing''s disease patients.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26951, 'Sigotryl 0.5mg 10 tab.', 'سيجوتريل 0.5مجم 10 اقراص', '2', NULL, 'Anti-epileptic.benzodiazepines', 'Clonazepam', 'Sigma', 'Tab', 'أقراص', '0.5mg', '1', NULL, 'about clonazepam benzodiazepine derivative anticonvulsant antipanic muscle relaxant. mechanism of action of clonazepam clonazepam binds to the bzd receptor in the cns. the binding will facilitate gaba mediated chloride channel opening and produce hyperpol', NULL, NULL, 789, '2022-07-17', 0, 'Clonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures.[FDA Label][F3787] Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides.[FDA Label][F3787] Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V.[FDA Label]



Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements.[L5572,F3796] Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy.[F3796]                                                                                                                                                                 ', 'Gamma-Aminobutyric acid (GABA) is considered the principal inhibitory neurotransmitter in the human body [A175423, A175438, A175441]. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors [A175423, A175438, A175441, F3787]. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons [A175423, A175438, A175441, F3787]. 



Subsequently, benzodiazepines like clonazepam can bind to benzodiazepine receptors that are components of various varieties of GABA(a) receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This binding acts to enhance the effects of GABA by increasing GABA affinity for the GABA(a) receptor, which ultimately enhances GABA ligand binding at the receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This enhanced ligand binding of the inhibitory neurotransmitter GABA to the receptors increases the aforementioned chloride ion conduction (perhaps reportedly via an increase in the frequency of the chloride channel opening), resulting in a hyperpolarized cell membrane that prevents further excitation of the associated neuron cells [A175423, A175438, A175441, F3787, L5572, F3763]. Combined with the notion that such benzodiazepine receptor associated GABA(a) receptors exist both peripherally and in the CNS, this activity consequently facilitates various effects like sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175423, A175438, A175441, F3787, L5572, F3763].



In particular, when out of the ordinary rapid and repetitive electrical signals are released in the CNS, it is proposed that the brain can become over-stimulated and ordinary functions are disrupted - resulting in seizure activity [A175441]. By enhancing the neuro-inhibitory activity of GABA, it is believed that clonazepam can facilitate in decreasing any excessive electrical nerve activity in the CNS that might be contributing to seizures [A175441]. Concurrently, it is also believed that clonazepam''s actions in enhancing GABA effects may inhibit neuronal activity proposed to occur in amygdala-centered fear circuits - therefore assisting in the management of anxiety or panic [A175438].', 'The pharmacodynamic properties of clonazepam are common among benzodiazepines and include anticonvulsive, sedative, muscle relaxing and anxiolytic effects [A175423, L5572, F3763, F3787]. Animal data and electroencephalographic investigations in man have shown that clonazepam rapidly suppresses many types of paroxysmal activity including the spike and wave discharge in absence seizures (petit mal), slow spike wave, generalized spike wave, spikes with temporal or other locations, as well as irregular spikes and waves [FDA Label] [A175423, L5572, F3763, F3787]. Moreover, the agent can also decrease the frequency, amplitude, duration, and spread of discharge in minor motor seizures [FDA Label] [F3763].



Generalized EEG abnormalities are more readily suppressed by clonazepam than are focal EEG abnormalities such as focal spikes [L5572]. Clonazepam has beneficial effects in generalized and focal epilepsies [L5572].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26952, 'Sigotryl 2mg 10 tab.', 'سيجوتريل 2مجم 10 اقراص', '3', NULL, 'Anti-epileptic.benzodiazepines', 'Clonazepam', 'Sigma', 'Tab', 'أقراص', '2mg', '1', NULL, 'about clonazepam benzodiazepine derivative anticonvulsant antipanic muscle relaxant. mechanism of action of clonazepam clonazepam binds to the bzd receptor in the cns. the binding will facilitate gaba mediated chloride channel opening and produce hyperpol', NULL, NULL, 785, '2022-07-12', 0, 'Clonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures.[FDA Label][F3787] Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides.[FDA Label][F3787] Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V.[FDA Label]



Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements.[L5572,F3796] Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy.[F3796]                                                                                                                                                                 ', 'Gamma-Aminobutyric acid (GABA) is considered the principal inhibitory neurotransmitter in the human body [A175423, A175438, A175441]. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors [A175423, A175438, A175441, F3787]. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons [A175423, A175438, A175441, F3787]. 



Subsequently, benzodiazepines like clonazepam can bind to benzodiazepine receptors that are components of various varieties of GABA(a) receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This binding acts to enhance the effects of GABA by increasing GABA affinity for the GABA(a) receptor, which ultimately enhances GABA ligand binding at the receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This enhanced ligand binding of the inhibitory neurotransmitter GABA to the receptors increases the aforementioned chloride ion conduction (perhaps reportedly via an increase in the frequency of the chloride channel opening), resulting in a hyperpolarized cell membrane that prevents further excitation of the associated neuron cells [A175423, A175438, A175441, F3787, L5572, F3763]. Combined with the notion that such benzodiazepine receptor associated GABA(a) receptors exist both peripherally and in the CNS, this activity consequently facilitates various effects like sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175423, A175438, A175441, F3787, L5572, F3763].



In particular, when out of the ordinary rapid and repetitive electrical signals are released in the CNS, it is proposed that the brain can become over-stimulated and ordinary functions are disrupted - resulting in seizure activity [A175441]. By enhancing the neuro-inhibitory activity of GABA, it is believed that clonazepam can facilitate in decreasing any excessive electrical nerve activity in the CNS that might be contributing to seizures [A175441]. Concurrently, it is also believed that clonazepam''s actions in enhancing GABA effects may inhibit neuronal activity proposed to occur in amygdala-centered fear circuits - therefore assisting in the management of anxiety or panic [A175438].', 'The pharmacodynamic properties of clonazepam are common among benzodiazepines and include anticonvulsive, sedative, muscle relaxing and anxiolytic effects [A175423, L5572, F3763, F3787]. Animal data and electroencephalographic investigations in man have shown that clonazepam rapidly suppresses many types of paroxysmal activity including the spike and wave discharge in absence seizures (petit mal), slow spike wave, generalized spike wave, spikes with temporal or other locations, as well as irregular spikes and waves [FDA Label] [A175423, L5572, F3763, F3787]. Moreover, the agent can also decrease the frequency, amplitude, duration, and spread of discharge in minor motor seizures [FDA Label] [F3763].



Generalized EEG abnormalities are more readily suppressed by clonazepam than are focal EEG abnormalities such as focal spikes [L5572]. Clonazepam has beneficial effects in generalized and focal epilepsies [L5572].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26953, 'Sikoor viscous vaginal sol. 240 ml', 'سيكور فيسكوس غسول مهبلي 240 مل', '58', '55', 'Vaginal wash', 'Menthol+panthenol+tea tree oil+chamomile+stearic acid+chlorhexidine', 'Egyptian company for cosmetics > santex pharma', 'Sol', 'محلول', '240 ml', '1', NULL, 'indications: vaginal infection & inflammation cooling & refreshing sensation bad odour', NULL, NULL, 922, '2024-02-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26957, 'Silden 100 mg 4 f.c. tabs', 'سيلدين 100مجم 4 اقراص', '33', '23', 'Tonic for men', 'Sildenafil', 'Eipico', 'Tab', 'أقراص', '100 mg', '4', 'مقوي للرجال', NULL, NULL, NULL, 11852, '2024-10-16', 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26959, 'Silden 50 mg 4 f.c. tabs.', 'سيلدين 50مجم 4 اقراص', '22', '15', 'Tonic for men', 'Sildenafil', 'Eipico', 'Tab', 'أقراص', '50 mg', '4', NULL, 'about sildenafil citrate phosphodiesterase-5 enzyme inhibitor anti-erectile dysfunction agent. mechanism of action of sildenafil citrate sildenafil is a phosphodiesterase enzyme (pde5) inhibitor. this enzyme is responsible for the degradation cyclic guano', '6221032118875', NULL, 2826, '2024-12-06', 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26960, 'Silderm dual action scar gel 15 gm', 'سيلدرم تأثير مزدوج سكار جل 15 جرام', '920', NULL, 'Scar therapy', NULL, 'Silderm ltd. > p.r.t.', 'Gel', 'جل', '15 gm', '1', '* لعلاج ندبات الجلد', 'all the silderm scar range will start to reduce the redness of the scar and flatten the scar within two weeks but for best results continue to use for 90 days. the larger the scar or the older the scar the longer it will take so keep using silderm until y', NULL, NULL, 2797, '2023-02-05', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26961, 'Silderm scar spray 30 ml', 'سيلديرم سكار سبراي 30 مل', '880', NULL, 'Scar therapy', NULL, 'Silderm ltd. > p.r.t.', 'Spray', 'بخاخ', '30 ml', '1', 'علاج الندبات والجلد الزائد -- علاج الحروق -- توحيد لون الجلد', 'all the silderm scar range will start to reduce the redness of the scar and flatten the scar within two weeks but for best results continue to use for 90 days. the larger the scar or the older the scar the longer it will take so keep using silderm until y', NULL, NULL, 1439, '2022-10-05', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26962, 'Sildinax 100 mg 3 f.c. tabs', 'سيلديناكس 100مجم 3 اقراص', '8', NULL, 'Tonic for men', 'Sildenafil', 'Al esraa pharmaceutical optima', 'Tab', 'أقراص', '100 mg', '1', 'علاج مرض إرتفاع ضغط الدم الرئوى — مقوي للرجال', NULL, NULL, NULL, 1980, '2022-06-02', 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26963, 'Sildinova 10mg pd. for susp. 120 ml', 'سيلدينوفا 10مجم معلق شراب 120 مل', '79', NULL, 'Tonic for men', 'Sildenafil', 'International drug agency (idi)', 'Susp', 'معلق', '10mg', '1', 'علاج مرض إرتفاع ضغط الدم الرئوى', NULL, NULL, NULL, 1131, '2022-10-05', 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26964, 'Sildocare 4mg 20 caps.', 'سيلدوكير 4مجم 20 كبسولة', '54', NULL, 'Urination-difficulty.alpha blocker', 'Silodosin', 'Andalous pharma', 'Cap', 'كبسولة', '4mg', '2', 'علاج إحتباس البول الناتج عن تضخم البروستاتا', NULL, NULL, NULL, 1468, '2022-11-11', 0, 'Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.[L32368]', 'The pathogenesis of benign prostatic hyperplasia is not fully understood: it is believed to involve several pathways, including inflammation, apoptosis, and cellular proliferation. Most drug therapies aim to alleviate symptoms of benign prostatic hyperplasia, silodosin included. Lower urinary tract symptoms of benign prostatic hyperplasia are categorized into three main groups: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Prostate contraction is the main contributor to lower urinary tract symptoms of benign prostatic hyperplasia. The smooth muscle tone of the prostate is regulated by α<sub>1A</sub>-adrenoceptors, which are the most highly expressed subtype of α<sub>1</sub>adrenoceptors in the human prostate tissue.[A231159] It has been reported that blockade of α<sub>1A</sub>-adrenoceptors relieves bladder outlet obstruction. Blockade of α<sub>1D</sub>-adrenoceptors, another subtype found in prostate tissue, is believed to alleviate storage symptoms due to detrusor overactivity.[A231229]



α<sub>1</sub>-adrenoceptors are G protein-coupled receptors: upon binding of its natural ligand, norepinephrine and epinephrine, leads to the activation of phospholipase C and downstream signalling molecules, including inositol triphosphate and diacylglycerol. Ultimately, there is an increase in intracellular calcium levels and, consequently, smooth muscle contraction. Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors, with the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype. By blocking the α<sub>1A</sub>-adrenoceptor signalling pathway, silodosin promotes prostatic and urethral smooth muscle relaxation, thereby improving lower urinary tract symptoms such as voiding. Silodosin also targets afferent nerves in the bladder, relieving bladder overactivity and storage symptoms.[A231159]', 'Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors. It has the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype, with a 162-fold greater affinity than α<sub>1B</sub>-adrenoceptor and about a 50-fold greater affinity than for α<sub>1D</sub>-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia.[A231159, A231174] Following oral administration, silodosin had a rapid onset of effect in men,[A231174] with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose.[A231229]



Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects.[A231199] As with all α<sub>1</sub>-adrenoceptor antagonists blocking α<sub>1</sub>-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking α1-AR antagonists.[A231229]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26965, 'Sildocare 8 mg 20 caps', 'سيلدوكير 8مجم 20 كبسولة', '118', '90', 'Urination-difficulty.alpha blocker', 'Silodosin', 'Andalous pharma', 'Cap', 'كبسولة', '8 mg', '2', 'علاج إحتباس البول الناتج عن تضخم البروستاتا', NULL, '6223004690174', NULL, 6382, '2025-09-12', 0, 'Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.[L32368]', 'The pathogenesis of benign prostatic hyperplasia is not fully understood: it is believed to involve several pathways, including inflammation, apoptosis, and cellular proliferation. Most drug therapies aim to alleviate symptoms of benign prostatic hyperplasia, silodosin included. Lower urinary tract symptoms of benign prostatic hyperplasia are categorized into three main groups: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Prostate contraction is the main contributor to lower urinary tract symptoms of benign prostatic hyperplasia. The smooth muscle tone of the prostate is regulated by α<sub>1A</sub>-adrenoceptors, which are the most highly expressed subtype of α<sub>1</sub>adrenoceptors in the human prostate tissue.[A231159] It has been reported that blockade of α<sub>1A</sub>-adrenoceptors relieves bladder outlet obstruction. Blockade of α<sub>1D</sub>-adrenoceptors, another subtype found in prostate tissue, is believed to alleviate storage symptoms due to detrusor overactivity.[A231229]



α<sub>1</sub>-adrenoceptors are G protein-coupled receptors: upon binding of its natural ligand, norepinephrine and epinephrine, leads to the activation of phospholipase C and downstream signalling molecules, including inositol triphosphate and diacylglycerol. Ultimately, there is an increase in intracellular calcium levels and, consequently, smooth muscle contraction. Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors, with the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype. By blocking the α<sub>1A</sub>-adrenoceptor signalling pathway, silodosin promotes prostatic and urethral smooth muscle relaxation, thereby improving lower urinary tract symptoms such as voiding. Silodosin also targets afferent nerves in the bladder, relieving bladder overactivity and storage symptoms.[A231159]', 'Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors. It has the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype, with a 162-fold greater affinity than α<sub>1B</sub>-adrenoceptor and about a 50-fold greater affinity than for α<sub>1D</sub>-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia.[A231159, A231174] Following oral administration, silodosin had a rapid onset of effect in men,[A231174] with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose.[A231229]



Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects.[A231199] As with all α<sub>1</sub>-adrenoceptor antagonists blocking α<sub>1</sub>-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking α1-AR antagonists.[A231229]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26967, 'Silimar 140mg 30 tabs', 'سيليمار 140مجم 30 قرص', '18', NULL, 'Hepatoprotective', 'Silymarin', 'El-obour', 'Tab', 'أقراص', '140mg', '3', 'نوع من أنواع الفيتامينات التي تساعد علي حماية الكبد من الفيروسات والميكروبات __ يعمل علي تحسين وظائف الكبد', NULL, NULL, NULL, 3332, '2022-04-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26968, 'Mo true 200 gm 10sachets', 'مو ترو 200 جم 10 اكياس', '100', NULL, 'Food supplement', 'Wheyprotein+vitamins', 'Bms pharma', 'Sachet', 'أكياس', '200 gm', '1', NULL, NULL, '6224009418367', NULL, 704, '2022-10-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26969, 'Silisab silicon gel 20 gm', 'سيليساب جل سيلكون 20 جم', '660', '560', 'Scar therapy', 'Cyclopentasiloxane+cyclomethicone+onion ext.+vitamin e+olive oil', 'Lana for toothpaste and cosmetics > sabshire pharmaceuticals', 'Gel', 'جل', '20 gm', '1', 'علاج الندبات و اثارها -- ترطيب الجلد وتنعيمه -- علاج اثار الشمس والحروق', 'flattens and softens raised scars.', '6224009836062', NULL, 5016, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26970, 'Silistarkish 2.5mg/5ml syp. 120 ml', 'سيليستاركش 2.5مجم/5مل شراب 120مل', '8', NULL, 'Antihistamine.antiallergy', 'Desloratadine', 'Alpac > egpi', 'Unknown', 'غير محدد', '2.5mg', '1', NULL, 'about desloratadine second generation long-acting tricyclic h1 antagonist antihistamine. mechanism of action of desloratadine this second generation antihistamine has a selective peripheral h1-antagonist action.desloratadine competes with free histamine f', NULL, NULL, 753, '2022-07-16', 0, 'For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.', 'Like other H1-blockers, Desloratadine competes with free histamine for binding at H<sub>1</sub>-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.', 'Desloratadine is a long-acting second-generation H<sub>1</sub>-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26971, 'Silistarkish 5 mg 20 f.c. tabs.', 'سيليستاركش 5مجم 20 اقراص', '9', NULL, 'Antihistamine.antiallergy', 'Desloratadine', 'Alpac > egpi', 'Tab', 'أقراص', '5 mg', '2', NULL, NULL, NULL, NULL, 1064, '2022-07-15', 0, 'For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.', 'Like other H1-blockers, Desloratadine competes with free histamine for binding at H<sub>1</sub>-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.', 'Desloratadine is a long-acting second-generation H<sub>1</sub>-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26972, 'Silkren hair cream gel 120 ml', 'سيكرين كريم جل 120مل', '85', NULL, 'Hair care', 'Zinc pyrithione+coconut oil+salicylic acid+sulphur+lanolin+vitamin d', 'Hi-care > pixel pharmaceutical company', 'Cream', 'كريم', '120 ml', '1', NULL, '*uses: -hair dandruff -hair loss -brittle dry breakage and split ends of hair -stressed hair -protection from sea water', NULL, NULL, 2028, '2022-07-14', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26973, 'Silkren shampoo 250 ml', 'سيلكرين شامبو 250مل', '150', '90', 'Hair care', 'Selenium sulphide+panthenol+vitamin (a+e)+aloe vera+thyme+salicylic acid', 'Hi-care > pixel pharmaceutical company', 'Amp', 'أمبول', '250 ml', '1', NULL, NULL, '6224000201777', NULL, 2271, '2024-05-31', 0, 'For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.', 'Topical selenium sulfide may act by an antimitotic action, resulting in a reduction in the turnover of epidermal cells. It also has local irritant, antibacterial, and mild antifungal activity, which may contribute to its effectiveness. An antimitotic mechanism of action is suggested by data showing that selenium sulfide decreases the rate of incorporation of radioactively labeled thymidine into the DNA of dermal epithelial cells. The following organisms are generally considered susceptible to selenium sulfide in vitro: <i>Malassezia furfur</i>, <i>Microsporum sp.</i> including <i>Microsporum audouinii</i> and <i>Microsporum canis</i>, <i>Pityrosporon sp.</i>, <i>Trichophyton sp.</i> including <i>Trichophyton schoenleinii</i> and <i>Trichophyton tonsurans</i>. Selenium sulfide has been shown to be sporicidal to <i>T. tonsurans</i>, the most common etiologic agent of tinea capitis. One in-vitro study demonstrated that 2.5% selenium sulfide was equivalent in sporicidal activity to both 1% and 2% zinc pyrithione.', 'Selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis. Selenium sulfide is highly active in inhibiting the growth of <i>P. ovale</i>. It is also a proven cytostatic agent, slowing the growth of both hyperproliferative and normal cells in dandruff and seborrheic dermatitis. A 0.6% micronized form of selenium sulfide is also safe and effective for dandruff.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26974, 'Silky hair cream 50 gm', 'سيلكي هير كريم 50 جم', '50', NULL, 'Hair care', NULL, 'Egyptian company for cosmetics > international egyptian co.', 'Cream', 'كريم', '50 gm', '1', NULL, 'intensive hair care', NULL, NULL, 619, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26975, 'Silky hair oil bath 120 ml', 'سيلكي حمام زيت للشعر 120 مل', '45', NULL, 'Hair care', NULL, 'Egyptian company for cosmetics > international egyptian co.', 'Hair oil', 'زيت شعر', '120 ml', '1', NULL, 'intensive hair care', '6225000078734', NULL, 779, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26976, 'Siloprostate 4 mg 30 caps.', 'سيلوبروستات 4مجم 30 كبسول', '81', NULL, 'Urination-difficulty.alpha blocker', 'Silodosin', 'October pharma', 'Cap', 'كبسولة', '4 mg', '3', NULL, 'it s selective alpha 1 a blocker used to treat symptoms associated with (bph) benign prostate hyperplasia recommended dose : once daily.', NULL, NULL, 914, '2022-07-11', 0, 'Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.[L32368]', 'The pathogenesis of benign prostatic hyperplasia is not fully understood: it is believed to involve several pathways, including inflammation, apoptosis, and cellular proliferation. Most drug therapies aim to alleviate symptoms of benign prostatic hyperplasia, silodosin included. Lower urinary tract symptoms of benign prostatic hyperplasia are categorized into three main groups: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Prostate contraction is the main contributor to lower urinary tract symptoms of benign prostatic hyperplasia. The smooth muscle tone of the prostate is regulated by α<sub>1A</sub>-adrenoceptors, which are the most highly expressed subtype of α<sub>1</sub>adrenoceptors in the human prostate tissue.[A231159] It has been reported that blockade of α<sub>1A</sub>-adrenoceptors relieves bladder outlet obstruction. Blockade of α<sub>1D</sub>-adrenoceptors, another subtype found in prostate tissue, is believed to alleviate storage symptoms due to detrusor overactivity.[A231229]



α<sub>1</sub>-adrenoceptors are G protein-coupled receptors: upon binding of its natural ligand, norepinephrine and epinephrine, leads to the activation of phospholipase C and downstream signalling molecules, including inositol triphosphate and diacylglycerol. Ultimately, there is an increase in intracellular calcium levels and, consequently, smooth muscle contraction. Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors, with the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype. By blocking the α<sub>1A</sub>-adrenoceptor signalling pathway, silodosin promotes prostatic and urethral smooth muscle relaxation, thereby improving lower urinary tract symptoms such as voiding. Silodosin also targets afferent nerves in the bladder, relieving bladder overactivity and storage symptoms.[A231159]', 'Silodosin is an antagonist of α<sub>1</sub>-adrenoceptors. It has the highest selectivity for the α<sub>1A</sub>-adrenoceptor subtype, with a 162-fold greater affinity than α<sub>1B</sub>-adrenoceptor and about a 50-fold greater affinity than for α<sub>1D</sub>-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia.[A231159, A231174] Following oral administration, silodosin had a rapid onset of effect in men,[A231174] with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose.[A231229]



Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects.[A231199] As with all α<sub>1</sub>-adrenoceptor antagonists blocking α<sub>1</sub>-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking α1-AR antagonists.[A231229]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26980, 'Silver seas 20 caps', 'سيلفر سيز 20 كبسولة', '175', '75', 'Omega 3', 'Cod liver oil', 'Arab caps > echemico for trade', 'Cap', 'كبسولة', NULL, '2', 'زيت كبد الحوت مع اوميجا 3', NULL, '6225000065413', NULL, 2936, '2024-07-18', 0, 'Cod liver oil is predominantly manufactured, marketed, and used by the population at large as a general nutraceutical dietary supplement [A27154, A33159, L2872].



Historically, cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin D deficiency and condition of rickets associated with it [A33159]. Over time, this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful all-purpose dietary supplement.



However, since cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



Regardless, because it does contain a combination of a number of important and healthy nutritional compounds, cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds, such as the potential use of cod liver oil supplements in post-heart attack patients for secondary prophylaxis associated with the use of omega-3 fatty acids [A33165].', 'As cod liver oil consists of the component compounds of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), vitamin A, and vitamin D [A33159, L2872, L2871] further information about the mechanisms of action of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'As cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



For example, one tablespoon of cod liver oil contains approximately 4,080 ug of retinol (vitamin A) and 34 ug (1,360 IU) of vitamin D [L2871]. Since the general dietary reference intake of vitamin A is only 900 ug per day for adult men, 700 ug per day for women, and 3000 ug per day as the tolerable upper intake level, the regular intake of cod liver oil as a regular supplement can result in harmful levels of vitamin A accumulating in the liver and sufficient to cause hypervitaminosis A [A33163], which is associated with various symptoms such as blurred vision, changes in consciousness, skin and hair changes, liver damage, among many others.



Moreover, while cod liver oil only contains a certain percentage of the omega-3 fatty acids EPA and DHA per amount of the oil [L2871], separate fish oils supplement products that exclusively consist of only EPA and DHA are available in a great variety of different percentage content formulations, even including prescription strength formulations should certain patients need such a level of therapy. Furthermore, such exclusive omega-3 fatty acid supplement products do not contain any vitamin A or D either, which allows patients to use the supplements without any concern about affecting their vitamin A or D levels or exposing themselves to the unnecessary excess intake of vitamins.



Subsequently, although cod liver oil contains a combination of healthy dietary supplements like EPA, DHA, vitamin A, and vitamin D, the presence in varying amounts of all of these compounds all at once makes it difficult to effectively titrate for appropriate amounts of intake for all the compounds involved when using cod liver oil as a general supplement, often resulting in either an excess or insufficient amount of one or more the aforementioned compounds.



Nevertheless, because cod liver oil does consist of the component compounds of EPA, DHA, vitamin A, and vitamin D, further information about the pharmacodynamics of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26981, 'Silver seas syrup 120 ml', 'سيلفر سيز شراب 120 مل', '110', '24', 'Cod liver oil', 'Cod liver oil+vitamin a+vitamin d', 'Al esraa pharmaceutical optima > brother pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, '*ingredients cod liver oil. vitamin a oil. vitamin d3 oil. indications 1- prevention & treatment of rickets in children. 2- building strong bones in children. 3- boosts the immune system. 4- improves the childs brain function and learning abilities. 5- go', '6225000065406', NULL, 1820, '2024-07-18', 0, 'Cod liver oil is predominantly manufactured, marketed, and used by the population at large as a general nutraceutical dietary supplement [A27154, A33159, L2872].



Historically, cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin D deficiency and condition of rickets associated with it [A33159]. Over time, this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful all-purpose dietary supplement.



However, since cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



Regardless, because it does contain a combination of a number of important and healthy nutritional compounds, cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds, such as the potential use of cod liver oil supplements in post-heart attack patients for secondary prophylaxis associated with the use of omega-3 fatty acids [A33165].', 'As cod liver oil consists of the component compounds of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), vitamin A, and vitamin D [A33159, L2872, L2871] further information about the mechanisms of action of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'As cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



For example, one tablespoon of cod liver oil contains approximately 4,080 ug of retinol (vitamin A) and 34 ug (1,360 IU) of vitamin D [L2871]. Since the general dietary reference intake of vitamin A is only 900 ug per day for adult men, 700 ug per day for women, and 3000 ug per day as the tolerable upper intake level, the regular intake of cod liver oil as a regular supplement can result in harmful levels of vitamin A accumulating in the liver and sufficient to cause hypervitaminosis A [A33163], which is associated with various symptoms such as blurred vision, changes in consciousness, skin and hair changes, liver damage, among many others.



Moreover, while cod liver oil only contains a certain percentage of the omega-3 fatty acids EPA and DHA per amount of the oil [L2871], separate fish oils supplement products that exclusively consist of only EPA and DHA are available in a great variety of different percentage content formulations, even including prescription strength formulations should certain patients need such a level of therapy. Furthermore, such exclusive omega-3 fatty acid supplement products do not contain any vitamin A or D either, which allows patients to use the supplements without any concern about affecting their vitamin A or D levels or exposing themselves to the unnecessary excess intake of vitamins.



Subsequently, although cod liver oil contains a combination of healthy dietary supplements like EPA, DHA, vitamin A, and vitamin D, the presence in varying amounts of all of these compounds all at once makes it difficult to effectively titrate for appropriate amounts of intake for all the compounds involved when using cod liver oil as a general supplement, often resulting in either an excess or insufficient amount of one or more the aforementioned compounds.



Nevertheless, because cod liver oil does consist of the component compounds of EPA, DHA, vitamin A, and vitamin D, further information about the pharmacodynamics of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26982, 'Silverhyalo cream 25 gm', 'سيلفرهيالو كريم 25 جم', '29', NULL, 'Topical bactericidal', 'Silver sulfadiazine+sodium hyaluronate', 'Debeiky > philo pharm pharmaceuticals', 'Cream', 'كريم', '25 gm', '1', 'كريم مضاد حيوي -- علاج الجروح والقرح -- تقليل الالام والاحمرار', 'indications: it is indicated for the management of skin lesions especially those at high risk of infection. in particular it is intended to cover acute and chronic wounds (first and second degree burns vascular and metabolic ulcers and pressure sores) and', NULL, NULL, 7016, '2022-10-29', 0, 'Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.', 'Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine''s effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. 

Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. 

Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.', 'Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram- negative and gram-positive bacteria as well as being effective against yeast. Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26983, 'Silverline cu 380 ag intrauterine device', 'سيلفرلاين نحاس 380 لولب نحاسي', '57', NULL, 'Iud', 'Copper', 'Pregna international limited-india > dkt', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 3667, '2023-05-18', 0, 'For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices [FDA Label] [L801].', 'Copper is absorbed from the gut via high affinity copper uptake protein and likely through low affinity copper uptake protein and natural resistance-associated macrophage protein-2 [A19528]. It is believed that copper is reduced to the Cu1+ form prior to transport. Once inside the enterocyte, it is bound to copper transport protein ATOX1 which shuttles the ion to copper transporting ATPase-1 on the golgi membrane which take up copper into the golgi apparatus. Once copper has been secreted by enterocytes into the systemic circulation it remain largely bound by ceruloplasmin (65-90%), albumin (18%), and alpha 2-macroglobulin (12%). 



Copper is an essential element in the body and is incorporated into many oxidase enzymes as a cofactor [A19518]. It is also a component of zinc/copper super oxide dismutase, giving it an anti-oxidant role. Copper defiency occurs in Occipital Horn Syndrome and Menke''s disease both of which are associated with impaired development of connective tissue due to the lack of copper to act as a cofactor in protein-lysine-6-oxidase. Menke''s disease is also associated with progressive neurological impairment leading to death in infancy. The precise mechanisms of the effects of copper deficiency are vague due to the wide range of enzymes which use the ion as a cofactor.



Copper appears to reduce the viabilty and motility of spermatozoa [A19526]. This reduces the likelihood of fertilization with a copper IUD, producing copper''s contraceptive effect [A19526]. The exact mechanism of copper''s effect on sperm are unknown.', 'Copper is incorporated into many enzymes throughout the body as an essential part of their function [A19518]. Copper ions are known to reduce fertility when released from copper-containing IUDs [A19526].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26984, 'Silverzine 1% gauze dressing .', 'سيلفرزين 1% ضمادة', '4', NULL, 'Antibiotic topical', 'Silver sulfadiazine', 'Mina pharm', 'Unknown', 'غير محدد', '1%', '1', NULL, 'indication indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. mechanism of action studies utilizing radioactive micronized silver sulfadiazine electron microscopy and biochemical techn', NULL, NULL, 786, '2022-07-24', 0, 'Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.', 'Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine''s effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. 

Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. 

Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.', 'Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram- negative and gram-positive bacteria as well as being effective against yeast. Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26985, 'Silvigo 50mg 5 f.c. tabs.', 'سيلفيجو 50مجم 5 اقراص', '24', NULL, 'Tonic for men', 'Sildenafil', 'Memphis', 'Tab', 'أقراص', '50mg', '1', NULL, 'about sildenafil citrate phosphodiesterase-5 enzyme inhibitor anti-erectile dysfunction agent. mechanism of action of sildenafil citrate sildenafil is a phosphodiesterase enzyme (pde5) inhibitor. this enzyme is responsible for the degradation cyclic guano', NULL, NULL, 893, '2022-07-12', 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26986, 'Silvirburn 1% cream 30 gm', 'سيلفربيرن 1% 30جم كريم', '38', '26', 'Topical bactericidal', 'Silver sulfadiazine', 'Mup', 'Cream', 'كريم', '1%', '1', NULL, 'indication indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. mechanism of action studies utilizing radioactive micronized silver sulfadiazine electron microscopy and biochemical techn', '6221508122016', NULL, 3272, '2024-09-20', 0, 'Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.', 'Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine''s effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. 

Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. 

Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.', 'Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram- negative and gram-positive bacteria as well as being effective against yeast. Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26987, 'Bioworld cal syrup 120 ml', 'بيوورلد كال شراب 120 مل', '59', '39.5', 'Multivitamin', 'Calcium+magnesium+vitamin d3+zinc', 'Bioworld', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, NULL, 1276, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26990, 'Silymarin zinc 30 caps.', 'سليمارين زنك 30 كبسولة', '21', NULL, 'Liver support supplements', 'Silymarin+zinc', 'Arab caps', 'Cap', 'كبسولة', NULL, '3', NULL, 'about silymarin a polyphenolic flavonoid hepatoprotective(antihepatotoxic) antioxidant. mechanism of action of silymarin silymarin stimulates rna polymerase a and results in an increase in ribosomal protein synthesis and leads to the synthesis of new hepa', '6221042200065', NULL, 1763, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26991, 'Simbrinza 2/10mg/ml eye drops 5 ml', 'سيمبرينزا 2/10مجم/مل قطرة للعين 5مل', '169', '135', 'Antiglaucoma', 'Brimonidine+brinzolamide', 'Alcon > novartis scientific office', 'Drops', 'نقط', '10mg', '1', NULL, '(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-', '7613421020170', NULL, 2346, '2024-05-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26993, 'Simethicone-mup 2% emulsion oral drops 30 ml', 'سايمثيكون المهن نقط فم 2% مستحلب 30 مل', '27', '18', 'Antiflatulent', 'Simethicone', 'Mup', 'Drops', 'نقط', '2%', '1', NULL, 'about simethicone oral anti-foaming agent silicones antiflatulent. mechanism of action of simethicone this anti-gas (anti-flatulence) medication acts in the stomach and intestines to change the surface tension of gas bubbles enabling smaller bubbles to jo', '6221508210218', NULL, 2474, '2025-01-11', 0, 'Simethicone is indicated for the treatment of bloating, pressure, and cramps caused by gas.[L31533] Simethicone is also used as part of bowel preparation for colonoscopies.[A228343] ', 'Simethicone is a surfactant that decreases the surface tension of gas bubbles in the gastrointestinal tract, more easily allowing gas to exit the body.[A228308]', 'Simethicone decreases the surface tension of gas bubbles in the gastrointestinal tract, facilitating their expulsion.[A228308] It has a short duration of action as it is generally given as needed, and a wide therapeutic index as it is not systemically absorbed.[A228308]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26994, 'Simethicone 80mg 30 tab', 'سايميثيكون 80مجم 30 قرص', '6', NULL, 'Antiflatulent', 'Simethicone', 'Amoun > pyramids for trading pharmaceuticals-egypt', 'Tab', 'أقراص', '80mg', '3', 'مضاد للانتفاخ -- لعلاج حالات الانتفاخ ومغص القولون -- لتخفيف الشعور بالامتلاء وغازات البطن', NULL, '6221025008152', NULL, 5006, '2022-12-08', 0, 'Simethicone is indicated for the treatment of bloating, pressure, and cramps caused by gas.[L31533] Simethicone is also used as part of bowel preparation for colonoscopies.[A228343] ', 'Simethicone is a surfactant that decreases the surface tension of gas bubbles in the gastrointestinal tract, more easily allowing gas to exit the body.[A228308]', 'Simethicone decreases the surface tension of gas bubbles in the gastrointestinal tract, facilitating their expulsion.[A228308] It has a short duration of action as it is generally given as needed, and a wide therapeutic index as it is not systemically absorbed.[A228308]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26996, 'Get white cream 30 gm', 'جيت ويت كريم 30 جم', '140', '125', NULL, NULL, 'Safe life', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, NULL, NULL, 1333, '2025-11-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26997, 'Simezet 10/10 mg 14 tab.', 'سايمزيت 10/10مجم 14 اقراص', '34', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Organopharma', 'Tab', 'أقراص', '10 mg', '2', NULL, 'ezetimibe+simvastatin about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the smal', NULL, NULL, 801, '2022-07-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26998, 'Simezet 10/40 mg 7 tab.', 'سايمزيت 10/40مجم 7 اقراص', '40', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Organopharma', 'Tab', 'أقراص', '40 mg', '1', NULL, 'ezetimibe+simvastatin about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the smal', NULL, NULL, 787, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (26999, 'Similac advance 1 milk 400 gm', 'سيميلاك ادفانس 1 لبن 400جم', '99', NULL, 'Milk products.first stage (age 0-6 months)', 'Milk formula stage 1', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, '5099864006407', NULL, 800, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27000, 'Similac elecare milk 400 gm', 'سيميلاك ايليكير لبن 400 جرام', '311', NULL, 'Hypo-allergenic milk', 'Hypo-allergenic milk formula', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, NULL, NULL, 844, '2022-06-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27001, 'Similac gain advance 2 milk 400 gm', 'سيميلاك 2 لبن 400جم', '99', NULL, 'Milk products.second stage (age 6-12 months)', 'Milk formula stage 2', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, '5099864006414', NULL, 695, '2022-07-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27002, 'Similac gain plus advance 3 milk 400 gm', 'سيميلاك جولد ادفانس لبن 3 400جم', '99', NULL, 'Milk products.third stage (age 1-3 years)', 'Milk formula stage 3', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, '5099864003734', NULL, 709, '2022-08-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27003, 'Similac gold 1 milk 400 gm', 'سيميلاك جولد 1 لبن اطفال 400 جم', '360', '224.4', 'Milk products.first stage (age 0-6 months)', 'Milk formula stage 1', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, 'not to replace mother s milk. for infants from birth to 6 months age. to be used within one month from opening.', '5099864011357', NULL, 847, '2025-09-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27004, 'Similac gold 2 milk 400 gm', 'سيميلاك جولد 2 لبن اطفال 400 جم', '360', '224.3', 'Milk products.second stage (age 6-12 months)', 'Milk formula stage 2', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, 'not to replace mother s milk. for infants from 6-12 months age. to be used within one month from opening.', '5099864011364', NULL, 809, '2025-09-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27005, 'Similac gold 3 milk 400 gm', 'سيميلاك جولد 3 لبن اطفال 400 جم', '360', '224.3', 'Milk products.third stage (age 1-3 years)', 'Milk formula stage 3', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '400 gm', '1', NULL, 'not to replace mother s milk. for infants from 1-3 years age. to be used within one month from opening.', NULL, NULL, 1207, '2025-09-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27006, 'Similac neosure milk 370 gm', 'سيميلاك نيوشور لبن اطفال 370 جم', '498', '475.5', 'Milk products.prematue milk formula', 'Premature milk formula', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '370 gm', '1', NULL, 'special formula for premature and low birth-weight babies for infants from birth to 12 months age. to be used within 3 weeks from opening.', '8427030000046', NULL, 1664, '2024-09-26', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27007, 'Similac total comfort 2 milk 360 gm', 'سيميلاك لبن توتال كومفورت 357جم', '480', '284.1', 'Extra care milk', 'Extra care milk formula', 'Abbott laboratories > ibn sina', 'Unknown', 'غير محدد', '360 gm', '1', NULL, 'not to replace mother s milk. follow-on formula from 6 to 12 months age. to be used within one month from opening. nutritionally complete formula - easy to digest.', NULL, NULL, 666, '2024-10-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27008, 'Simponi 50mg/0.5 ml prefilled pen', 'سيمبوني 50مجم/0.5مل اقلام معبأة', '13,597', '9502', 'Immunosuppressive', 'Golimumab', 'Baxter ag > janssen cilag', 'Pen', 'قلم', '50mg', '1', 'مثبط مناعي', 'indications and usage *rheumatoid arthritis simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. psoriatic arthritis simponi alone or in combination with methotr', '8992500115143', NULL, 6971, '2024-11-30', 0, 'Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA)[L16626], (ii) in patients 2 years old and above with active psoriatic arthritis (PsA)[L16626], (iii) as a single agent in patients with active ankylosing spondylitis (AS) or in combination with methotrexate[L16631], and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.[L16631] It is also indicated (v) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.[L16626]

', 'As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.', 'Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFα). In areas such as the joints and blood, increased TNFα is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27009, 'Simulect 20 mg powder vial for i.v. infusion', 'سيميوليكت 20مجم باودر فيال للتسريب الوريدي', '13,854', '6441', 'Immunosuppressants', 'Basiliximab', 'Novartis', 'Vial', 'فيال', '20 mg', '1', 'مثبط للمناعة', NULL, NULL, NULL, 1415, '2025-08-16', 0, 'For prophylactic treatment of kidney transplant rejection', 'Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.', 'Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27011, 'Simvacor 40mg 7 f.c. tab.', 'سيمفاكور 40مجم 7 اقراص', '30', NULL, 'Antihyperlipidemic.statins', 'Simvastatin', 'Sigma', 'Tab', 'أقراص', '40mg', '1', NULL, 'about simvastatin statins hmg-coa reductase inhibitor a hypolipidemic agent. mechanism of action of simvastatin it is a precursor lactone converted in to active form in the body which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl co', '6221051011072', NULL, 858, '2022-12-08', 0, 'Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658]



This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658]



Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421] Simvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Simvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).[F4655, F4658] The overall effect is a decrease in plasma LDL and VLDL. 



At therapeutic doses, the HMG-CoA enzyme is not completely blocked by simvastatin activity, thereby allowing biologically necessary amounts of mevalonate to remain available. As mevalonate is an early step in the biosynthetic pathway for cholesterol, therapy with simvastatin would also not be expected to cause any accumulation of potentially toxic sterols. In addition, HMG-CoA is metabolized readily back to acetyl-CoA, which participates in many biosynthetic processes in the body.[F4658]



In vitro and in vivo animal studies also demonstrate that simvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.



Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]', 'Simvastatin is an oral antilipemic agent which inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.[A181087, A181406]



Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403]



**Skeletal Muscle Effects**



Simvastatin occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.[F4655, F4658]



In a clinical trial database of 41,413 patients, the incidence of myopathy was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively, while the risk of myopathy with simvastatin 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. It''s therefore recommended that the 80mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. As well, patients already stabilized on simvastatin 80mg should be monitored closely for evidence of muscle toxicity; if they need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction.[F4655, F4658]



The risk of myopathy during treatment with simvastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.[F4655, F4658]



**Liver Enzyme Abnormalities**



Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. [F4655, F4658]



In the Scandinavian Simvastatin Survival Study (4S),[A181538] the number of patients with more than one transaminase elevation to >3 times the ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). The frequency of single elevations of ALT to 3 times the ULN was significantly higher in the simvastatin group in the first year of the study (20 vs. 8, p=0.023), but not thereafter. In the HPS (Heart Protection Study),[A181475] in which 20,536 patients were randomized to receive simvastatin 40 mg/day or placebo, the incidences of elevated transaminases (>3X ULN confirmed by repeat test) were 0.21% (n=21) for patients treated with simvastatin and 0.09% (n=9) for patients treated with placebo.[F4655, F4658] 



**Endocrine Effects**



Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.[F4655]



Although cholesterol is the precursor of all steroid hormones, studies with simvastatin have suggested that this agent has no clinical effect on steroidogenesis. Simvastatin caused no increase in biliary lithogenicity and, therefore, would not be expected to increase the incidence of gallstones.[F4658]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27012, 'Simvacor 80mg 7 f.c.tab.', 'سيمفاكور 80مجم 7 اقراص', '42', NULL, 'Antihyperlipidemic.statins', 'Simvastatin', 'Sigma', 'Tab', 'أقراص', '80mg', '1', NULL, 'about simvastatin statins hmg-coa reductase inhibitor a hypolipidemic agent. mechanism of action of simvastatin it is a precursor lactone converted in to active form in the body which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl co', '6221051011096', NULL, 631, '2022-12-08', 0, 'Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658]



This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658]



Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421] Simvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Simvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).[F4655, F4658] The overall effect is a decrease in plasma LDL and VLDL. 



At therapeutic doses, the HMG-CoA enzyme is not completely blocked by simvastatin activity, thereby allowing biologically necessary amounts of mevalonate to remain available. As mevalonate is an early step in the biosynthetic pathway for cholesterol, therapy with simvastatin would also not be expected to cause any accumulation of potentially toxic sterols. In addition, HMG-CoA is metabolized readily back to acetyl-CoA, which participates in many biosynthetic processes in the body.[F4658]



In vitro and in vivo animal studies also demonstrate that simvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.



Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]', 'Simvastatin is an oral antilipemic agent which inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.[A181087, A181406]



Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403]



**Skeletal Muscle Effects**



Simvastatin occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.[F4655, F4658]



In a clinical trial database of 41,413 patients, the incidence of myopathy was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively, while the risk of myopathy with simvastatin 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. It''s therefore recommended that the 80mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. As well, patients already stabilized on simvastatin 80mg should be monitored closely for evidence of muscle toxicity; if they need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction.[F4655, F4658]



The risk of myopathy during treatment with simvastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.[F4655, F4658]



**Liver Enzyme Abnormalities**



Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. [F4655, F4658]



In the Scandinavian Simvastatin Survival Study (4S),[A181538] the number of patients with more than one transaminase elevation to >3 times the ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). The frequency of single elevations of ALT to 3 times the ULN was significantly higher in the simvastatin group in the first year of the study (20 vs. 8, p=0.023), but not thereafter. In the HPS (Heart Protection Study),[A181475] in which 20,536 patients were randomized to receive simvastatin 40 mg/day or placebo, the incidences of elevated transaminases (>3X ULN confirmed by repeat test) were 0.21% (n=21) for patients treated with simvastatin and 0.09% (n=9) for patients treated with placebo.[F4655, F4658] 



**Endocrine Effects**



Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.[F4655]



Although cholesterol is the precursor of all steroid hormones, studies with simvastatin have suggested that this agent has no clinical effect on steroidogenesis. Simvastatin caused no increase in biliary lithogenicity and, therefore, would not be expected to increase the incidence of gallstones.[F4658]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27013, 'Simva-eze 10/10 mg 7 tab.', 'سيمفا ايز 10/10مجم 7 اقراص', '19', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Pharco', 'Tab', 'أقراص', '10 mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6221151001812', NULL, 912, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27014, 'Simva-eze 20/10mg 7 tab.', 'سيمفا ايز 20/10مجم 7 اقراص', '22', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Pharco', 'Tab', 'أقراص', '10mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, NULL, 1015, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27015, 'Simva-eze 40/10mg 7 tab.', 'سيمفا ايز 40/10مجم 7 اقراص', '28', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Pharco', 'Tab', 'أقراص', '10mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6221151001836', NULL, 1042, '2022-07-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27017, 'Simva-map 10/10mg 10 bilayer f.c. tab.', 'سيمفا ماب 10/10مجم 10 اقراص', '43', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Multi-apex', 'Tab', 'أقراص', '10mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, NULL, 754, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27018, 'Simva-map 10/20mg 10 bilayer f.c. tab.', 'سيمفا ماب 10/20مجم 10 اقراص', '70', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Multi-apex', 'Tab', 'أقراص', '20mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, NULL, 900, '2022-07-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27019, 'Simva-map 10/40mg 10 bilayer f.c. tab.', 'سيمفا ماب 10/40مجم 10 اقراص', '70', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Multi-apex', 'Tab', 'أقراص', '40mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, NULL, 903, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27020, 'Simva-map 10/80mg 10 bilayer f.c. tab.', 'سيمفا ماب 10/80مجم 10 اقراص', '90', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Multi-apex', 'Tab', 'أقراص', '80mg', '1', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, NULL, 824, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27021, 'Simvastat 10mg 7 tab.', 'سيمفاستات 10مجم 7 اقراص', '25', NULL, 'Antihyperlipidemic.statins', 'Simvastatin', 'T3a pharma > rexcel', 'Tab', 'أقراص', '10mg', '1', NULL, 'about simvastatin statins hmg-coa reductase inhibitor a hypolipidemic agent. mechanism of action of simvastatin it is a precursor lactone converted in to active form in the body which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl co', NULL, NULL, 734, '2022-07-16', 0, 'Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658]



This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658]



Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421] Simvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Simvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).[F4655, F4658] The overall effect is a decrease in plasma LDL and VLDL. 



At therapeutic doses, the HMG-CoA enzyme is not completely blocked by simvastatin activity, thereby allowing biologically necessary amounts of mevalonate to remain available. As mevalonate is an early step in the biosynthetic pathway for cholesterol, therapy with simvastatin would also not be expected to cause any accumulation of potentially toxic sterols. In addition, HMG-CoA is metabolized readily back to acetyl-CoA, which participates in many biosynthetic processes in the body.[F4658]



In vitro and in vivo animal studies also demonstrate that simvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.



Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]', 'Simvastatin is an oral antilipemic agent which inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.[A181087, A181406]



Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403]



**Skeletal Muscle Effects**



Simvastatin occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.[F4655, F4658]



In a clinical trial database of 41,413 patients, the incidence of myopathy was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively, while the risk of myopathy with simvastatin 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. It''s therefore recommended that the 80mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. As well, patients already stabilized on simvastatin 80mg should be monitored closely for evidence of muscle toxicity; if they need to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction.[F4655, F4658]



The risk of myopathy during treatment with simvastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.[F4655, F4658]



**Liver Enzyme Abnormalities**



Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. [F4655, F4658]



In the Scandinavian Simvastatin Survival Study (4S),[A181538] the number of patients with more than one transaminase elevation to >3 times the ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). The frequency of single elevations of ALT to 3 times the ULN was significantly higher in the simvastatin group in the first year of the study (20 vs. 8, p=0.023), but not thereafter. In the HPS (Heart Protection Study),[A181475] in which 20,536 patients were randomized to receive simvastatin 40 mg/day or placebo, the incidences of elevated transaminases (>3X ULN confirmed by repeat test) were 0.21% (n=21) for patients treated with simvastatin and 0.09% (n=9) for patients treated with placebo.[F4655, F4658] 



**Endocrine Effects**



Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.[F4655]



Although cholesterol is the precursor of all steroid hormones, studies with simvastatin have suggested that this agent has no clinical effect on steroidogenesis. Simvastatin caused no increase in biliary lithogenicity and, therefore, would not be expected to increase the incidence of gallstones.[F4658]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27022, 'Boston cal vitamin syrup 100 ml', 'بوسطن كال فيتامين شراب 100 مل', '99', NULL, 'Calcium', 'Calcium', 'Boston pharmaceuticals', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, NULL, NULL, 970, '2024-07-29', 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27024, 'Simvastimibe 10/40mg 30 tabs.', 'سيمفاستيميب 10/40مجم 30 قرص', '75', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Eva pharma', 'Tab', 'أقراص', '40mg', '3', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6223002453825', NULL, 901, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27025, 'Simvastimibe 10/80mg 20 tabs.', 'سيمفاستيميب 10/80مجم 20 اقراص', '84', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Eva pharma', 'Tab', 'أقراص', '80mg', '2', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6223002453269', NULL, 745, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27026, 'Simvaxibe 10/10mg 21 f.c.tab.', 'سيمفاكسيب 10/10مجم 21 قرص', '44', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Sabaa > pharma de france-egypt', 'Tab', 'أقراص', '10mg', '3', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6224000808525', NULL, 908, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27027, 'Simvaxibe 10/20mg 21 f.c. tabs.', 'سيمفاكسيب 10/20مجم 21 قرص', '57', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Sabaa > pharma de france-egypt', 'Tab', 'أقراص', '20mg', '3', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6224000808532', NULL, 827, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27028, 'Simvaxibe 10/40mg 21 f.c.tab.', 'سيمفاكسيب 10/40مجم 21 قرص', '72', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Ezetimibe+simvastatin', 'Sabaa > pharma de france-egypt', 'Tab', 'أقراص', '40mg', '30', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', '6224000808549', NULL, 751, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27029, 'Sina seas 20 caps.', 'سينا سيز 20 كبسولة', '23', NULL, 'Omega 3', 'Cod liver oil', 'Safe pharma > sina pharm', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, '6221051840023', NULL, 952, '2023-04-25', 0, 'Cod liver oil is predominantly manufactured, marketed, and used by the population at large as a general nutraceutical dietary supplement [A27154, A33159, L2872].



Historically, cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin D deficiency and condition of rickets associated with it [A33159]. Over time, this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful all-purpose dietary supplement.



However, since cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



Regardless, because it does contain a combination of a number of important and healthy nutritional compounds, cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds, such as the potential use of cod liver oil supplements in post-heart attack patients for secondary prophylaxis associated with the use of omega-3 fatty acids [A33165].', 'As cod liver oil consists of the component compounds of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), vitamin A, and vitamin D [A33159, L2872, L2871] further information about the mechanisms of action of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'As cod liver oil is a composite of several other nutritional compounds including the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as well as vitamin A and vitamin D [A33159, L2872, L2871], the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiency.



For example, one tablespoon of cod liver oil contains approximately 4,080 ug of retinol (vitamin A) and 34 ug (1,360 IU) of vitamin D [L2871]. Since the general dietary reference intake of vitamin A is only 900 ug per day for adult men, 700 ug per day for women, and 3000 ug per day as the tolerable upper intake level, the regular intake of cod liver oil as a regular supplement can result in harmful levels of vitamin A accumulating in the liver and sufficient to cause hypervitaminosis A [A33163], which is associated with various symptoms such as blurred vision, changes in consciousness, skin and hair changes, liver damage, among many others.



Moreover, while cod liver oil only contains a certain percentage of the omega-3 fatty acids EPA and DHA per amount of the oil [L2871], separate fish oils supplement products that exclusively consist of only EPA and DHA are available in a great variety of different percentage content formulations, even including prescription strength formulations should certain patients need such a level of therapy. Furthermore, such exclusive omega-3 fatty acid supplement products do not contain any vitamin A or D either, which allows patients to use the supplements without any concern about affecting their vitamin A or D levels or exposing themselves to the unnecessary excess intake of vitamins.



Subsequently, although cod liver oil contains a combination of healthy dietary supplements like EPA, DHA, vitamin A, and vitamin D, the presence in varying amounts of all of these compounds all at once makes it difficult to effectively titrate for appropriate amounts of intake for all the compounds involved when using cod liver oil as a general supplement, often resulting in either an excess or insufficient amount of one or more the aforementioned compounds.



Nevertheless, because cod liver oil does consist of the component compounds of EPA, DHA, vitamin A, and vitamin D, further information about the pharmacodynamics of these cod liver oil components can be found by searching for fish oil, vitamin A, and vitamin D on DrugBank.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27031, 'Sinadry syrup 120 ml', 'سينادراي شراب 120 مل', '40', '25', 'Anti-cough', 'Pimpinella root ext+grindelia herb ext+primula root tincture ext+thyme+rose ext+honey', 'Sigma > novell pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, '*rich with honey. *for children and adults.', '6223004070273', NULL, 1136, '2024-02-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27032, 'Sinawet syrup 120 ml', 'سيناويت شراب 120 مل', '25', NULL, 'Anti-cough', 'Pimpinella root ext+grindelia herb ext+primula root tincture ext+thyme herb ext+quebracho cortex ext', 'Sigma > novell pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, '6223004070266', NULL, 1005, '2022-12-19', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27033, 'Sine up 20 tab.', 'ساين اب 20 قرص', '7', NULL, 'Cold drugs', 'Chlorpheniramine+paracetamol(acetaminophen)+phenylephrine', 'Pharco', 'Tab', 'أقراص', NULL, '2', NULL, NULL, '6223000011980', NULL, 2055, '2022-07-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27034, 'Sine up syrup 120 ml', 'ساين اب شراب 120 مل', '29', '12', 'Cold drugs', 'Chlorpheniramine+phenylephrine', 'Pharco', 'Syrup', 'شراب', '120 ml', '1', NULL, 'description a histamine h1 antagonist used in allergic reactions hay fever rhinitis urticaria and asthma. indication for the treatment of rhinitis urticaria allergy common cold asthma and hay fever. pharmacodynamics in allergic reactions an allergen inter', '6221151001485', NULL, 2964, '2024-11-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27035, 'Fair and lovely cream big 40 gm', 'فير اند لفلي كريم تفتيح البشرة حجم كبير 40 جم', '35', NULL, NULL, NULL, 'Company', 'Cream', 'كريم', '40 gm', '1', NULL, NULL, '6221155114488', NULL, 1023, '2022-10-07', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27036, 'Sinecod 0.5% oral drops 15 ml(n/a)', 'ساينيكود 0.5% نقط للفم 15 مل', '5', NULL, 'Antitussive', 'Butamirate citrate', 'Novartis > glaxo smithkline', 'Drops', 'نقط', '0.5%', '1', NULL, 'about butamirate citrate antitussive non addictive opioid mechanism of action of butamirate citrate butamirate citrate depress the cough center and suppresses cough indications for butamirate citrate 1.cough typical dosage for butamirate citrate tablet: a', '6223002640706', NULL, 799, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27038, 'Sinemet cr 50/200mg 30 tab.(n/a)', 'سينميت سي ار 50/200مجم 30 قرص', '87', NULL, 'Parkinson s disease.dopamine agonist', 'Carbidopa+levodopa', 'Merck sharp & dohme > merck sharp & dohme scientific office', 'Tab', 'أقراص', '200mg', '3', NULL, NULL, NULL, NULL, 1102, '2023-02-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27039, 'Singukast 5mg 10 chewable tab.', 'سينجوكاست 5مجم 10 اقراص', '30', NULL, 'Asthma.anti-inflammatory.leukotriene antagonist', 'Montelukast', 'Epci', 'Tab', 'أقراص', '5mg', '1', NULL, 'about montelukast leukotriene(cyslt1) receptor antagonist antiinflammatory antiasthma. mechanism of action of montelukast montelukast is competitively and selectively antagonizes cyslt1 receptor (leukotrienes receptor) mediated bronchoconstriction.montelu', NULL, NULL, 949, '2022-07-13', 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27042, 'Singulair 4 mg paed. 14 chew. tabs.', 'سينجولير 4مجم اطفال 14 قرص للمضغ', '138', '103', 'Asthma.anti-inflammatory.leukotriene antagonist', 'Montelukast', 'Merck sharp & dohme', 'Tab', 'أقراص', '4 mg', '2', 'علاج أزمات الصدر وصعوبة وضيق التنفس', NULL, NULL, NULL, 2126, '2024-11-19', 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27043, 'Singulair 4 mg paed. oral gran. 14 sachets', 'سينجولير اطفال 4 مجم حبيبات للفم 14 كيس', '123', '98', 'Asthma.anti-inflammatory.leukotriene antagonist', 'Montelukast', 'Merck sharp & dohme > global napi pharmaceuticals', 'Sachet', 'أكياس', '4 mg', '1', 'علاج أزمات الصدر وصعوبة وضيق التنفس', NULL, '6223002149759', NULL, 3674, '2023-09-07', 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27044, 'Sinlerg 20 tabs.', 'سينليرج 20 قرص', '56', '37', 'Cold drugs', 'Chlorpheniramine+ibuprofen+pseudoephedrine', 'Eva pharma', 'Tab', 'أقراص', NULL, '2', 'التهاب الجيوب الأنفية ونزلات البرد.', 'for cold & flu', '6223002454457', NULL, 22347, '2024-09-25', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27046, 'Sinomarin adult nasal spray 125ml', 'سينومارين كبار بخاخ للانف 125 مل', '370', '335', 'Nasal decongestant spray', 'Hypertonic seawater', 'Gerolymatos > eva pharma', 'Spray', 'بخاخ', '125ml', '1', NULL, '*relieves nasal congestion - cleanses and moisturises.', '5206892101855', NULL, 3653, '2025-03-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27047, 'Sinomarin children nasal spray 100ml', 'سينومارين اطفال بخاخ للانف 100مل', '330', '298', 'Nasal decongestant spray', 'Hypertonic seawater', 'Gerolymatos > eva pharma', 'Spray', 'بخاخ', '100ml', '1', NULL, '*relieves nasal congestion - cleanses and moisturises.', '5206892101862', NULL, 3152, '2025-03-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27048, 'Sinomarin cold & flu nasal spray 30ml', 'سينومارين كولد اند فلو سبراي للانف 30مل', '115', '108', 'Nasal decongestant spray', 'Hypertonic seawater+eucalyptus+thyme+spearmint essential oils', 'Gerolymatos > eva pharma', 'Spray', 'بخاخ', '30ml', '1', NULL, '*relieves nasal congestion - cleanses and moisturises.', NULL, NULL, 1239, '2023-08-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27049, 'Sinomarin e.n.t. nasal spray 200ml', 'سينومارين اي .إن .تي بخاخ للانف 200مل', '370', '250', 'Nasal decongestant spray', 'Hypertonic seawater', 'Gerolymatos > eva pharma', 'Spray', 'بخاخ', '200ml', '1', 'بخاخ لتنظيف الانف يعمل على ازالة الاحتقان وتكسير المخاط اللزج', '*relieves nasal congestion - cleanses and moisturises - promotes recovery following endonasal surgery.', '5206892101886', NULL, 1735, '2025-03-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27051, 'Sinopril 10mg 30 tab.', 'سينوبريل 10مجم 30 قرص', '69', '51', 'Antihypertensive.ace', 'Lisinopril', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '10mg', '3', NULL, 'about lisinopril dicarboxylate-containing angiotensin-converting enzyme (ace) inhibitor antihypertensive. mechanism of action of lisinopril it is an angiotensin converting enzyme inhibitor prevents the conversion of angiotensin-1 to angiotensin-2 and abol', '6223002142330', NULL, 4867, '2024-08-16', 0, 'Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]', 'Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption.[A184781] This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation.[A184781]



Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II.[A184781,A184808] This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients.[A184808] Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs.[A184808] Lisinopril also inhibits renin''s conversion of angiotensin to angiotensin I.[A184817]', 'Lisinopril is an angiotensin converting enzyme inhibitor used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril is not a prodrug, and functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] It has a wide therapeutic index and a long duration of action as patients are generally given 10-80mg daily.[L8384,L8387,L8390]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27052, 'Sinopril 20mg 10 tab.', 'سينوبريل 20مجم 10 اقراص', '17', NULL, 'Antihypertensive.ace', 'Lisinopril', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, '6223002142330', NULL, 1123, '2023-01-25', 0, 'Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]', 'Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption.[A184781] This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation.[A184781]



Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II.[A184781,A184808] This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients.[A184808] Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs.[A184808] Lisinopril also inhibits renin''s conversion of angiotensin to angiotensin I.[A184817]', 'Lisinopril is an angiotensin converting enzyme inhibitor used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril is not a prodrug, and functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] It has a wide therapeutic index and a long duration of action as patients are generally given 10-80mg daily.[L8384,L8387,L8390]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27055, 'Sinuc 0.9% syrup 100 ml', 'سينوك 0.9% شراب 100 مل', '16', NULL, 'Cough drugs', 'Ivy leaves', 'Novartis', 'Syrup', 'شراب', '0.9%', '1', NULL, 'due to their broncholytic and secretolic properties ivy leaf dried extract has long provided its worth in practice. their efficacy has been demonstrated in numerous scientific studies. according to a pharmacological investigation its constituent appears t', '6223002642304', NULL, 1032, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27056, 'Sinufen 800mg sr 20 f.c. tabs.', 'سينوفين 800مجم 20 قرص', '16', NULL, 'Nsaid.propionic acid derivatives', 'Ibuprofen', 'International drug agency (idi) > novell pharma', 'Tab', 'أقراص', '800mg', '2', NULL, 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', '6223004070372', NULL, 926, '2022-12-08', 0, 'Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]



The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]



Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.[A39092]



As ibuprofen is a widely used medication, the main therapeutic indications are:



* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]



* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]



* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]



* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]



* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]



* Pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] It is also used to manage mild to moderate pain and moderate to severe pain as an adjunct to opioid analgesics.[L40208]



* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer''s disease, Parkinson disease, and breast cancer.[A39092]', 'The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and thus it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway.[L4614]



Ibuprofen is a non-selective COX inhibitor and hence, it inhibits the activity of both COX-1 and COX-2. The inhibition of COX-2 activity decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever, and swelling while the inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration.[A39195]', 'Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic inflammation. The main effects reported in ibuprofen are related to the control of pain, fever and acute inflammation by the inhibition of the synthesis of prostanoids by COX-1 and COX-2. Pain relief is attributed to peripheral affected regions and central nervous system effects in the pain transmission mediated by the dorsal horn and higher spinothalamic tract. Some reports have tried to link the pain regulation with a possible enhancement on the synthesis of endogenous cannabinoids and action on the NMDA receptors. The effect on pain has been shown to be related to the cortically evoked potentials.[A39190]



The antipyretic effect is reported to be linked to the effect on the prostanoid synthesis due to the fact that the prostanoids are the main signaling mediator of pyresis in the hypothalamic-preoptic region.[A39190]



The use of ibuprofen in dental procedures is attributed to the local inhibition of prostanoid production as well as to anti-oedemic activity and an increase of plasma beta-endorphins. Some reports have suggested a rapid local reduction of the expression of COX-2 in dental pulp derived by the administration of ibuprofen.[A39190]



The administration of ibuprofen in patients with rheumatic diseases has shown to control joint symptoms.[A39092] 



Ibuprofen is largely used in OTC products such as an agent for the management of dysmenorrhea which has been proven to reduce the amount of menstrual prostanoids and to produce a reduction in the uterine hypercontractility.[A39181] As well, it has been reported to reduce significantly the fever and the pain caused by migraines.[A39182, A39183] This effect is thought to be related to the effect on platelet activation and thromboxane A2 production which produces local vascular effects in the affected regions. This effect is viable as ibuprofen can enter in the central nervous system.[A39190]



In the investigational uses of ibuprofen, it has been reported to reduce neurodegeneration when given in low doses over a long time.[A39184] On the other hand, its use in Parkinson disease is related to the importance of inflammation and oxidative stress in the pathology of this condition.[A39185] The use of ibuprofen for breast cancer is related to a study that shows a decrease of 50% in the rate of breast cancer.[A39186]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27058, 'Sinupret 50 sugar coated tab', 'سينوبريت 50 قرص', '160', '120', 'Decongestant', 'Elder flowers+gentian root+primose flowers+shop vervain wort+sorrel herb', 'Bionorica ag-germany > technomed group-egypt', 'Tab', 'أقراص', NULL, '2', 'يستخدم فى معالجة السعال ومضاد للالتهابات ويدعم عمل الجهاز التنفسي', NULL, '4029799121327', NULL, 4059, '2025-08-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27059, 'Sinutab 8 tab.', 'ساينوتاب 8 قرص', '3', NULL, 'Cold drugs', 'Paracetamol(acetaminophen)+pseudoephedrine', 'Hikma pharma > johnson & johnson usa', 'Tab', 'أقراص', NULL, '1', 'مسكن وخافض للحرارة ومضاد للالتهابات ويعمل على تخفيف اعراض البرد', 'about paracetamol acetanilide derivative non narcotic analgesic antipyretic. mechanism of action of paracetamol paracetamol has analgesic and antipyretic action. it is more active on cyclo-oxygenase enzyme in brain. peripherally it is a poor inhibitor of', NULL, NULL, 1128, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27062, 'Siri pro hair serum 120 ml', 'سيري برو سيروم للشعر 120مل', '75', NULL, 'Hair care', 'Caffeine+rosemary oil+panthenol+tocopherol+almond oil+jojoba oil+silicon oil+menthol+olive oil+sesam', 'Cosmopack > rival pharma', 'Serum', 'سيروم', '120 ml', '1', NULL, 'advanced hair care serum spray - 12 powerful extracts with caffeine & rosemary', NULL, NULL, 565, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27063, 'Sirto 50mg 10 f.c. tabs.', 'سيرتو 50مجم 10 اقراص', '34', '25.2', 'Psychiatric.antidepressants', 'Sertraline', 'Hi-pharm', 'Tab', 'أقراص', '50mg', '1', NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6224001050435', NULL, 1104, '2023-11-26', 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27064, 'Sisley cream 50 gm', 'سيسلي كريم 50جم', '56', NULL, 'Healing topical', 'Silicone gel+hydrolyzed wheat protein+safflower oil+olive oil+coenzyme a+soybean oil+l-carnitine+caf', 'Cosmopack for cosmetics > meritoya pharmaceuticals', 'Cream', 'كريم', '50 gm', '1', NULL, 'skin healing. remodelling. firming cream.', NULL, NULL, 671, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27066, 'Sk albumin 20% (100ml) vial', 'اس كيه البيومين 20% فيال 100 مل', '255', NULL, 'Hypoalbuminemia', 'Human albumin', 'Sk chemicals co korea. > faripharma medical co-egypt', 'Vial', 'فيال', '20%', '1', NULL, NULL, NULL, NULL, 1210, '2022-06-16', 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27067, 'Sk albumin 20% (50ml) vial', 'اس كي البومين 20% 50مل فيال', '501', NULL, 'Hypoalbuminemia', 'Human albumin', 'Sk chemicals co korea. > faripharma medical co-egypt', 'Vial', 'فيال', '20%', '1', NULL, NULL, NULL, NULL, 705, '2022-07-15', 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27068, 'Skilful cream 30 gm', 'سكيلفول كريم 30 جم', '45', NULL, 'Anti-acne', 'Lemon extract+chamomile+panthenol+salicylic acid+stearic acid+lanette o+bees wax+methyl paraben+prop', 'Egyptian company for cosmetics > ramacin pharmaceutical company', 'Cream', 'كريم', '30 gm', '1', 'علاج حب الشباب', 'face cream', NULL, NULL, 1130, '2023-01-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27069, 'Skilful soap 100 gm', 'سكيلفول صابونة 100 جم', '20', NULL, 'Soap', NULL, 'Egyptian company for cosmetics > ramacin pharmaceutical company', 'Soap', 'صابون', '100 gm', '1', NULL, 'moisturizing soap', NULL, NULL, 734, '2023-01-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27070, 'Skin mix lightening cleanser 200 ml', 'سكين ميكس غسول لتفتيح البشرة 200 مل', '85', NULL, 'Whitening topical', NULL, 'Egyptian company for cosmetics > pharmix', 'Cleanser', 'منظف', '200 ml', '1', NULL, NULL, NULL, NULL, 856, '2022-06-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27071, 'Skin mix cream 60 gm', 'سكين مكس كريم 60جم', '150', NULL, 'Whitening topical', 'Liquorice+titanium dioxide+vitamin c', 'Egyptian company for cosmetics > pharmix', 'Cream', 'كريم', '60 gm', '1', NULL, 'whitening & lightening cream skin-refining cream to enhance radiance & improve texture', NULL, NULL, 756, '2022-07-17', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27072, 'Skin mix soap 100 gm', 'سكين ميكس صابونة 100جم', '40', NULL, 'Whitening topical', 'Titanium dioxide+lanolin+castor oil+vitamin c+licorice ext+hyaluronic acid+caviar ext+ collagen', 'Egyptian company for cosmetics > pharmix', 'Soap', 'صابون', '100 gm', '1', NULL, 'whitening soap - skin ph maintenance soap - for sensitive & combined skin', NULL, NULL, 736, '2022-07-08', 0, 'Titanium dioxide is used in most sunscreens to block UVA and UVB rays, similar to [zinc oxide].', 'Diminish the penetration of ultraviolet (UV) light through the epidermis by absorbing UV radiation within a specific wavelength range. The amount and wavelength of UV radiation absorbed are affected by the molecular structure of the sunscreen agent. ', NULL, 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27073, 'Skin so pure mask 75 gm', 'سكين سو بيور ماسك 75جم', '95', NULL, 'Facial wash', 'Liquorice+bearberry+jojoba oil+mulberry+titanium dioxide+kojic dipalmitate+niacinamide+vitamin(c+e)', 'Egyptian company for cosmetics > l origine laboratoire', 'Unknown', 'غير محدد', '75 gm', '1', NULL, 'whitening facial mask', NULL, NULL, 931, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27074, 'Skinatra top. oint. 15 gm', 'سكيناترا مرهم 15 جم', '59', '41', NULL, 'Chloramphenicol+collagenase', 'Zad', 'Oint', 'مرهم', '15 gm', '1', 'يستخدم فى التنظيف الإنزيمي للجروح المتكررة والقروح والحروق, ولعلاج العديد من الالتهابات الجلدية مثل تقرح القدم ٬ وقرح الفراش ٬ والغرغرينا ٬ وخاصة الناتجة عن مرض السكر, .', NULL, '6224001358050', NULL, 1985, '2024-06-10', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27075, 'Skinnatra cleansing gel 150ml', 'سكيناترا جل منظف 150 مل', '120', '95', 'Skin care', NULL, 'Hi-care > pharma zone', 'Gel', 'جل', '150ml', '1', 'جل منظف للجلد', 'ingredients: sorbitan sesquicaprylate (antil soft sc) + cucumis sativus (cucumber) extract + aloe vera extract + salicylic acid + glycolic acid + citric acid + panthenol + glycerin + imidazolidinyl urea + disodium edta + phenoxyethanol + ethylhexylglyceri', NULL, NULL, 2238, '2024-05-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27076, 'Skinnatra moist cream 50gm', 'سكيناترا كريم ترطيب 50 جرام', '110', '90', 'Moisturizing topicals', NULL, 'Hi-care > pharma zone', 'Cream', 'كريم', '50gm', '1', 'كريم ترطيب وتلطيف للجلد -- كريم للتشقق الجلدي -- حالات الحروق -- التئام الجروح', 'ingredients: hyaluronic acid + aloe vera + tocopherol (vitamin e) + glycerin + urea + carboxyvinyl polymer + glyceryl caprylate + potassium hydroxide 10% indication: oil-free moisturizing cream for oily and acne prone skin.', NULL, NULL, 8587, '2024-06-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27077, 'Skinnatra soap 100gm', 'سكيناترا صابونة 100جم', '40', '25', 'Whitening topical', NULL, 'Hi-care > pharma zone', 'Soap', 'صابون', '100gm', '1', NULL, 'for acne prone skin ingredients: salicylic acid + glycolic acid + tea tree oil + liquorice extract + aloe vera + panthenol + glycerin', NULL, NULL, 995, '2024-05-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27079, 'Skivalorine 2.5mg/5ml syrup 100ml', 'سكيفالورين 2.5مجم/4مل شراب 100مل', '8', NULL, 'Antihistamine.antiallergy', 'Desloratadine', 'Egpi > sonesta pharmaceuticals co', 'Syrup', 'شراب', '2.5mg', '1', NULL, 'about desloratadine second generation long-acting tricyclic h1 antagonist antihistamine. mechanism of action of desloratadine this second generation antihistamine has a selective peripheral h1-antagonist action.desloratadine competes with free histamine f', NULL, NULL, 823, '2022-07-24', 0, 'For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.', 'Like other H1-blockers, Desloratadine competes with free histamine for binding at H<sub>1</sub>-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.', 'Desloratadine is a long-acting second-generation H<sub>1</sub>-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27080, 'Skrofad cream 100 gm', 'سكرو فاد كريم 100 جم', '80', NULL, 'Firming topical', 'Collagen+elastin+cocoa butter+allantoin+dimethicon+grape fruit seed extract+vit.e&c+retinol+glycerin', 'Hi-care > scin.off scientific office', 'Cream', 'كريم', '100 gm', '1', 'علاج لعلامات تمدد الجلد.', 'stretch marks reducing cream', NULL, NULL, 893, '2022-05-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27081, 'Skykur cream 60 gm', 'سكايكور كريم 60جم', '120', '100', 'Soothing topical', NULL, 'Egyptian company for cosmetics > prime international pharma', 'Cream', 'كريم', '60 gm', '1', NULL, 'rejuvenation cream with spf 25', '6224011686167', NULL, 1207, '2025-07-31', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27083, 'Sleep-aid 5mg 10 tab.', 'سليب ايد 5مجم 10 اقراص', '9', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Zaleplon', 'October pharma', 'Tab', 'أقراص', '5mg', '1', NULL, 'about zaleplon pyrazolopyrimidine derivative( a nonbenzodiazepine sedative-hypnotic. mechanism of action of zaleplon zaleplon is a non benzodiazepine sedative-hypnotic drug. it binds to the benzodiazepine binding site on gaba-a receptors containing the al', '6221088010826', NULL, 812, '2022-12-08', 0, 'For the treatment of short-term treatment of insomnia in adults.', 'Zaleplon exerts its action through subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.', 'Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABA<sub>A</sub>-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27084, 'Sleepback 10 mg 14 caps.', 'سليباك 10مجم 14 كبسول', '9', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Zaleplon', 'Arab drug company.', 'Cap', 'كبسولة', '10 mg', '1', NULL, 'about zaleplon pyrazolopyrimidine derivative( a nonbenzodiazepine sedative-hypnotic. mechanism of action of zaleplon zaleplon is a non benzodiazepine sedative-hypnotic drug. it binds to the benzodiazepine binding site on gaba-a receptors containing the al', NULL, NULL, 766, '2022-07-15', 0, 'For the treatment of short-term treatment of insomnia in adults.', 'Zaleplon exerts its action through subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.', 'Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABA<sub>A</sub>-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27085, 'Sleepez 1 mg 20 f.c.tabs.', 'سليبيز 1مجم 20 قرص', '32', '21', 'Psychiatric.anxiolytics-hypnotics', 'Eszopiclone', 'Chemipharm', 'Tab', 'أقراص', '1 mg', '2', NULL, NULL, '6222006500603', NULL, 1505, '2025-08-04', 0, 'Eszopiclone is indicated for the treatment of insomnia.[L6769]', 'The exact mechanism of action of eszopiclone is unknown at this time but is thought to occur via binding with the GABA receptor complexes at binding sites located near benzodiazepine receptors, possibly explaining its hypnotic and sedative effects.[A179659,L6769] It has particular affinity for GABA-A (or GABAA) receptor subunits 1, 3 and 5.[A179788,A15625,A15626] Eszopiclone increases GABA-A channel currents significantly.[A179788] GABA-A channels are major inhibitory channels that cause CNS depression when their receptors are activated.[A179800]', 'Eszopiclone rapidly induces sleep and decreases sleep latency. It also aids in the maintenance of sleep, preventing frequent awakenings.[A179659,A179662,L6769] This drug has shown anticonvulsant and muscle relaxant properties in animals but is used in humans for its sedating effects.[A179827]



Eszopiclone is a central nervous system depressant with various effects. These include changes in alertness and motor coordination and the risk of next morning impairment, increasing with the amount of eszopiclone administered.  Exercise caution and advise against driving a motor vehicle or activities that require full mental alertness the next morning.[L6769] Complex sleep behaviors may result from eszopiclone use. Eszopiclone should be discontinued in these cases.[L6874] Avoid the use of alcohol and other CNS depressants when eszopiclone is administered. Advise patients to skip the eszopiclone dose if alcohol has been consumed before bed or during the evening. Use the smallest dose of eszopiclone as possible, especially in elderly patients, who may experience exaggerated drug effects. Though the potential for dependence and abuse with eszopiclone is lower than for other hypnotic drugs, this drug has been abused and is known to cause dependence.[L6868]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27088, 'Sleepoclone 2 mg 10 f.c. tabs.', 'سليبوكلون 2مجم 10 اقراص', '7', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Eszopiclone', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '2 mg', '1', NULL, 'about eszopiclone benzodiazepine agonist sedative and hypnotics. mechanism of action of eszopiclone eszopiclone acts on benzodiazepine binding site situated on gabaa neurons as an agonist increases the conduction of chloride ions across the neuronal cell', NULL, NULL, 1231, '2022-07-15', 0, 'Eszopiclone is indicated for the treatment of insomnia.[L6769]', 'The exact mechanism of action of eszopiclone is unknown at this time but is thought to occur via binding with the GABA receptor complexes at binding sites located near benzodiazepine receptors, possibly explaining its hypnotic and sedative effects.[A179659,L6769] It has particular affinity for GABA-A (or GABAA) receptor subunits 1, 3 and 5.[A179788,A15625,A15626] Eszopiclone increases GABA-A channel currents significantly.[A179788] GABA-A channels are major inhibitory channels that cause CNS depression when their receptors are activated.[A179800]', 'Eszopiclone rapidly induces sleep and decreases sleep latency. It also aids in the maintenance of sleep, preventing frequent awakenings.[A179659,A179662,L6769] This drug has shown anticonvulsant and muscle relaxant properties in animals but is used in humans for its sedating effects.[A179827]



Eszopiclone is a central nervous system depressant with various effects. These include changes in alertness and motor coordination and the risk of next morning impairment, increasing with the amount of eszopiclone administered.  Exercise caution and advise against driving a motor vehicle or activities that require full mental alertness the next morning.[L6769] Complex sleep behaviors may result from eszopiclone use. Eszopiclone should be discontinued in these cases.[L6874] Avoid the use of alcohol and other CNS depressants when eszopiclone is administered. Advise patients to skip the eszopiclone dose if alcohol has been consumed before bed or during the evening. Use the smallest dose of eszopiclone as possible, especially in elderly patients, who may experience exaggerated drug effects. Though the potential for dependence and abuse with eszopiclone is lower than for other hypnotic drugs, this drug has been abused and is known to cause dependence.[L6868]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27089, 'Slim safe 120mg 30 caps.', 'سليم سيف 120مجم 30 كبسولة', '162', '105', 'Weight loss', 'Orlistat', 'Amoun', 'Cap', 'كبسولة', '120mg', '3', '1- تخسيس البطن والأرداف.', 'about orlistat anti-obese drug. saturated derivative of lipstatin. mechanism of action of orlistat its primary function is preventing the absorption of fats from the human diet thereby reducing caloric intake.orlistat works by inhibiting gastric and pancr', '6221025023384', NULL, 5595, '2024-03-23', 0, 'Orlistat is indicated for obesity management including weight loss and weight maintenance when used in combination with calorie reduction in overweight and obese adults; this indication applies to both the prescription formulation of 120 mg[L11130] and the over-the-counter formulation of 60 mg.[L31963] Orlistat in the 120 mg prescription formulation is also indicated to reduce the risk of weight regain following weight loss.[L11130]', 'Orlistat is a potent and selective inhibitor of various lipase enzymes responsible for the metabolism of fat. It acts in the gastrointestinal (GI) tract via covalent binding to the serine residues located on the active site of both gastric and pancreatic lipase. When orlistat is taken with food containing fat, it partially inhibits the hydrolysis of triglycerides. This decreases absorption of monoaclglycerides and free fatty acids, contributing to weight maintenance and weight loss.[A37653,L11130]', 'Orlistat helps with weight reduction and maintenance by inhibiting the absorption of dietary fats via the inhibition of lipase enzymes.[A1734,A1735]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27090, 'Slimmer sweetener 100 sachets', 'سليمر سويتنر 100 كيس', '135', '99', 'Sweetener', 'Sucralose', 'Eva pharma', 'Sachet', 'أكياس', NULL, '1', NULL, '1 sachet = 2 teaspoonful of normal sugar', NULL, NULL, 807, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27091, 'Slimmer sweetener 300 sachets', 'سليمر سويتنر 300 كيس', '410', '360', 'Sweetener', 'Sucralose', 'Eva pharma', 'Sachet', 'أكياس', NULL, '1', NULL, '1 sachet = 2 teaspoonful of normal sugar', '6223002454617', NULL, 783, '2025-10-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27092, 'Slimmer sweetener 50 sachets', 'سليمر سويتنر 50 كيس', '85', '62', 'Sweetener', 'Sucralose', 'Eva pharma', 'Sachet', 'أكياس', NULL, '1', NULL, '1 sachet = 2 teaspoonful of normal sugar', '6223002454266', NULL, 1002, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27093, 'Slow k 600mg 20 f.c.tab.', 'سلو كيه 600مجم 20 قرص', '8', NULL, 'Potassium supplement', 'Potassium chloride', 'Novartis', 'Tab', 'أقراص', '600mg', '2', 'مكمل غذائي غني بالبوتاسيوم والكلوريد--يستخدم لعلاج نقص البوتاسيوم--نقص الكلوريد', 'about potassium chloride electrolyte replenisher potassium supplement. mechanism of action of potassium chloride potassium chloride is used when the action of potassium cation is desired.it is used in the treatment of hypokalaemia or hypochloremic alkalos', '6223002640652', NULL, 2398, '2022-08-18', 0, 'For use as an electrolyte replenisher and in the treatment of hypokalemia.', 'Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.', 'The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27094, 'Slowurge 10 mg 30 f.c.tabs', 'سلو ارج 10مجم 30 قرص', '144', '106.5', 'Urinary incontinence.antispasmodics.muscarinic antagonists', 'Solifenacin succinate', 'Mash premiere', 'Tab', 'أقراص', '10 mg', '3', 'لعلاج مشاكل التبول اللارادي -- وعدم القدرة على التحكم في مثانة البول', NULL, '6222001401745', NULL, 5172, '2025-01-01', 0, 'Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]', 'Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin''s antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]', 'Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder.[L7511,A181262] It has a long duration of action as it is usually taken once daily.[L7511] Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.[L7511]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27095, 'Slow-zem 120mg 10 caps.', 'سلوزيم 120مجم10 كبسولة', '8', NULL, 'Antihypertensive.nonselective calcium channel blocker', 'Diltiazem', 'Pharopharma', 'Cap', 'كبسولة', '120mg', '1', NULL, 'about diltiazem a benzothiazepine derivative calcium channel blocker anti hypertensive anti-anginal class iv antiarrhythmic. mechanism of action of diltiazem diltiazem is a benzothiazepine- ca channel blocker. it exerts it`s antianginal antihypertensive a', NULL, NULL, 796, '2022-07-28', 0, '**Oral**



Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[L10556]



Indicated for use to improve exercise tolerance in patients with chronic stable angina.[L10556]



Indicated for the management of variant angina (Prinzmetal''s angina).[L6298]



**Intravenous**



Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292]



Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292]



**Off-label**



Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]', 'Excitation of cardiac muscle involves the activation of a slow calcium inward current that is induced by L-type slow calcium channels, which are voltage-sensitive, ion-selective channels[A178444] associated with a high activation threshold and slow inactivation profile.[T28] L-type calcium channels are the main current responsible for the late phase of the pacemaker potential.[A178492] Acting as the main Ca2+ source for contraction in smooth and cardiac muscle, activation of L-type calcium channels allows the influx of calcium ions into the muscles upon depolarization and excitation of the channel.[A178444] It is proposed that this cation influx may also trigger the release of additional calcium ions from intracellular storage sites.[A178444] Diltiazem is a slow calcium channel blocker that binds to the extracellular site of the alpha-1C subunit of the channel, which is thought to be the S5-6 linker region of the transmembrane domain IV and/or S6 segment of domain III.[A178492]  Diltiazem can get access to this binding site from either the intracellular or extracellular side, but it requires a voltage-induced conformational changes in the membrane.[A178492] Diltiazem inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes.[L10556] In isolated human atrial and ventricular myocardium, diltiazem suppressed tension over the range of membrane potentials associated with calcium channel activity but had little effect on the tension-voltage relations at more positive potentials.[A178453] This effect is thought to be mediated by the voltage-dependent block of the L-type calcium channels and inhibition of calcium ion release from the ER stores, without altering the sodium-calcium coupled transport or calcium sensitivity of myofilaments.[A178453] Through inhibition of inward calcium current, diltiazem exerts a direct ionotropic and energy sparing effect on the myocardium.[A178444] Diltiazem fslows atrioventricular nodal conduction, which is due to its ability to impede slow channel function.[A178444]



Reduced intracellular calcium concentrations equate to increased smooth muscle relaxation resulting in arterial vasodilation and therefore, decreased blood pressure.[L6289] The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.[L6289,L10556] Through its actions on reducing calcium levels in cardiac and vascular smooth muscles, diltiazem causes a reduction in the contractile processes of the myocardial smooth muscle cells and vasodilation of the coronary and systemic arteries, including epicardial and subendocardial. This subsequently leads to increased oxygen delivery to the myocardial tissue, improved cardiac output due to increased stroke volume, decreased total peripheral resistance, decreased systemic blood pressure and heart rate, and decreased afterload.[L6289,L10556] Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility; this leads to a therapeutic effect in improving exercise tolerance in chronic stable angina.[A178432,L6289] ', 'Diltiazem is an antihypertensive and vasodilating agent that works by relaxing the vascular muscle and reducing blood pressure. This is related to the long-term therapeutic effects, as lowering the blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.[L10556] Diltiazem inhibits the influx of extracellular calcium ions across the myocardial and vascular smooth muscle cell membranes during depolarization. Diltiazem is classified as a negative inotrope (decreased force) and negative chronotrope (decreased rate).[L6289] It is also considered a rate-control drug as it reduces heart rate.[A178432,T28] Diltiazem is exerts hemodynamic actions by reducing blood pressure, systemic vascular resistance, the rate-pressure product, and coronary vascular resistance while increasing coronary blood flow.[L6292] Diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations.[L10556] In supraventricular tachycardia, diltiazem prolongs AV nodal refractories.[L6292]



As the magnitude of blood pressure reduction is related to the degree of hypertension, the antihypertensive effect of diltiazem is most pronounced in individuals with hypertension. In a randomized, double-blind, parallel-group, dose-response study involving patients with essential hypertension, there was a reduction in the diastolic blood pressure by 1.9, 5.4, 6.1, and 8.6 mmHg in the patients receiving diltiazem at doses of 120, 240, 360, and 540 mg, respectively. In patients receiving placebo, there was a reduction in the diastolic blood pressure by 2.6 mmHg.In a randomized, double-blind study involving patients with chronic stable angina, variable doses of diltiazem administered at night all caused an increased exercise tolerance in the after 21 hours, compared to placebo.[L10556] In the NORDIL study of patients with hypertension, the therapeutic effectiveness of diltiazem in reducing cardiovascular morbidity and mortality was assessed.[A178432] When using the combined primary endpoint as fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death, fatal and non-fatal stroke was shown to be reduced by 25% in the diltiazem group. Although the clinical significance to this effect remains unclear, it is suggested that diltiazem may exert a protective role against cerebral stroke in hypertensive patients.[A178432] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27096, 'Slow-zem 180mg 10 caps.', 'سلو زيم 180مجم 10 كبسول', '12', NULL, 'Antihypertensive.nonselective calcium channel blocker', 'Diltiazem', 'Pharopharma', 'Cap', 'كبسولة', '180mg', '1', NULL, 'about diltiazem a benzothiazepine derivative calcium channel blocker anti hypertensive anti-anginal class iv antiarrhythmic.ssmechanism of action of diltiazemsdiltiazem is a benzothiazepine- ca channel blocker. it exerts it`s antianginal antihypertensive', NULL, NULL, 712, '2022-07-23', 0, '**Oral**



Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[L10556]



Indicated for use to improve exercise tolerance in patients with chronic stable angina.[L10556]



Indicated for the management of variant angina (Prinzmetal''s angina).[L6298]



**Intravenous**



Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292]



Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292]



**Off-label**



Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]', 'Excitation of cardiac muscle involves the activation of a slow calcium inward current that is induced by L-type slow calcium channels, which are voltage-sensitive, ion-selective channels[A178444] associated with a high activation threshold and slow inactivation profile.[T28] L-type calcium channels are the main current responsible for the late phase of the pacemaker potential.[A178492] Acting as the main Ca2+ source for contraction in smooth and cardiac muscle, activation of L-type calcium channels allows the influx of calcium ions into the muscles upon depolarization and excitation of the channel.[A178444] It is proposed that this cation influx may also trigger the release of additional calcium ions from intracellular storage sites.[A178444] Diltiazem is a slow calcium channel blocker that binds to the extracellular site of the alpha-1C subunit of the channel, which is thought to be the S5-6 linker region of the transmembrane domain IV and/or S6 segment of domain III.[A178492]  Diltiazem can get access to this binding site from either the intracellular or extracellular side, but it requires a voltage-induced conformational changes in the membrane.[A178492] Diltiazem inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes.[L10556] In isolated human atrial and ventricular myocardium, diltiazem suppressed tension over the range of membrane potentials associated with calcium channel activity but had little effect on the tension-voltage relations at more positive potentials.[A178453] This effect is thought to be mediated by the voltage-dependent block of the L-type calcium channels and inhibition of calcium ion release from the ER stores, without altering the sodium-calcium coupled transport or calcium sensitivity of myofilaments.[A178453] Through inhibition of inward calcium current, diltiazem exerts a direct ionotropic and energy sparing effect on the myocardium.[A178444] Diltiazem fslows atrioventricular nodal conduction, which is due to its ability to impede slow channel function.[A178444]



Reduced intracellular calcium concentrations equate to increased smooth muscle relaxation resulting in arterial vasodilation and therefore, decreased blood pressure.[L6289] The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.[L6289,L10556] Through its actions on reducing calcium levels in cardiac and vascular smooth muscles, diltiazem causes a reduction in the contractile processes of the myocardial smooth muscle cells and vasodilation of the coronary and systemic arteries, including epicardial and subendocardial. This subsequently leads to increased oxygen delivery to the myocardial tissue, improved cardiac output due to increased stroke volume, decreased total peripheral resistance, decreased systemic blood pressure and heart rate, and decreased afterload.[L6289,L10556] Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility; this leads to a therapeutic effect in improving exercise tolerance in chronic stable angina.[A178432,L6289] ', 'Diltiazem is an antihypertensive and vasodilating agent that works by relaxing the vascular muscle and reducing blood pressure. This is related to the long-term therapeutic effects, as lowering the blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.[L10556] Diltiazem inhibits the influx of extracellular calcium ions across the myocardial and vascular smooth muscle cell membranes during depolarization. Diltiazem is classified as a negative inotrope (decreased force) and negative chronotrope (decreased rate).[L6289] It is also considered a rate-control drug as it reduces heart rate.[A178432,T28] Diltiazem is exerts hemodynamic actions by reducing blood pressure, systemic vascular resistance, the rate-pressure product, and coronary vascular resistance while increasing coronary blood flow.[L6292] Diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations.[L10556] In supraventricular tachycardia, diltiazem prolongs AV nodal refractories.[L6292]



As the magnitude of blood pressure reduction is related to the degree of hypertension, the antihypertensive effect of diltiazem is most pronounced in individuals with hypertension. In a randomized, double-blind, parallel-group, dose-response study involving patients with essential hypertension, there was a reduction in the diastolic blood pressure by 1.9, 5.4, 6.1, and 8.6 mmHg in the patients receiving diltiazem at doses of 120, 240, 360, and 540 mg, respectively. In patients receiving placebo, there was a reduction in the diastolic blood pressure by 2.6 mmHg.In a randomized, double-blind study involving patients with chronic stable angina, variable doses of diltiazem administered at night all caused an increased exercise tolerance in the after 21 hours, compared to placebo.[L10556] In the NORDIL study of patients with hypertension, the therapeutic effectiveness of diltiazem in reducing cardiovascular morbidity and mortality was assessed.[A178432] When using the combined primary endpoint as fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death, fatal and non-fatal stroke was shown to be reduced by 25% in the diltiazem group. Although the clinical significance to this effect remains unclear, it is suggested that diltiazem may exert a protective role against cerebral stroke in hypertensive patients.[A178432] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27097, 'Slow-zem 90mg 10 caps.', 'سلو زيم 90مجم 10 كبسول', '8', NULL, 'Antihypertensive.nonselective calcium channel blocker', 'Diltiazem', 'Pharopharma', 'Cap', 'كبسولة', '90mg', '1', NULL, 'about diltiazem a benzothiazepine derivative calcium channel blocker anti hypertensive anti-anginal class iv antiarrhythmic. mechanism of action of diltiazem diltiazem is a benzothiazepine- ca channel blocker. it exerts it`s antianginal antihypertensive a', NULL, NULL, 778, '2022-07-18', 0, '**Oral**



Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[L10556]



Indicated for use to improve exercise tolerance in patients with chronic stable angina.[L10556]



Indicated for the management of variant angina (Prinzmetal''s angina).[L6298]



**Intravenous**



Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292]



Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292]



**Off-label**



Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]', 'Excitation of cardiac muscle involves the activation of a slow calcium inward current that is induced by L-type slow calcium channels, which are voltage-sensitive, ion-selective channels[A178444] associated with a high activation threshold and slow inactivation profile.[T28] L-type calcium channels are the main current responsible for the late phase of the pacemaker potential.[A178492] Acting as the main Ca2+ source for contraction in smooth and cardiac muscle, activation of L-type calcium channels allows the influx of calcium ions into the muscles upon depolarization and excitation of the channel.[A178444] It is proposed that this cation influx may also trigger the release of additional calcium ions from intracellular storage sites.[A178444] Diltiazem is a slow calcium channel blocker that binds to the extracellular site of the alpha-1C subunit of the channel, which is thought to be the S5-6 linker region of the transmembrane domain IV and/or S6 segment of domain III.[A178492]  Diltiazem can get access to this binding site from either the intracellular or extracellular side, but it requires a voltage-induced conformational changes in the membrane.[A178492] Diltiazem inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes.[L10556] In isolated human atrial and ventricular myocardium, diltiazem suppressed tension over the range of membrane potentials associated with calcium channel activity but had little effect on the tension-voltage relations at more positive potentials.[A178453] This effect is thought to be mediated by the voltage-dependent block of the L-type calcium channels and inhibition of calcium ion release from the ER stores, without altering the sodium-calcium coupled transport or calcium sensitivity of myofilaments.[A178453] Through inhibition of inward calcium current, diltiazem exerts a direct ionotropic and energy sparing effect on the myocardium.[A178444] Diltiazem fslows atrioventricular nodal conduction, which is due to its ability to impede slow channel function.[A178444]



Reduced intracellular calcium concentrations equate to increased smooth muscle relaxation resulting in arterial vasodilation and therefore, decreased blood pressure.[L6289] The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.[L6289,L10556] Through its actions on reducing calcium levels in cardiac and vascular smooth muscles, diltiazem causes a reduction in the contractile processes of the myocardial smooth muscle cells and vasodilation of the coronary and systemic arteries, including epicardial and subendocardial. This subsequently leads to increased oxygen delivery to the myocardial tissue, improved cardiac output due to increased stroke volume, decreased total peripheral resistance, decreased systemic blood pressure and heart rate, and decreased afterload.[L6289,L10556] Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility; this leads to a therapeutic effect in improving exercise tolerance in chronic stable angina.[A178432,L6289] ', 'Diltiazem is an antihypertensive and vasodilating agent that works by relaxing the vascular muscle and reducing blood pressure. This is related to the long-term therapeutic effects, as lowering the blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.[L10556] Diltiazem inhibits the influx of extracellular calcium ions across the myocardial and vascular smooth muscle cell membranes during depolarization. Diltiazem is classified as a negative inotrope (decreased force) and negative chronotrope (decreased rate).[L6289] It is also considered a rate-control drug as it reduces heart rate.[A178432,T28] Diltiazem is exerts hemodynamic actions by reducing blood pressure, systemic vascular resistance, the rate-pressure product, and coronary vascular resistance while increasing coronary blood flow.[L6292] Diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations.[L10556] In supraventricular tachycardia, diltiazem prolongs AV nodal refractories.[L6292]



As the magnitude of blood pressure reduction is related to the degree of hypertension, the antihypertensive effect of diltiazem is most pronounced in individuals with hypertension. In a randomized, double-blind, parallel-group, dose-response study involving patients with essential hypertension, there was a reduction in the diastolic blood pressure by 1.9, 5.4, 6.1, and 8.6 mmHg in the patients receiving diltiazem at doses of 120, 240, 360, and 540 mg, respectively. In patients receiving placebo, there was a reduction in the diastolic blood pressure by 2.6 mmHg.In a randomized, double-blind study involving patients with chronic stable angina, variable doses of diltiazem administered at night all caused an increased exercise tolerance in the after 21 hours, compared to placebo.[L10556] In the NORDIL study of patients with hypertension, the therapeutic effectiveness of diltiazem in reducing cardiovascular morbidity and mortality was assessed.[A178432] When using the combined primary endpoint as fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death, fatal and non-fatal stroke was shown to be reduced by 25% in the diltiazem group. Although the clinical significance to this effect remains unclear, it is suggested that diltiazem may exert a protective role against cerebral stroke in hypertensive patients.[A178432] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27098, 'Smecta 20% suspension 120 ml', 'سميكتا 20% معلق 120 مل', '11', NULL, 'Antidiarrheal', 'Dioctahedral smectite', 'Amriya > ipsen', 'Suspension', 'معلق', '20%', '1', NULL, 'mode of action dioctahedral has adsorbent properties and is used in the management of diarrhoea. dioctahedral has unique properties that allow for the adsorption of different toxins (such as rotavirus e. coli and staphylococcus). dioctahedral interacts wi', '6221075200636', NULL, 968, '2023-04-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27099, 'Smecta 20% suspension 60 ml', 'سميكتا 20% معلق 60 مل', '7', NULL, 'Antidiarrheal', 'Dioctahedral smectite', 'Amriya > ipsen', 'Suspension', 'معلق', '20%', '1', NULL, 'mode of action dioctahedral has adsorbent properties and is used in the management of diarrhoea. dioctahedral has unique properties that allow for the adsorption of different toxins (such as rotavirus e. coli and staphylococcus). dioctahedral interacts wi', '6221075200063', NULL, 956, '2023-04-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27100, 'Smecta 20% suspension 90 ml', 'سميكتا 20% معلق 90 مل', '9', NULL, 'Antidiarrheal', 'Dioctahedral smectite', 'Amriya > ipsen', 'Suspension', 'معلق', '20%', '1', NULL, 'mode of action dioctahedral has adsorbent properties and is used in the management of diarrhoea. dioctahedral has unique properties that allow for the adsorption of different toxins (such as rotavirus e. coli and staphylococcus). dioctahedral interacts wi', '6221075200070', NULL, 938, '2023-04-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27101, 'Smecta 3gm 10 sachet', 'سميكتا 3جم 10 اكياس', '11', NULL, 'Antidiarrheal', 'Dioctahedral smectite', 'Amriya > ipsen', 'Sachet', 'أكياس', '3gm', '1', NULL, 'mode of action dioctahedral has adsorbent properties and is used in the management of diarrhoea. dioctahedral has unique properties that allow for the adsorption of different toxins (such as rotavirus e. coli and staphylococcus). dioctahedral interacts wi', '6221075180013', NULL, 1062, '2023-04-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27102, 'Smile baby cream 60 gm', 'سمايل بيبي كريم 60جم', '10', NULL, 'Diaper rash', 'Zinc oxide+chamomile+cod liver oil+castor oil', 'Hi-care > phoenix-egypt', 'Cream', 'كريم', '60 gm', '1', NULL, 'protection of delicate skin of children and adults (fragrance free steroid free)', NULL, NULL, 663, '2022-07-26', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27103, 'Smile lotion 120 ml', 'سمايل لوشن 120 ملي', '10', NULL, 'Soothing topical', 'Zinc oxide+menthol+camphor+red iron oxide', 'H.c.p co. > phoenix-egypt', 'Lotion', 'لوشن', '120 ml', '1', NULL, 'soothing lotion', '6225000027411', NULL, 662, '2022-12-08', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27104, 'Smofkabiven peripheral 1904ml=1300kcal emulsion for inf.', 'سموفكابيفن بريفرال 1300كيلو كالوري مستحلب للتنقيط الوريدي', '1,008', '593', 'Sterile solution', 'Glucose+amino acids+lipids', 'Fresenius kabi', 'Unknown', 'غير محدد', '1904ml', '1', 'محلول معقم', NULL, NULL, NULL, 9667, '2024-11-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27105, 'Smofkabiven peripheral 1206ml=800kcal emulsion for inf.', 'سموفكابيفين بيرفرال 800 كيلو كالوري مستحلب للتسريب الوريدي', '3,320', '833', 'Sterile solution', 'Glucose+amino acids+lipids', 'Fresenius kabi', 'Unknown', 'غير محدد', '1206ml', '1', 'يستخدم كمحلول معقم -- علاج إنخفاض سكر الدم', NULL, NULL, NULL, 2827, '2025-03-22', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27106, 'Smoflipid 20% emulsion 100ml i.v. inf.', 'سموفليبيد 20% مستحلب 100 مل للحقن الوريدي', '110', NULL, 'Sterile solution', 'Fish oil+olive oil+soya bean oil+triglyceride', 'Fresenius kabi', 'Unknown', 'غير محدد', '20%', '1', 'محلول لدعم الصحة -- مصدر للسعرات الحرارية والاحماض الدهنية', NULL, NULL, NULL, 1044, '2022-05-28', 0, 'Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label, F36].



Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].', 'The specific mechanism of action by which the fish oil EPA and DHA acids are capable of reducing serum triglyceride levels is not yet fully understood [FDA Label, A32933]. Nevertheless, it is proposed that such omega-3-fatty acids may not be the preferred substrates of the enzyme diacylglycerol O-acyltransferase that participates in the generation of triglycerides; that  they might interact with nuclear transcription factors that manage lipogenesis; or that their presence and increase in levels can cause cellular metabolism to subsequently shift toward a decrease in triglyceride synthesis and an increase in fatty acid oxidation [A32933]. Moreover, the EPA and DHA acids are also believed to be able to promote apolipoprotein B degradation in the liver through the stimulation of an autophagic process [A32933]. It may also be possible that these fish oil acids can accelerate the clearance of very-low-density lipoprotein (VLDL) particles and chylomicron [A32933]. The combination of all these actions results in fewer VLDL particles being assembled and secreted, which is of considerable importance as VLDL particles are the major endogenous source of triglycerides [A32933].



Moreover, new paradigms of how inflammation is contained and dissipated involve various newly discovered chemical mediators, resolvins, and protectins [A32933]. Such agents are believed to be directly involved in blocking neutrophil migration, infiltration, recruitment, as well as blocking T-cell migration and promoting T-cell apoptosis [A32933]. Additionally, such protectins can also reduce tumor necrosis factor and interferon secretion [A32933]. Of particular importance, however, is the fact that protectins and resolvins are exclusively derived from omega-3-fatty acids and that EPA is the substrate of the resolvins family and DHA can be converted to both resolvins and protectins [A32933]. It is believed that these effects of such fish oil acids underlie the actions that fish oil have demonstrated on eliciting stability for vulnerable inflammatory plaques [A32933].



Finally, fish oil acids have demonstrated certain direct electrophysiological effects on the myocardium [A32933]. In animal studies, it was shown that the ventricular fibrillation threshold could be increased in both animals fed or infused with omega-3-fatty acids [A32933]. Further studies subsequently revealed that such fatty acids could reduce both sodium currents and L-type calcium currents on a cellular and ion channel level [A32933]. It is consequently hypothesized that during ischemia, a reduction in the sodium ion current protects hyperexcitable tissue, and a reduction in the calcium ion current could reduce arrhythmogenic depolarizing currents - and that perhaps the use of EPA and DHA fish oil acids could facilitate such activity [A32933]. For the time being, however, omega-3-fatty acids in pharmaceutical supplement form have not been shown to elicit such protection against heart conditions [L2662].', 'In general, the only practical method of obtaining and increasing the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fish oil omega-3-fatty acids in the body is to consume them directly from foods and/or dietary supplements [L784]. Having EPA and DHA is important because they facilitate numerous important functions in the human body. As an example, such supplementation of fish oil EPA and DHA demonstrates a legitimate ability to decrease triglyceride levels as their presence in the body can act as poor substrates for the enzymes that are ordinarily responsible for triglyceride synthesis and also inhibit the esterification of other fatty acids, among other mechanisms [FDA Label, L2661].



Moreover, such fish oil acids can become important components of the phospholipids that form the structures of cell membranes [L784]. Specifically, DHA is particularly high in the retina, brain, and sperm [L784]. Additionally, these acids also provide energy for the body and are used to form eicosanoids - signaling molecules that have similar chemical structures to the fish oil fatty acids from which they are derived [L784]. Furthermore, such eicosanoids possess wide-ranging functions in the cardiovascular, pulmonary, immune, and endocrine systems [L784].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27107, 'Smoflipid 20% emulsion 250ml i.v. inf.', 'سموفيليبيد 20% مستحلب 250 مل محلول وريدي', '169', NULL, NULL, 'Fish oil+olive oil+soya bean oil+triglyceride', 'Fresenius kabi', 'Unknown', 'غير محدد', '20%', '1', 'محلول لدعم الصحة -- مصدر للسعرات الحرارية والاحماض الدهنية', NULL, NULL, NULL, 2622, '2022-05-28', 0, 'Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label, F36].



Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].', 'The specific mechanism of action by which the fish oil EPA and DHA acids are capable of reducing serum triglyceride levels is not yet fully understood [FDA Label, A32933]. Nevertheless, it is proposed that such omega-3-fatty acids may not be the preferred substrates of the enzyme diacylglycerol O-acyltransferase that participates in the generation of triglycerides; that  they might interact with nuclear transcription factors that manage lipogenesis; or that their presence and increase in levels can cause cellular metabolism to subsequently shift toward a decrease in triglyceride synthesis and an increase in fatty acid oxidation [A32933]. Moreover, the EPA and DHA acids are also believed to be able to promote apolipoprotein B degradation in the liver through the stimulation of an autophagic process [A32933]. It may also be possible that these fish oil acids can accelerate the clearance of very-low-density lipoprotein (VLDL) particles and chylomicron [A32933]. The combination of all these actions results in fewer VLDL particles being assembled and secreted, which is of considerable importance as VLDL particles are the major endogenous source of triglycerides [A32933].



Moreover, new paradigms of how inflammation is contained and dissipated involve various newly discovered chemical mediators, resolvins, and protectins [A32933]. Such agents are believed to be directly involved in blocking neutrophil migration, infiltration, recruitment, as well as blocking T-cell migration and promoting T-cell apoptosis [A32933]. Additionally, such protectins can also reduce tumor necrosis factor and interferon secretion [A32933]. Of particular importance, however, is the fact that protectins and resolvins are exclusively derived from omega-3-fatty acids and that EPA is the substrate of the resolvins family and DHA can be converted to both resolvins and protectins [A32933]. It is believed that these effects of such fish oil acids underlie the actions that fish oil have demonstrated on eliciting stability for vulnerable inflammatory plaques [A32933].



Finally, fish oil acids have demonstrated certain direct electrophysiological effects on the myocardium [A32933]. In animal studies, it was shown that the ventricular fibrillation threshold could be increased in both animals fed or infused with omega-3-fatty acids [A32933]. Further studies subsequently revealed that such fatty acids could reduce both sodium currents and L-type calcium currents on a cellular and ion channel level [A32933]. It is consequently hypothesized that during ischemia, a reduction in the sodium ion current protects hyperexcitable tissue, and a reduction in the calcium ion current could reduce arrhythmogenic depolarizing currents - and that perhaps the use of EPA and DHA fish oil acids could facilitate such activity [A32933]. For the time being, however, omega-3-fatty acids in pharmaceutical supplement form have not been shown to elicit such protection against heart conditions [L2662].', 'In general, the only practical method of obtaining and increasing the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fish oil omega-3-fatty acids in the body is to consume them directly from foods and/or dietary supplements [L784]. Having EPA and DHA is important because they facilitate numerous important functions in the human body. As an example, such supplementation of fish oil EPA and DHA demonstrates a legitimate ability to decrease triglyceride levels as their presence in the body can act as poor substrates for the enzymes that are ordinarily responsible for triglyceride synthesis and also inhibit the esterification of other fatty acids, among other mechanisms [FDA Label, L2661].



Moreover, such fish oil acids can become important components of the phospholipids that form the structures of cell membranes [L784]. Specifically, DHA is particularly high in the retina, brain, and sperm [L784]. Additionally, these acids also provide energy for the body and are used to form eicosanoids - signaling molecules that have similar chemical structures to the fish oil fatty acids from which they are derived [L784]. Furthermore, such eicosanoids possess wide-ranging functions in the cardiovascular, pulmonary, immune, and endocrine systems [L784].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27108, 'Smoflipid 20% emulsion 500ml i.v. inf.', 'سموفليبيد 20% مستحلب 500 مل للحقن الوريدي', '362', NULL, 'Sterile solution', 'Fish oil+olive oil+soya bean oil+triglyceride', 'Fresenius kabi', 'Unknown', 'غير محدد', '20%', '1', 'محلول لدعم الصحة -- مصدر للسعرات الحرارية والاحماض الدهنية', NULL, NULL, NULL, 2762, '2022-08-13', 0, 'Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label, F36].



Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].', 'The specific mechanism of action by which the fish oil EPA and DHA acids are capable of reducing serum triglyceride levels is not yet fully understood [FDA Label, A32933]. Nevertheless, it is proposed that such omega-3-fatty acids may not be the preferred substrates of the enzyme diacylglycerol O-acyltransferase that participates in the generation of triglycerides; that  they might interact with nuclear transcription factors that manage lipogenesis; or that their presence and increase in levels can cause cellular metabolism to subsequently shift toward a decrease in triglyceride synthesis and an increase in fatty acid oxidation [A32933]. Moreover, the EPA and DHA acids are also believed to be able to promote apolipoprotein B degradation in the liver through the stimulation of an autophagic process [A32933]. It may also be possible that these fish oil acids can accelerate the clearance of very-low-density lipoprotein (VLDL) particles and chylomicron [A32933]. The combination of all these actions results in fewer VLDL particles being assembled and secreted, which is of considerable importance as VLDL particles are the major endogenous source of triglycerides [A32933].



Moreover, new paradigms of how inflammation is contained and dissipated involve various newly discovered chemical mediators, resolvins, and protectins [A32933]. Such agents are believed to be directly involved in blocking neutrophil migration, infiltration, recruitment, as well as blocking T-cell migration and promoting T-cell apoptosis [A32933]. Additionally, such protectins can also reduce tumor necrosis factor and interferon secretion [A32933]. Of particular importance, however, is the fact that protectins and resolvins are exclusively derived from omega-3-fatty acids and that EPA is the substrate of the resolvins family and DHA can be converted to both resolvins and protectins [A32933]. It is believed that these effects of such fish oil acids underlie the actions that fish oil have demonstrated on eliciting stability for vulnerable inflammatory plaques [A32933].



Finally, fish oil acids have demonstrated certain direct electrophysiological effects on the myocardium [A32933]. In animal studies, it was shown that the ventricular fibrillation threshold could be increased in both animals fed or infused with omega-3-fatty acids [A32933]. Further studies subsequently revealed that such fatty acids could reduce both sodium currents and L-type calcium currents on a cellular and ion channel level [A32933]. It is consequently hypothesized that during ischemia, a reduction in the sodium ion current protects hyperexcitable tissue, and a reduction in the calcium ion current could reduce arrhythmogenic depolarizing currents - and that perhaps the use of EPA and DHA fish oil acids could facilitate such activity [A32933]. For the time being, however, omega-3-fatty acids in pharmaceutical supplement form have not been shown to elicit such protection against heart conditions [L2662].', 'In general, the only practical method of obtaining and increasing the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) fish oil omega-3-fatty acids in the body is to consume them directly from foods and/or dietary supplements [L784]. Having EPA and DHA is important because they facilitate numerous important functions in the human body. As an example, such supplementation of fish oil EPA and DHA demonstrates a legitimate ability to decrease triglyceride levels as their presence in the body can act as poor substrates for the enzymes that are ordinarily responsible for triglyceride synthesis and also inhibit the esterification of other fatty acids, among other mechanisms [FDA Label, L2661].



Moreover, such fish oil acids can become important components of the phospholipids that form the structures of cell membranes [L784]. Specifically, DHA is particularly high in the retina, brain, and sperm [L784]. Additionally, these acids also provide energy for the body and are used to form eicosanoids - signaling molecules that have similar chemical structures to the fish oil fatty acids from which they are derived [L784]. Furthermore, such eicosanoids possess wide-ranging functions in the cardiovascular, pulmonary, immune, and endocrine systems [L784].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27109, 'Smooth face soap 100 gm', 'سموث فيس صابون 100 جم', '25', NULL, 'Soap', NULL, 'A one pharma', 'Soap', 'صابون', '100 gm', '1', NULL, 'for acne black heads and dark spots', '6224007676004', NULL, 1250, '2022-07-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27110, 'Smoothderm cream 60 gm', 'سموثديرم كريم 60جم', '25', NULL, 'Soothing topical', 'Zinc oxide+benzyl alcohol+benzyl benzoate+benzyl cinnamate', 'Medizen pharmaceutical industries', 'Cream', 'كريم', '60 gm', '1', 'يستخدم في علاج طفح الحفاض ، قرح الفراش ، حب الشباب ، الحروق الطفيفة وحروق الشمس ، والعناية بالبشرة و حمايتها.', 'soothing cream for diaper rash bedsores acne minor burns sunburn and skin care & protection', '6222012400249', NULL, 1417, '2022-12-08', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27111, 'Snafi 20 mg 2 f.c.tab', 'سنافي 20 مجم 2 قرص', '148', '148', 'Tonic for men', 'Tadalafil', 'Spimaco > eimc', 'Tab', 'أقراص', '20 mg', '2', 'مقوي للرجال', NULL, '6281086001783', NULL, 3059, '2025-08-16', 0, 'Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105,L50622]', 'Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. [L39095] Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. [A242392] These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP).[A242287, A242377] cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection.



In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.



Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.



The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100, L39105, A242287]', 'Tadalafil exerts a therapeutic effect in ED by increasing sexual stimulation-dependant smooth muscle relaxation in the penis, allowing the corpus cavernosum to fill with blood to produce an erection.[A242287, A242377] Smooth muscle relaxation in the pulmonary vasculature helps to produce vasodilation in PAH which reduces blood pressure in the pulmonary arteries.[A242377] In BPH, tadalafil may contribute to decreased smooth muscle cell proliferation which may reduce the size of the prostate and relieve the anatomical obstruction which produces urinary symptoms of BPH.[A242382] The decreased affinity of tadalafil for PDE6 compared to other PDE5 inhibitors may explain the reduced incidence of visual side effects.[L39100, L39105, A242287]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27113, 'Snapgab 300 mg 30 caps.', 'سنابجاب 300مجم 30 كبسول', '114', NULL, 'Anti-epileptic.gaba analogs', 'Pregabalin', 'Mash premiere > ta pharma', 'Cap', 'كبسولة', '300 mg', '3', NULL, 'about pregabalin a gaba agonist anticonvulsant. mechanism of action of pregabalin pregabalin is a gaba neurotransmitter analog. it produces its action by modulating calcium channels and also reduces the release of neurotransmitters such as glutamate norep', NULL, NULL, 849, '2022-07-17', 0, 'Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]', 'Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.[L7066]  



By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.[A31163] In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.[A36628] 



Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[A31165]  ', 'Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.[A31163,A187190] Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.[A31163,A187190] Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.[A187190] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27114, 'Snapgab 75 mg 30 caps.', 'سنابجاب 75مجم 30 كبسول', '50', NULL, 'Anti-epileptic.gaba analogs', 'Pregabalin', 'Mash premiere > ta pharma', 'Cap', 'كبسولة', '75 mg', '3', NULL, 'about pregabalin a gaba agonist anticonvulsant. mechanism of action of pregabalin pregabalin is a gaba neurotransmitter analog. it produces its action by modulating calcium channels and also reduces the release of neurotransmitters such as glutamate norep', NULL, NULL, 1065, '2022-07-15', 0, 'Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]', 'Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.[L7066]  



By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.[A31163] In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.[A36628] 



Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[A31165]  ', 'Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.[A31163,A187190] Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.[A31163,A187190] Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.[A187190] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27115, 'Snello 5 gm 12 sachets', 'سنيلو 5 جرام 12 كيس', '240', '90', 'Weight loss', 'Psyllium husks powder+diet sugar+colour(sunset yellow)+orange flavour', 'Lemaco egypt > aglan pharma', 'Sachet', 'أكياس', '5 gm', '1', NULL, 'soluble fibre that is used in weight loss', NULL, NULL, 1119, '2024-12-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27117, 'Sniffacan 50mcg/g nasal spray 15 ml', 'سنيفاكان 50مكجم/جم سبراي للانف 15مل', '25', NULL, 'Anti-inflammatory.glucocorticoid.', 'Mometasone furoate', 'Sigma tec', 'Spray', 'بخاخ', '50mcg', '1', NULL, 'about mometasone a glucocorticoid steroid anti psoriatic anti asthma anti inflammatory. mechanism of action of mometasone mometasone is a topical medium potency glucocorticoid. the drug exerts its pharmacological action by penetrating and binding to cytop', NULL, NULL, 1204, '2022-07-24', 0, 'The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.', 'Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A<sub>2</sub> inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.', 'Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27119, 'Snor no more nasal spray 10 ml', 'سنور نو مور سبراي للانف 10مل', '119', NULL, NULL, NULL, 'Bioes laboratoire > multipharma', 'Spray', 'بخاخ', '10 ml', '1', NULL, 'indications: it is a non medicated nasal spray which by keeping the mucous membrane of the nose and the pharynx moist so prevent the noise of snoring. use: spray into each nostril before going to bed and repeat during the night if necessary.', NULL, NULL, 824, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27120, 'Snow white cream bar 100 gm', 'سنو وايت كريم بار 100جم', '18', NULL, 'Soap', NULL, 'Egyptian company for cosmetics > ilac', 'Cream', 'كريم', '100 gm', '1', NULL, 'whitening soap', NULL, NULL, 718, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27121, 'Snuffle babe vapour rub 24 gm', 'سنافل بيبي فيبور راب 24جم', '17', NULL, NULL, 'Petrolatum+eucalyptus globus leaf oil+menthol+thymus vulgaris oil', 'D d d > inter pharm', 'Unknown', 'غير محدد', '24 gm', '1', NULL, 'for clear and easy breathing. *direction for use: gently massage a small amount of ointment on upper chest and throat. alternatively ointment may be placed in a tissue or handkerchief tied to the cot out of the baby s reach. at night-time loosen clothes s', NULL, NULL, 342, '2022-08-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27122, 'Sobek max cream 50 gm', 'سوبك ماكس كريم 50جم', '140', NULL, 'Massage', 'Water+mineral oil+stearic acid+glycerin+cumin seed oil+aniseed oil+coriander herb oil+cetearyl alcoh', 'Nif e > brother pharma', 'Cream', 'كريم', '50 gm', '1', NULL, '*ingredients: anise oil. cumin seed oil. coriander herb oil. *indications 1- arthritis . 2- peripheral neuritis. 3- varicose veins. 4- spasmodic muscles. 5- bruises. *properties sobek max relieves the arthritis pain by stimulating the blood circulation. s', NULL, NULL, 484, '2022-08-06', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27123, 'Sobocusate 120mg/10gm rectal micro enema', 'سوبوكيوسيت 120مجم/10جم حقنة شرجية', '10', NULL, 'Laxative', 'Docusate sodium', 'Multi-apex > sobol el dawa misr-egypt', 'Unknown', 'غير محدد', '120mg', '1', NULL, 'docusate is a stool softener. it works by increasing the amount of water the stool absorbs in the gut making the stool softer and easier to pass. side effects stomach pain diarrhea or cramping may occur. irritated throat (with liquid or syrup forms) may a', NULL, NULL, 950, '2022-07-10', 0, 'Indicated for the treatment of constipation associated with dry, hard stools or opioid induced constipation[A176984]. Though recently, pressure has been building to end the use of docusate over concerns of efficacy[A176972,A176987,L5912].', 'Recent studies suggest that docusate''s mechanism of action is due largely to it''s surfactant effect in the intestines, which allow fat and water into the feces to soften the stool[A176984].



Docusate’s mechanism of action was investigated in 1985 on healthy patients.[A32201] Docusate was added directly to the jejunum based on calculated concentrations of docusate in the jejunum.[A32201] At this concentration, there was an increase in secretion of water, sodium, chloride, and potassium as well as a decrease in absorption of glucose and bicarbonate[A32201]. Based on in vitro data, the authors suggested this effect was due to an increase in intracellular cyclic AMP either directly through docusate or E series prostaglandins.[A32201]', 'Docusate sodium is a laxative and an anionic detergent that supposedly promotes incorporation of water and fats into stool through a reduction in surface tension, resulting in softer fecal mass [L1801,A176984]. Docusate''s onset of action is 6-72 hours orally and 2-15 minutes rectally [L1801, L1804]. The effects of docusate are thought to be exerted locally in the jejunum[A32201]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27124, 'Sobopexole 0.25mg 10 tab.', 'سوبوبيكسول 0.25مجم 10 اقراص', '8', NULL, 'Parkinson s disease.dopamine agonist', 'Pramipexol', 'Multi-apex > sobol el dawa misr-egypt', 'Tab', 'أقراص', '0.25mg', '1', NULL, 'about pramipexole a nonergot dopamine agonist antiparkinsonism. mechanism of action of pramipexole pramipexole is a non-ergot dopamine agonist. it stimulates dopamine receptor in the striatum. it binds with high affinity to d3 receptors than d2 or d4 rece', NULL, NULL, 698, '2022-07-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27125, 'Sobopexole 1mg 10 tab', 'سوبوبيكسول 1مجم 10 اقراص', '23', NULL, 'Parkinson s disease.dopamine agonist', 'Pramipexol', 'Multi-apex > sobol el dawa misr-egypt', 'Tab', 'أقراص', '1mg', '1', NULL, 'about pramipexole a nonergot dopamine agonist antiparkinsonism. mechanism of action of pramipexole pramipexole is a non-ergot dopamine agonist. it stimulates dopamine receptor in the striatum. it binds with high affinity to d3 receptors than d2 or d4 rece', NULL, NULL, 769, '2022-07-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27126, 'Soboxidant 300mg 30 f.c. tab.', 'سوبوكسيدانت 300مجم 30 اقراص', '32', NULL, 'Antioxidant', 'Thioctic acid(alpha lipoic acid)', 'Multi-apex > sobol el dawa misr-egypt', 'Tab', 'أقراص', '300mg', '3', NULL, 'uses alpha-lipoic acid (ala) has been used as an antioxidant for the treatment of diabetes and hiv. it also has been used for cancer liver ailments and various other conditions. dosing oral dosage of alpha-lipoic acid given in numerous clinical studies ra', NULL, NULL, 1281, '2022-07-12', 0, 'Investigated for use/treatment in diabetes mellitus type 2, neuropathy (diabetic), and vascular diseases.', NULL, NULL, 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27128, 'Soditrate 2.4gm/2.5gm granules 280 gm', 'سوديتريت 2.4جم/2.5جم حبيبات 280جم', '125', '82', 'Nephrolithiasis.urinary alkalinizer', 'Potassium sodium hydrogen citrate', 'Royal link pharma > activa therapeutics', 'Unknown', 'غير محدد', '2.4gm', '1', NULL, NULL, '6224000808518', NULL, 1241, '2024-06-13', 0, 'For use as an electrolyte replenisher and in the treatment of hypokalemia.', 'Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.', 'The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27129, 'Sodium bicarbonate 2.1% (vacsera) i.v. inj. (n/a)', 'صوديوم بيكربونات 2.1% حقن وريد', '8', NULL, 'Alkalinizer', 'Sodium bicarbonate', 'Vacsera', 'Inj', 'حقن', '2.1%', '1', NULL, NULL, '796548084816', NULL, 841, '2022-07-22', 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27130, 'Sodium bicarbonate 5% (mottahedoon) i.v. inf. 500 ml', 'صوديوم بيكربونات 5% المتحدون محلول وريدي 500 مل', '28', '13.5', 'Alkalinizer', 'Sodium bicarbonate', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '5%', '1', NULL, NULL, NULL, NULL, 851, '2024-11-17', 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27131, 'Sodium bicarb 500 mg 30 caps.', 'صوديوم بايكارب 500 مجم 30 كبسولة', '65', '51', 'Alkalinizer', 'Sodium bicarbonate', 'Pharmaceutical solution industries > al kamal importing & marketing co', 'Cap', 'كبسولة', '500 mg', '3', NULL, NULL, NULL, NULL, 3317, '2025-11-13', 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27132, 'Sodium bicarbonate 8.4% (otsuka) i.v. inf. 25 ml', 'صوديوم بيكربونات 8.4% محلول وريدي اوتسوكا 25 مل', '14', '10.5', 'Alkalinizer', 'Sodium bicarbonate', 'Otsuka', 'Unknown', 'غير محدد', '8.4%', '1', NULL, NULL, NULL, NULL, 1079, '2024-11-17', 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27134, 'Sodium bicarbonate 5% (mottahedoon) i.v. inf. 10 ml', 'صوديوم بيكربونات 5% المتحدون محلول وريدي 10 مل', '4', NULL, 'Alkalinizer', 'Sodium bicarbonate', 'Vacsera', 'Unknown', 'غير محدد', '5%', '1', NULL, NULL, NULL, NULL, 677, '2022-08-01', 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27136, 'Sodium bicarbonate 8.4% (sunny pharma.) i.v. inf. vial 50 ml', 'صوديوم بيكربونات صني فارما 8.4 % فيال حقن وريدي 50 مل', '20', NULL, 'Alkalinizer', 'Sodium bicarbonate', 'Sunny medical', 'Vial', 'فيال', '8.4%', '1', 'يعادل حموضة الجسم -- يزيد من قلوية الدم -- يقلل من اعراض الحموضة و الترجيع', NULL, NULL, NULL, 1399, NULL, 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27137, 'Sodium chloride 0.18% & dextrose 4.3% (el nasr) i.v. inf. 500 ml', 'صوديوم كلوريد 0.18% دكستروز 4.3% ش النصر محلول وريدي 500 مل', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.18%', '1', NULL, 'about dextrose dextrorotatory form of monosaccharide(((glucose))) in hypoglycemia and as a sweetner. mechanism of action of dextrose dextrose is used as an intravenous (((iv))) solution used to supply water and calories to the body. it is also used as dil', NULL, NULL, 714, '2022-07-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27138, 'Sodium chloride 0.18% & dextrose 4.3% (otsuka ateco) i.v. inf. 500 ml', 'صوديوم كلوريد 0.18% و دكستروز 4.3% (اوتسوكا اتيكو) محلول وريدي 500 مل', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.18%', '1', NULL, 'about dextrose dextrorotatory form of monosaccharide(((glucose))) in hypoglycemia and as a sweetner. mechanism of action of dextrose dextrose is used as an intravenous (((iv))) solution used to supply water and calories to the body. it is also used as dil', NULL, NULL, 784, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27140, 'Sodium chloride 0.18% & dextrose 5% (el nasr) i.v. inf. 500 ml', 'صوديوم كلوريد 0.18% دكستروز 4.3% النصر محلول وريدي 500 مل', '3', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.18%', '1', NULL, 'about dextrose dextrorotatory form of monosaccharide(((glucose))) in hypoglycemia and as a sweetner. mechanism of action of dextrose dextrose is used as an intravenous (((iv))) solution used to supply water and calories to the body. it is also used as dil', NULL, NULL, 946, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27141, 'Sodium chloride 0.18% & glucose 10% (otsuka) i.v. inf. 1000 ml (rubber cap)', 'صوديوم كلوريد 0.18% جلوكوز 10% وريد', '15', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.18%', '1', NULL, 'about glucosesmonosaccharide aldohexose nutritive sweetner.smechanism of action of glucosesglucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, NULL, 885, '2022-07-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27143, 'Sodium chloride 0.18% & glucose 10% (otsuka) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلورايد 0.18% و جلوكوز 10% محلول وريدي اوتوسوكا 500 مل بغطاء مطاطي', '12', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.18%', '1', NULL, 'about glucosesmonosaccharide aldohexose nutritive sweetner.smechanism of action of glucosesglucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, NULL, 720, '2022-06-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27144, 'Sodium chloride 0.18% & glucose 4.3% (mottahedoon) i.v. inf. 500 ml.', 'صوديوم كلوريد 0.18% و جولوكوز 4.3%محلول', '5', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '0.18%', '1', NULL, NULL, NULL, NULL, 793, '2022-07-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27145, 'Sodium chloride 0.18% & glucose 4.3% (otsuka) i.v. inf. 500 ml', 'صوديوم كلورايد 0.18% و جلوكوز 4.3% اوتوسوكا محلول وريدي 500 مل', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Unknown', 'غير محدد', '0.18%', '1', NULL, NULL, NULL, NULL, 898, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27146, 'Sodium chloride 0.18% & glucose 5% (otsuka) i.v. inf. 1000 ml (rubber cap)', 'صوديوم كلوريد 0.18%و جولوكوز 5%محلول وريدي غطاء مطاط', '15', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.18%', '1', NULL, 'about glucose monosaccharide aldohexose nutritive sweetner. mechanism of action of glucose glucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, NULL, 735, '2022-07-26', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27147, 'Sodium chloride 0.18% & glucose 5% (otsuka) i.v. inf. 250 ml (rubber cap)', 'صوديوم كلوريد 0.18% جلوكوز 5% وريد غطاء مطاط 250 مل', '10', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.18%', '1', NULL, 'about glucose monosaccharide aldohexose nutritive sweetner.smechanism of action of glucosesglucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, NULL, 869, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27148, 'Sodium chloride 0.18% & glucose 5% (otsuka) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.18% جلوكوز 5% محلول دستور الادوية البريطاني 2001 غطاء مطاط 500 مل', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.18%', '1', NULL, 'about glucose monosaccharide aldohexose nutritive sweetner.smechanism of action of glucosesglucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, NULL, 664, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27150, 'Sodium chloride 0.45% & glucose 5% (mottahedoon) i.v. inf. 500 ml', 'صوديوم كلوريد 0.18% و جلوكوز 5% المتحدون محلول وريدي 500 مل', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '0.45%', '1', NULL, NULL, NULL, NULL, 684, '2022-07-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27151, 'Sodium chloride 0.18% & dextrose 5% (el nasr) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.18%و دكستروز 5% النصر محلول وريدي 500 مل غطاء مطاط', '3', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Cap', 'كبسولة', '0.18%', '1', NULL, NULL, NULL, NULL, 663, '2022-07-30', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27152, 'Sodium chloride 0.45% (el nasr) i.v inf. 500 ml', 'صوديوم كلورايد 0.45% النصر محلول ملح وريدي 500 مل', '9', NULL, 'Sterile solution', 'Sodium chloride', 'Otsuka', 'Unknown', 'غير محدد', '0.45%', '1', NULL, NULL, NULL, NULL, 1060, '2022-07-12', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27155, 'Sodium chloride 0.45% (ultimate) i.v. inf. 500 ml', 'صوديوم كلوريد 0.45% التيميت محلول وريدي 500 مل', '9', NULL, 'Normal saline', 'Sodium chloride', 'El nasr > ultimate pharma', 'Unknown', 'غير محدد', '0.45%', '1', NULL, NULL, NULL, NULL, 765, '2022-07-09', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27156, 'Sodium chloride 0.45% (el nasr) i.v inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.45% 500مل غطاء مطاط', '10', NULL, 'Normal saline', 'Sodium chloride', 'El nasr > ultimate pharma', 'Cap', 'كبسولة', '0.45%', '1', NULL, NULL, NULL, NULL, 708, '2022-07-18', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27157, 'Sodium chloride 0.45% (mottahedoon) i.v. inf. 500 ml (l.v.p drip)', 'صوديوم كلوريد 0.45%محلول وريد', '9', NULL, 'Sterile solution', 'Sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.45%', '1', NULL, NULL, NULL, NULL, 774, '2022-07-12', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27158, 'Sodium chloride 0.45% (ultimate) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.45% التيميت محلول وريدي 500 مل بغطاء مطاطي', '10', NULL, 'Sterile solution', 'Sodium chloride', 'El nasr', 'Cap', 'كبسولة', '0.45%', '1', NULL, NULL, NULL, NULL, 892, '2022-07-11', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27161, 'Sodium chloride 0.9 % (el nile) i.v. inf. 100 ml (rubber cap)', 'صوديوم كلورايد 0.9% النيل محلول ملح وريدي 100 مل بغطاء مطاطي', '5', NULL, 'Normal saline', 'Sodium chloride', 'El nile', 'Cap', 'كبسولة', '0.9 %', '1', NULL, NULL, NULL, NULL, 1273, '2022-07-08', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27162, 'Sodium chloride 0.9 % (el nile) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% 500 مل محلول', '11', NULL, 'Normal saline', 'Sodium chloride', 'El nile.', 'Unknown', 'غير محدد', '0.9 %', '1', NULL, NULL, '6221067010922', NULL, 947, '2022-12-08', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27163, 'Sodium chloride 0.9 % (el nile) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% 500 مل محلول غطاء مطاط', '11', NULL, 'Normal saline', 'Sodium chloride', 'El nile.', 'Cap', 'كبسولة', '0.9 %', '1', NULL, NULL, NULL, NULL, 1007, '2022-07-15', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27164, 'Sodium chloride 0.9% & dextrose 5% (al kamal) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلورايد 0.9% و دكستروز 5% الكمال محلول وريدي 500 مل بغطاء مطاطي', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 668, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27165, 'Sodium chloride 0.9% & dextrose 5% (el nasr) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% ديكستروز 5% حقن', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.9%', '1', NULL, 'about dextrose dextrorotatory form of monosaccharide(((glucose))) in hypoglycemia and as a sweetner. mechanism of action of dextrose dextrose is used as an intravenous (((iv))) solution used to supply water and calories to the body. it is also used as dil', NULL, NULL, 729, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27167, 'Sodium chloride 0.9% & dextrose 5% (el nasr) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% ديكستروز 5% حقن غطاء مطاط', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El nasr', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 667, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27168, 'Sodium chloride 0.9% & dextrose 5% (otsuka ateco) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9%& ديكستروز 5%محلول غطاء مطاط', '11', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka ateco pharma', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 998, '2022-07-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27169, 'Sodium chloride 0.9% & dextrose 5% (fipco) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% ديكستروز 5% فيبكو محلول وريدي 500 مل', '11', '10.5', 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'El-fath for the industry of medicine & cosmetics', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 960, '2023-12-23', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27171, 'Sodium chloride 0.9% (otsuka ateco) i.v. inf. 500ml', 'صوديوم كلوريد 0.9% اوتوسوكا اتيكو محلول ملح وريدي 500 مل', '14', NULL, 'Normal saline', 'Sodium chloride', 'Otsuka', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 1141, '2022-07-12', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27172, 'Sodium chloride 0.9% (otsuka ateco) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% اوتوسوكا اتيكو محلول ملح وريدي 500 مل بغطاء مطاطي', '14', NULL, 'Normal saline', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, '6224000983307', NULL, 790, '2022-07-22', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27173, 'Sodium chloride 0.9% (ultimate) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% التيميت محلول ملح وريدي 500 مل بغطاء مطاطي', '11', NULL, 'Normal saline', 'Sodium chloride', 'Ultimate pharma', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 758, '2022-07-11', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27174, 'Sodium chloride 0.9% & dextrose 5% (el nasr) i.v. inf. 500ml (polypropylene bag)', 'صوديوم كلوريد 0.9% ودكستروز 5% النصر محلول وريدي 500 مل بولي بروبيلين باج', '14', NULL, 'Normal saline', 'Sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 756, '2022-07-15', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27175, 'Sodium chloride 0.9% & dextrose 5% (vacsera) i.v. inf. 500 ml', 'صوديوم كلورايد 0.9% وديكستروز 5% فاكسيرا محلول وريدي 500 مل', '9', NULL, 'Normal saline', 'Sodium chloride', 'Vacsera', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 759, '2022-07-13', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27176, 'Sodium chloride 0.9% & glucose 5% (mottahedoon) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% وجلوكوز 5% المتحدون محلول وريدي 500 مل', '35', '16.5', 'Normal saline', 'Sodium chloride', 'Mottahedoon', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 1018, '2025-06-30', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27177, 'Sodium chloride 0.9% (al kamal) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% الكمال محلول وريدي 500 مل بغطاء مطاطي', '11', NULL, 'Normal saline', 'Sodium chloride', 'Al kamal', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 944, '2022-07-18', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27178, 'Sodium chloride 0.9% (allmed) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% اولميد محلول وريدي 500 مل', '11', NULL, 'Normal saline', 'Sodium chloride', 'Allmed', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 803, '2022-07-10', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27179, 'Sodium chloride 0.9% & glucose 5% (mottahedoon) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد0.9% وجلوكوز 5% المتحدون محلول وريدي 500 مل بغطاء مطاطي', '18', NULL, 'Normal saline', 'Sodium chloride', 'Al mottahedoon pharma', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 697, '2022-07-15', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27180, 'Sodium chloride 0.9% (averroes) i.v. inf. 500 ml (polypropylene bottle)', 'صوديوم كلورايد 0.9% افيرروز محلول ملح وريدي 500 مل بولي بروبيلين باج', '18', '14', 'Normal saline', 'Sodium chloride', 'Averroes pharma-egypt', 'Bottle', 'زجاجة', '0.9%', '1', 'تعويض نقص السوائل في الجسم -- يستخدم في حالات النزيف الشديد -- يستخدم لحل بعض الادوية', NULL, NULL, NULL, 1127, '2023-09-06', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27182, 'Sodium chloride 0.9% (allmed) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% اولميد محلول وريدي 500 مل بغطاء مطاطي', '11', NULL, 'Normal saline', 'Sodium chloride', 'Allmed', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 952, '2022-07-24', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27183, 'Sodium chloride 10% (mottahedoon) i.v. amp. 10 ml', 'صوديوم كلوريد 10% المتحدون امبول وريدي 10 مل', '10', '1', 'Normal saline', 'Sodium chloride', 'Al mottahedoon pharma', 'Amp', 'أمبول', '10%', '1', NULL, NULL, NULL, NULL, 687, '2025-11-17', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27188, 'Sodium chloride 0.9% (fipco) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% فيبكو محلول ملح وريدي 500 مل', '14', NULL, 'Normal saline', 'Sodium chloride', 'El-fath (fipco)', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 753, '2022-07-09', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27189, 'Sodium chloride 0.9% (fipco) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% فيبكو محلول ملح وريدي بغطاء مطاطي 500 مل', '15', NULL, 'Normal saline', 'Sodium chloride', 'El-fath (fipco)', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 1050, '2022-07-11', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27191, 'Sodium chloride 0.9% (otsuka) irrigation soln. 2000 ml (n/a)', 'صوديوم كلوريد 0.9% اوتوسوكا محلول تروية 2000 مل', '14', NULL, 'Normal saline', 'Sodium chloride', 'Otsuka', 'Sol', 'محلول', '0.9%', '1', NULL, NULL, NULL, NULL, 691, '2022-07-13', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27192, 'Sodium chloride 10% (otsuka) i.v. inf. 250 ml (rubber cap)', 'صوديوم كلوريد 10% اوتوسوكا محلول ملح وريدي 250 مل بغطاء مطاطي', '10', NULL, 'Normal saline', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '10%', '1', NULL, NULL, NULL, NULL, 1012, '2022-07-17', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27195, 'Sodium chloride 0.9% & dextrose 5% (otsuka ateco) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% ديكستروز 5% محلول 500 مل', '8', NULL, 'Sterile solution', 'Glucose (dextrose)+sodium chloride', 'Otsuka ateco pharma', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 742, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27196, 'Sodium chloride 0.9% (ultimate) i.v. inf. 500 ml', 'صوديوم كلوريد 0.9% التيميت محلول ملح وريدي 500 مل', '10', NULL, 'Normal saline', 'Sodium chloride', 'Ultimate pharma', 'Unknown', 'غير محدد', '0.9%', '1', NULL, NULL, NULL, NULL, 827, '2022-07-13', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27197, 'Sodium chloride 10% (otsuka) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 10% 500مل محلول غطاء مطاط', '11', NULL, 'Normal saline', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '10%', '1', NULL, NULL, NULL, NULL, 1001, '2022-07-15', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27198, 'Sodium chloride 0.9% (otsuka) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 0.9% محلول ملح وريدي اوتوسوكا زجاجة 500 مل بغطاء مطاطي', '15', NULL, 'Sterile solution', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 729, '2022-07-22', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27199, 'Sodium chloride 0.9% (otsuka) i.v. inf. 1000 ml (rubber cap)', 'صوديوم كلوريد 0.9% محلول ملح وريدي اوتوسوكا زجاجة 1000 مل بغطاء مطاطي', '19', NULL, 'Sterile solution', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, '6223003950286', NULL, 945, '2022-07-18', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27200, 'Sodium chloride 0.9% (otsuka) i.v. inf. 250 ml (rubber cap)', 'صوديوم كلوريد 0.9% محلول ملح وريدي اوتوسوكا زجاجة 250 مل بغطاء مطاطي', '14', NULL, 'Sterile solution', 'Sodium chloride', 'Otsuka', 'Cap', 'كبسولة', '0.9%', '1', NULL, NULL, NULL, NULL, 792, '2022-07-12', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27201, 'Sodium chloride 2.7% (el nasr) i.v. inf. 500 ml', 'صوديوم كلورايد 2.7% النصر محلول ملح وريدي 500 مل', '6', NULL, 'Sterile solution', 'Sodium chloride', 'El nasr', 'Unknown', 'غير محدد', '2.7%', '1', NULL, NULL, NULL, NULL, 692, '2022-07-17', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27202, 'Sodium chloride 3% (otsuka) i.v. inf. 250 ml', 'صوديوم كلوريد 3% 250 مل محلول وريدي', '8', NULL, 'Sterile solution', 'Sodium chloride', 'Otsuka', 'Unknown', 'غير محدد', '3%', '1', NULL, 'hypertonic sodium chloride solutions contain a higher concentration of sodium and chloride than normally contained in plasma. infusion of hypertonic sodium chloride solution shifts fluids from the intracellular space into the intravascular and interstitia', NULL, NULL, 1482, '2022-07-24', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27204, 'Sodium chloride 3% (otsuka) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلورايد 3% اوتوسوكا محلول ملح وريدي 500 مل بغطاء مطاطي', '15', NULL, 'Sterile solution', 'Sodium chloride', 'Al mottahedoon pharma', 'Cap', 'كبسولة', '3%', '1', NULL, 'hypertonic sodium chloride solutions contain a higher concentration of sodium and chloride than normally contained in plasma. infusion of hypertonic sodium chloride solution shifts fluids from the intracellular space into the intravascular and interstitia', NULL, NULL, 751, '2022-07-24', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27205, 'Sodium chloride 3% (ultimate) i.v. inf. 500 ml', 'صوديوم كلورايد 3% 500 مل محلول للتسريب الوريدي', '11', NULL, 'Normal saline', 'Sodium chloride', 'El nasr > ultimate pharma', 'Unknown', 'غير محدد', '3%', '1', NULL, 'hypertonic sodium chloride solutions contain a higher concentration of sodium and chloride than normally contained in plasma. infusion of hypertonic sodium chloride solution shifts fluids from the intracellular space into the intravascular and interstitia', NULL, NULL, 2764, '2022-06-28', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27206, 'Sodium chloride 3% (ultimate) i.v. inf. 500 ml (rubber cap)', 'صوديوم كلوريد 3% التيميت فارما محلول ملح وريدي 500 مل بغطاء مطاطي', '11', NULL, 'Normal saline', 'Sodium chloride', 'El nasr > ultimate pharma', 'Cap', 'كبسولة', '3%', '1', NULL, 'hypertonic sodium chloride solutions contain a higher concentration of sodium and chloride than normally contained in plasma. infusion of hypertonic sodium chloride solution shifts fluids from the intracellular space into the intravascular and interstitia', NULL, NULL, 802, '2022-07-12', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27207, 'Sodium chloride 5% eye drops 15 ml', 'صوديوم كلوريد 5% قطرة عين معقمة 15 مل', '18', NULL, 'Sterile solution', 'Sodium chloride', 'Orchidia pharmaceutical industries', 'Drops', 'نقط', '5%', '1', NULL, 'it s a hypertonic solution which acts topically by increasing osmotic pressure. this effect results in increasing water loss from the odemateous cornea. *indication: to reduce swelling of the cornea in certain eye conditions. *dose: 1-2 drops every 3-4 ho', NULL, NULL, 1016, '2022-07-15', 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27208, 'Sodium lactate 1/6 molar (el nasr) i.v. inf. 500 ml', 'صوديوم لاكتات النصر 1/6مولار 500 مل محلول وريد', '11', NULL, 'Sterile solution', 'Sodium lactate', 'El nasr', 'Unknown', 'غير محدد', '500 ml', '1', NULL, NULL, NULL, NULL, 909, '2022-07-14', 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27209, 'Sodium lactate 1.85% (mottahedoon) i.v. inf. 500 ml', 'صوديوم لاكتات 1.85% المتحدون محلول وريدي 500 مل', '6', NULL, 'Sterile solution', 'Sodium lactate', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '1.85%', '1', NULL, 'about sodium lactate skin smoothening agent moisturizers keratolytic. mechanism of action of sodium lactate sodium lactate is used as skin smoothening agent moisturizers and keratolytics. these penetrate into the stratum corneum where they attract and ret', NULL, NULL, 740, '2022-07-14', 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27210, 'Sodium lactate 1/6 molar (otsuka) i.v. inf. 500 ml', 'صوديوم لاكتات 1/6مولار اوتوسوكا محلول وريدي 500 مل', '11', NULL, 'Sterile solution', 'Sodium lactate', 'Otsuka', 'Unknown', 'غير محدد', '500 ml', '1', NULL, NULL, NULL, NULL, 695, '2022-07-09', 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27211, 'Sofa ananas 15 sachets', 'صوفا اناناس 15 كيس', '70', NULL, 'Weight loss', 'Psyllium husk powder+pineapple extract+vitamin c+sucralose', 'Al wefak al soudy > scientific center', 'Sachet', 'أكياس', NULL, '1', NULL, '-for fat burn. -improvement of ibs. -lowering cholestrol level.', NULL, NULL, 841, '2022-07-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27212, 'Sofa hair lotion 120 ml', 'صوفا لوشن للشعر 120 مل', '155', NULL, 'Hair care', NULL, 'El-helou perfumes & cosmetics > newgen pharma', 'Lotion', 'لوشن', '120 ml', '1', 'لوشن للشعر لتنعيمه -- ترطيب الجلد وتقويته -- الحد من الهيشان والتقصف', NULL, NULL, NULL, 2609, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27214, 'Sofenacin 10mg 20 f.c.tab', 'سوفيناسين 10مجم 20 قرص', '122', '92', 'Urinary incontinence.antispasmodics.muscarinic antagonists', 'Solifenacin succinate', 'Marcyrl co.', 'Tab', 'أقراص', '10mg', '2', 'علاج التبول اللارادي -- تقليل تقلصات المثانة', NULL, '6223003570064', NULL, 3728, '2024-08-05', 0, 'Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]', 'Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin''s antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]', 'Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder.[L7511,A181262] It has a long duration of action as it is usually taken once daily.[L7511] Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.[L7511]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27216, 'Sofical 14 sachets 18 gm', 'سوفيكال 18 جم 14 كيس', '75', NULL, 'Calcium supplement plus vitamin d', 'Calcium+vitamin d3+whey protein', 'Pharma zad > famila medifood', 'Sachet', 'أكياس', '18 gm', '1', 'مصدر للكالسيوم -- تقوية العظام والاسنان -- مصدر لفيتامين د لامتصاص الكالسيوم في الدم', 'nutrition to help kids grow. 21 essential vitamins & minerals with 6 gm protein. calcium and vitamin d to help build strong bones. use: dissolve one sachet on glass of water or milk once daily.', NULL, NULL, 3352, '2023-03-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27217, 'Sofocivir 400mg 28 tablets', 'سوفوسيفر 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Future pharmaceutical industries (fpi) > zeta pharm', 'Tablet', 'أقراص', '400mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 797, '2022-07-28', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27218, 'Sofolanork 400mg 28 tablets', 'سوفولانورك 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Mash premiere', 'Tablet', 'أقراص', '400mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 1785, '2022-07-30', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27219, 'Sofolanork plus 90/400mg 28 tablets', 'سوفولانورك بلس 90/400مجم 28 اقراص', '1,100', NULL, 'Hepatitis c treatment', 'Ledipasvir+sofosbuvir', 'Mash premiere', 'Tablet', 'أقراص', '400mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 1253, '2022-07-31', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27220, 'Sofomerase 400 mg 28 tablets', 'سوفوميراز 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Amoun', 'Tablet', 'أقراص', '400 mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 718, '2022-08-01', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27221, 'Sofosbuvir-mup 400mg 28 tablets', 'سوفوبوفر ميوب 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Mup', 'Tablet', 'أقراص', '400mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 1777, '2022-07-12', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27222, 'Sofovirotal 400mg 28 tablets', 'سوفوفيروتال 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Future pharmaceutical industries (fpi)', 'Tablet', 'أقراص', '400mg', '4', NULL, NULL, NULL, NULL, 769, '2022-07-27', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27223, 'Sofozav 400 mg 28 tablets', 'سوفوزاز 400مجم 28 اقراص', '900', NULL, 'Antiviral', 'Sofosbuvir', 'Hikma pharma > epci', 'Tablet', 'أقراص', '400 mg', '4', NULL, 'indications and usage: it is a hepatitis c virus (hcv) nucleotide analog ns5b polymerase inhibitor indicated for the treatment of chronic hepatitis c (chc) infection as a component of a combination antiviral treatment regimen. *efficacy has been establish', NULL, NULL, 728, '2022-07-31', 0, 'Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.



When used in combination with [DB09027], sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.



When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis.



Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].', 'Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase''s GDD active site motif and preventing further replication of HCV genetic material [A19638, FDA Label].



', 'Sofosbuvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).



At a dose 3 times the recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent [FDA Label].', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27224, 'Soft cleanser vag.douche 200 ml', 'سوفت غسول مهبلي 200مل', '75', '58', 'Vaginal wash', NULL, 'Leader cosmetics > aglan pharma', 'Cleanser', 'منظف', '200 ml', '1', NULL, NULL, NULL, NULL, 1136, '2024-12-01', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27226, 'Soft skin care cream 30 gm', 'سوفت سكين كير كريم للعناية بالبشرة 30 جم', '80', '55', 'Anti-acne', 'Sulphur+adapalene+triclosan', 'Leader cosmetics > aglan pharma', 'Cream', 'كريم', '30 gm', '1', NULL, 'treatment of all types of acne', '4006000059303', NULL, 1896, '2024-12-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27227, 'Soft skin lotion 75ml', 'سوفت سكن لوشن 75مل', '50', NULL, 'Anti-acne', NULL, 'Egyptian company for cosmetics > excel pharma', 'Lotion', 'لوشن', '75ml', '1', NULL, 'for acne.', '6225000098527', NULL, 853, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27228, 'Softa vag.douche 200 ml', 'سوفتا غسول مهبلي 200 مل', '36', NULL, 'Vaginal wash', 'Thyme+tegobetain+menthol+cetrimide+chlorhexidine', 'Hi-care > diamond pharma', 'Unknown', 'غير محدد', '200 ml', '1', NULL, NULL, NULL, NULL, 1203, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27229, 'Softlees conditioner 450 gm', 'سوفتليس 450جم', '190', NULL, 'Hair care', 'Argan oil+vitamin e+panthenol+pumpkin& silicon& jojoba& sesame oils+hydrolyzed keratin+almond oil+lactic acid', 'Cosmopack > care mid east pharma', 'Conditioner', 'بلسم', '450 gm', '1', NULL, NULL, NULL, NULL, 853, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27230, 'Softlees hair protein 400 ml', 'سوفتليس بروتين للشعر 400مل', '1,200', NULL, 'Hair care', 'Vitamin e+ vitamin b5+glycolic acid+argan oil+sesame oil+almond oil+keratin +protein+collagen+jojoba oil', 'Cosmopack > care mid east pharma', 'Unknown', 'غير محدد', '400 ml', '1', NULL, NULL, NULL, NULL, 893, '2022-08-02', 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27231, 'Softlees hair protein 800 ml', 'سوفتليس بروتين للشعر 800مل', '2,400', NULL, 'Hair care', 'Vitamin e+ vitamin b5+glycolic acid+argan oil+sesame oil+almond oil+keratin +protein+collagen+jojoba oil', 'Cosmopack > care mid east pharma', 'Unknown', 'غير محدد', '800 ml', '1', NULL, NULL, NULL, NULL, 676, '2022-07-26', 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27232, 'Softlees hair serum 60 ml', 'سوفتليس سيروم للشعر 60مل', '180', NULL, 'Hair care', 'Argan oil+vitamin e+jojoba oil+cyclopentasiloxane+pmx-1501+pmx-245+dmdm hydantoin', 'Cosmopack > care mid east pharma', 'Serum', 'سيروم', '60 ml', '1', NULL, NULL, NULL, NULL, 623, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27233, 'Softlees shampoo 400 ml', 'سوفتليس شامبو 400مل', '180', NULL, 'Hair care', 'Argan oil+vitamin e+almond &sesame &olive & jojoba oil+panthenol+glycerin+keratin+glycolic acid', 'Cosmopack > care mid east pharma', 'Amp', 'أمبول', '400 ml', '1', NULL, NULL, NULL, NULL, 862, '2022-08-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27234, 'Sokinal whitening cream 50 gm', 'سوكينال كريم تبييض 50جم', '90', NULL, 'Whitening topical', 'Lactic acid+vitamins(c+e+a)+allantoin+bees honey+glycolic acid+arbutin+shea butter', 'Egyptian company for cosmetics > excellence pharm', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 745, '2022-07-13', 0, 'For use as an alkalinizing agent.', 'Lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.', 'Lactic acid produces a metabolic alkalinizing effect.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27235, 'Sol cough syrup 120 ml', 'سول كاف شراب 120 مل', '12', NULL, 'Cough drugs', 'Guava leaves+tilia flower+fennel oil', 'El-obour > sol pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, 'improve respiratory functions', NULL, NULL, 1195, '2022-06-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27236, 'Solantra anti-wrinkle cream 50 ml', 'سولانترا كريم مضاد للتجاعيد 50 مل', '350', NULL, 'Skin care', NULL, 'Mash premiere', 'Cream', 'كريم', '50 ml', '1', NULL, NULL, NULL, NULL, 2837, '2023-02-04', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27237, 'Solantra 50+ spf sun block lotion 100ml', 'سولانترا 50+ صن بلوك لوشن 100 مل', '220', NULL, 'Sun block', 'Sun protection formula', 'Mash premiere', 'Lotion', 'لوشن', '100ml', '1', NULL, 'water resistance during swimming. for sensitive & delicate skin of children and adults.', NULL, NULL, 978, '2022-06-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27238, 'Solantra 50+ spf sun block lotion 50ml', 'سولانترا صن بلوك بمعامل حماية 50 50 مل', '130', NULL, 'Sun block', 'Sun protection formula', 'Mash premiere', 'Lotion', 'لوشن', '50ml', '1', 'واقى شمس', 'water resistance during swimming. for sensitive & delicate skin of children and adults.', '6222001402520', NULL, 1117, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27239, 'Solarine 18 spf sun block lotion 70ml', 'سولارين 18+ للحماية من الشمس 70مل', '40', NULL, 'Sun block', 'Sun protection formula', 'Weiser', 'Lotion', 'لوشن', '70ml', '1', NULL, 'water resistance during swimming. for sensitive & delicate skin of children and adults.', NULL, NULL, 878, '2022-07-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27240, 'Solarine 36 spf sun block lotion 100ml', 'سولارين معامل حماية ضد اشعة الشمس 36 صن بلوك لوشن 100 مل', '155', '105', 'Sun block', 'Sun protection formula', 'Weiser', 'Lotion', 'لوشن', '100ml', '1', NULL, 'water resistance during swimming. for sensitive & delicate skin of children and adults.', '6223002260966', NULL, 1811, '2024-06-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27241, 'Solcoseryl 42.5mg/ml 5 amps.', 'سولكوسيريل 42.5مجم/مل 5 امبول', '300', NULL, NULL, 'Extract free from calves blood', 'Misr > meda ab', 'Amp', 'أمبول', '42.5mg', '5', NULL, 'a protein-free standardized dialysate ultrafiltrate derived from calf blood it has demonstrated to be effective to enhance corneal epithelial wounds healing in both experimental animal studies and human beings. calf blood extract protein-free eye gel had', NULL, NULL, 1048, '2022-10-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27242, 'Cortopect advance 20 tabs.', 'كورتوبيكت ادفانس 20 قرص', '150', '130', 'Mucolytic', 'Acetylcysteine+vitamin c+quercetin+zinc+vitamin d3', 'Biomed', 'Tab', 'أقراص', NULL, '2', 'مذيب للبلغم ويعمل على التحسين من وظائف الجهاز التنفسي', NULL, NULL, NULL, 2729, '2025-04-28', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27245, 'Solian 200mg 30 scored tablets', 'سوليان 200مجم 30 قرص', '219', NULL, 'Psychiatric.antipsychotics', 'Amisulpride', 'Sanofi winthrop > ramco', 'Tablet', 'أقراص', '200mg', '3', NULL, 'amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. low-dose amisulpride has been found to be an effective treatment for postoperative emesis. amisulpride function primarily as a d2', '3582910079996', NULL, 1430, '2022-12-08', 0, 'Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not received prophylaxis.[L32759]



Oral amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, characterized by positive symptoms with delusions, hallucinations, thought disorders, hostility and suspicious behavior; or primarily negative symptoms (deficit syndrome) with blunted affect, emotional and social withdrawal. Amisulpride also controls secondary negative symptoms in productive conditions as well as affective disorders such as depressive mood or retardation.[L32764]', 'Dopamine is an essential and critical neurotransmitter produced in the substantia nigra and ventral tegmental regions of the brain. Dopaminergic projection function in the nigrostriatal, mesolimbic, and mesocortical systems. Hyperactive dopamine transmission in the mesolimbic areas, or dopamine dysregulation in various major brain regions, is understood as the key driver of positive and negative symptoms of schizophrenia.[A189156] Many antipsychotic agents act as D2 receptor antagonists, as with amisulpride.[A6752] Amisulpride is a selective dopamine D2 and D3 receptor antagonist.[L32759] It has high preferential activity towards dopamine receptors in the limbic system rather than the striatum, leading to a lower risk of extrapyramidal side effects than other atypical antipsychotic agents.[A6754, A232269] At low doses, amisulpride reduces negative symptoms of schizophrenia by blocking pre-synaptic dopamine D2 and D3 receptors, increasing the levels of dopamine in the synaptic cleft and facilitating dopaminergic transmission.[A6754] At higher doses, amisulpride blocks postsynaptic receptors, inhibiting dopaminergic hyperactivity: this explains the drug improving positive symptoms.[A6751] Amisulpride also works as an antagonist at 5-HT<sub>7A</sub> receptors [A16931] and 5-HT<sub>2A</sub> receptors,[A6754] which may be related to its antidepressant effects.[A6755]



The chemoreceptor trigger zone (CTZ), also commonly known as the area postrema (AP), is an important brain region located within the dorsal surface of the medulla oblongata. CTZ is involved in emesis: it contains receptors, such as dopamine receptors, that are activated in response to emetic agents in the blood and relay information to the vomiting center, which is responsible for inducing the vomiting reflex.[A232374] Amisulpride is an antiemetic agent that works to limit signals that promote nausea and vomiting. Amisulpride binds to D2 and D3 receptors in the CTZ, leading to reduced dopaminergic signalling into the vomiting center.[L32759]



', 'Amisulpride is a selective dopamine D2 and D3 receptor antagonist with no affinity towards other dopamine receptor subtypes. Amisulpride is an atypical antipsychotic agent that works as an antagonist at dopamine receptors in the limbic system. Since it works preferentially in the limbic system, amisulpride is less likely to be associated with extrapyramidal adverse effects than other atypical antipsychotic agents. Amisulpride has no affinity for serotonin, alpha-adrenergic, H1-histamine, cholinergic, and sigma receptors. In clinical trials, amisulpride improved reduced secondary negative symptoms, affective symptoms, and psychomotor retardation in patients with acute exacerbation of schizophrenia. Notably, amisulpride has a differential target binding profile at different doses: at low doses, amisulpride selectively binds to presynaptic dopamine autoreceptors. At high doses, it preferentially binds to post-synaptic dopamine receptors.[A6753] This explains how amisulpride reduces negative symptoms at low doses and mediates antipsychotic effects at high doses.[L32764] One study alluded that the antinociceptive effects of amisulpride are mediated through opioid receptor acvitation and D2 receptor antagonism. [A6753, A6755] The actions of amisulpride at opioid receptors may explain its pro-convulsant properties.[A6755]



Amisulpride is also an antiemetic agent that prevents and alleviates postoperative nausea and vomiting. It primarily works by blocking dopamine signalling in the chemoreceptor trigger zone, which is a brain area that relays stimuli to the vomiting center.[L32764]



In clinical trials comprising Caucasian and Japanese subjects, amisulpride caused dose- and concentration-dependent prolongation of the QT interval; thus, intravenous infusion under a strict dosing regimen and close monitoring of patients with pre-existing cardiovascular conditions are recommended.[L32759] Amisulpride increases plasma prolactin levels, leading to an association with benign pituitary tumours such as prolactinoma.[L32764]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27246, 'Solian 400mg 30 scored tablets', 'سوليان 400مجم 30 اقراص', '280', NULL, 'Psychiatric.antipsychotics', 'Amisulpride', 'Sanofi winthrop > ramco', 'Tablet', 'أقراص', '400mg', '3', NULL, 'amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. low-dose amisulpride has been found to be an effective treatment for postoperative emesis. amisulpride function primarily as a d2', '3582910009429', NULL, 1017, '2022-12-08', 0, 'Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not received prophylaxis.[L32759]



Oral amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, characterized by positive symptoms with delusions, hallucinations, thought disorders, hostility and suspicious behavior; or primarily negative symptoms (deficit syndrome) with blunted affect, emotional and social withdrawal. Amisulpride also controls secondary negative symptoms in productive conditions as well as affective disorders such as depressive mood or retardation.[L32764]', 'Dopamine is an essential and critical neurotransmitter produced in the substantia nigra and ventral tegmental regions of the brain. Dopaminergic projection function in the nigrostriatal, mesolimbic, and mesocortical systems. Hyperactive dopamine transmission in the mesolimbic areas, or dopamine dysregulation in various major brain regions, is understood as the key driver of positive and negative symptoms of schizophrenia.[A189156] Many antipsychotic agents act as D2 receptor antagonists, as with amisulpride.[A6752] Amisulpride is a selective dopamine D2 and D3 receptor antagonist.[L32759] It has high preferential activity towards dopamine receptors in the limbic system rather than the striatum, leading to a lower risk of extrapyramidal side effects than other atypical antipsychotic agents.[A6754, A232269] At low doses, amisulpride reduces negative symptoms of schizophrenia by blocking pre-synaptic dopamine D2 and D3 receptors, increasing the levels of dopamine in the synaptic cleft and facilitating dopaminergic transmission.[A6754] At higher doses, amisulpride blocks postsynaptic receptors, inhibiting dopaminergic hyperactivity: this explains the drug improving positive symptoms.[A6751] Amisulpride also works as an antagonist at 5-HT<sub>7A</sub> receptors [A16931] and 5-HT<sub>2A</sub> receptors,[A6754] which may be related to its antidepressant effects.[A6755]



The chemoreceptor trigger zone (CTZ), also commonly known as the area postrema (AP), is an important brain region located within the dorsal surface of the medulla oblongata. CTZ is involved in emesis: it contains receptors, such as dopamine receptors, that are activated in response to emetic agents in the blood and relay information to the vomiting center, which is responsible for inducing the vomiting reflex.[A232374] Amisulpride is an antiemetic agent that works to limit signals that promote nausea and vomiting. Amisulpride binds to D2 and D3 receptors in the CTZ, leading to reduced dopaminergic signalling into the vomiting center.[L32759]



', 'Amisulpride is a selective dopamine D2 and D3 receptor antagonist with no affinity towards other dopamine receptor subtypes. Amisulpride is an atypical antipsychotic agent that works as an antagonist at dopamine receptors in the limbic system. Since it works preferentially in the limbic system, amisulpride is less likely to be associated with extrapyramidal adverse effects than other atypical antipsychotic agents. Amisulpride has no affinity for serotonin, alpha-adrenergic, H1-histamine, cholinergic, and sigma receptors. In clinical trials, amisulpride improved reduced secondary negative symptoms, affective symptoms, and psychomotor retardation in patients with acute exacerbation of schizophrenia. Notably, amisulpride has a differential target binding profile at different doses: at low doses, amisulpride selectively binds to presynaptic dopamine autoreceptors. At high doses, it preferentially binds to post-synaptic dopamine receptors.[A6753] This explains how amisulpride reduces negative symptoms at low doses and mediates antipsychotic effects at high doses.[L32764] One study alluded that the antinociceptive effects of amisulpride are mediated through opioid receptor acvitation and D2 receptor antagonism. [A6753, A6755] The actions of amisulpride at opioid receptors may explain its pro-convulsant properties.[A6755]



Amisulpride is also an antiemetic agent that prevents and alleviates postoperative nausea and vomiting. It primarily works by blocking dopamine signalling in the chemoreceptor trigger zone, which is a brain area that relays stimuli to the vomiting center.[L32764]



In clinical trials comprising Caucasian and Japanese subjects, amisulpride caused dose- and concentration-dependent prolongation of the QT interval; thus, intravenous infusion under a strict dosing regimen and close monitoring of patients with pre-existing cardiovascular conditions are recommended.[L32759] Amisulpride increases plasma prolactin levels, leading to an association with benign pituitary tumours such as prolactinoma.[L32764]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27247, 'Soliqua 100 units+33 mcg/ml 3 prefilled pens 3 ml', 'سوليكا 100 وحدة+33 مكجم/مل 3 اقلام معبأة 3 مل', '1,785', '1248', 'Anti-diabetic.long-acting', 'Insulin glargine+lixisenatide', 'Sanofi', 'Pen', 'قلم', '33 mcg', '3', 'انسولين لمرضى السكر -- انسولين طويل المفعول', 'soliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors. posology: soliqua is avail', '3664798035728', NULL, 3475, '2024-11-25', 0, 'Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.', 'The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.

Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.', 'Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27248, 'Soliqua 100 units+50 mcg/ml 3 prefilled pens 3 ml', 'سوليكا 100 وحدة 50مكجم/مل 3 اقلام معبأة 3 مل', '2,531', '1770', 'Anti-diabetic.long-acting', 'Insulin glargine+lixisenatide', 'Sanofi', 'Pen', 'قلم', '50 mcg', '3', 'لمرضى السكر', 'soliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors. posology: soliqua is avail', '660298035735', NULL, 2023, '2024-11-25', 0, 'Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.', 'The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.

Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.', 'Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27249, 'Solitract 10 mg 30 f.c. tab.', 'سوليتراكت 10مجم 30 قرص', '114', NULL, 'Urinary incontinence.antispasmodics.muscarinic antagonists', 'Solifenacin succinate', 'Eva pharma', 'Tab', 'أقراص', '10 mg', '3', 'مضاد للتقلصات وعلاج لسلس البول.', 'indication for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and urinary frequency. mechanism of action solifenacin is a competitive muscarinic acetylcholine receptor antagonist. the binding of acetylcholine to the', '6224009763863', NULL, 1676, '2022-05-22', 0, 'Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]', 'Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin''s antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]', 'Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder.[L7511,A181262] It has a long duration of action as it is usually taken once daily.[L7511] Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.[L7511]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27250, 'Solitract 5 mg 30 f.c. tab.', 'سوليتراكت 5مجم 30 قرص', '87', NULL, 'Urinary incontinence.antispasmodics.muscarinic antagonists', 'Solifenacin succinate', 'Eva pharma', 'Tab', 'أقراص', '5 mg', '3', NULL, 'indication for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and urinary frequency. mechanism of action solifenacin is a competitive muscarinic acetylcholine receptor antagonist. the binding of acetylcholine to the', '6224009967186', NULL, 1794, '2022-07-05', 0, 'Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]', 'Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin''s antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]', 'Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder.[L7511,A181262] It has a long duration of action as it is usually taken once daily.[L7511] Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.[L7511]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27251, 'Solo care aqua solution 90 ml', 'سولو كير اكوا محلول مائي 90 مل للعدسات اللاصقة', '20', NULL, 'Contact lenses solution', 'Polyhexanide+hydrolock+sodium phosphate+tromethamine+poloxamer 407+disodium edetate', 'Ciba vision faure > amico', 'Solution', 'محلول', '90 ml', '1', NULL, 'multi-purpose solution for soft contact lenses including silicon hydrogels', NULL, NULL, 743, '2022-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27252, 'Solo sept foaming skin cleanser 200 ml', 'سولو سيبت غسول للجلد برغوة 200 مل', '95', '75', 'Antiseptic', 'Chlorhexidine+hexamine+chlorocresol', 'City pharma > cosmo pack', 'Sol', 'محلول', '200 ml', '1', 'غسول للجلد مضاد للبكتيريا -- تقليل الالتهابات -- تقليل الاحمرار', NULL, NULL, NULL, 3498, '2024-09-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27253, 'Solo topical lotion 120ml', 'سولو لوسيون موضعي 120 مل', '65', '45', 'Soothing topical', 'Zinc oxide+titanium dioxide+vitamin e+dexpanthenol+glycerol+menthol', 'Hi-care > health well egypt', 'Lotion', 'لوشن', '120ml', '1', NULL, 'soothing lotion that relieves redness and symptoms of dry skin and sun burns.', '6224000911041', NULL, 2138, '2024-04-30', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27254, 'Solodine antiseptic soln. 10% 100 ml', 'سولودين محلول مطهر 10% 100مل', '14', NULL, 'Antiseptic', 'Povidone- iodine', 'Panax pharma > tiba pharma', 'Sol', 'محلول', '10%', '1', NULL, 'about povidone iodine iodine preparation external broad microbicidal spectrum antiseptic. mechanism of action of povidone iodine povidone iodine is an iodophore antiseptic and is a microbicidal drug. it releases iodine from its complex and produces pharma', '6224007728970', NULL, 1254, '2022-07-24', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27255, 'Solofresh 0.2% eye drops 10 ml', 'سولوفريش قطرة عين 0.2% عبوة 10 مل', '67', '48', 'Eye surgery.tissue lubricant', 'Sodium hyaluronate', 'Orchidia pharmaceutical industries', 'Sol', 'محلول', '0.2%', '1', NULL, 'about sodium hyaluronate a visco-elastic polymer(glycosaminoglycan) a tissue lubricant(prevent vaginal dryness) in osteoarthritis. mechanism of action of sodium hyaluronate sodium hyaluronate is a sterile nonpyrogenic highly purified noninflammatory high', '6224000219956', NULL, 7187, '2024-09-22', 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27256, 'Sologati 0.3% eye dps. 5 ml', 'سولوجاتي 0.3% قطرة للعين 5مل', '17', NULL, 'Antibiotic.quinolone', 'Gatifloxacin', 'Grand pharma > city pharma', 'Sol', 'محلول', '0.3%', '1', NULL, 'uses: gatifloxacin is used to treat a variety of bacterial infections. it works by stopping the growth of bacteria. this medication belongs to a class of drugs called quinolone antibiotics. this antibiotic only treats bacterial infections. it will not wor', NULL, NULL, 746, '2022-07-24', 0, 'For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes', 'The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.', 'Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration. is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gatifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27257, 'Solpadol 2.5mg 6 oro-dispersible tablets', 'سولبادول 2.5مجم 6 اقراص ذائبة بالفم', '60', '42', 'Antimigraine.vasoconstrictor agents.selective serotonin agonist', 'Zolmitriptan', 'Global napi pharmaceuticals', 'Tablet', 'أقراص', '2.5mg', '1', 'لعلاج حالات الصداع النصفي', 'about zolmitriptan selective serotonin (5ht1) agonists anti migraine mechanism of action of zolmitriptan zolmitriptan is a selective agonist for serotonin (5ht1 receptors). it relieves migraine by selective constriction of intracranial blood vessels neuro', '6223002142989', NULL, 5164, '2024-01-28', 0, 'Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]', 'Migraines are complex physiological events characterized by unilateral throbbing headaches combined with photophobia and other aversions to sensory input. Migraine attacks are generally divided into phases: the premonitory phase, which typically involves irritability, fatigue, yawning, and stiff neck; the headache phase, which lasts for between four and 72 hours; and the postdrome phase, which lasts for up to a day following resolution of pain and whose symptoms are similar to those of the premonitory phase. In addition, neurological deficits, collectively termed migraine aura, may precede the headache phase.[A193797, A193794]



The underlying pathophysiology of migraines is a matter of active research but involves both neurological and vascular components. The head pain associated with migraine is thought to be a consequence of activation of the nociceptive nerves comprising the trigeminocervical complex (TCC).[A193794] Terminals of nociceptive nerves that innervate the dura matter release vasoactive peptides, such as calcitonin gene-related peptide (CGRP), resulting in cranial vasodilation. Finally, when present, migraine aura appears to correlate with a transient wave(s) of cortical depolarization, termed cortical spreading depression (CSD).[A193794,A193851]



Triptans, including zolmitriptan, are proposed to act in three ways. The main mechanism is through modulation of nociceptive nerve signalling in the central nervous system through 5-HT<sub>1B/1D</sub> receptors throughout the TCC and associated areas of the brain. In addition, triptans can enhance vasoconstriction, both through direct 5-HT<sub>1B</sub>-mediated dilation of cranial blood vessels,[A462, A198741] as well as through 5-HT<sub>1D</sub>-mediated suppression of CGRP release.[A193794, L12978]



Although triptans are classically described solely in terms of their effects on 5-HT<sub>1B/1D</sub> receptors, they also act as 5-HT<sub>1F</sub> agonists as well. This 5-HT subtype is also found throughout the TCC, but is not present appreciably in cerebral vasculature; the significance of triptan-mediated 5-HT<sub>1F</sub> activation is currently not well described.[A193791] Additionally, CSD that initiates in the ipsilateral parietal region may exert its effects in a manner that relies on 5-HT<sub>1B/1D</sub> receptor activation, suggesting that triptans may have some effect on CSD-mediated symptoms.[A193794, A198738]', 'Zolmitriptan, like other triptans, is a serotonin (5-hydroxytryptamine; 5-HT) receptor agonist, with enhanced specificity for the 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor subtypes. It is through the downstream effects of 5-HT<sub>1B/1D</sub> activation that triptans are proposed to provide acute relief of migraines.[L12978,A462,A193791] Zolmitriptan is also a vasoconstrictor,[A193803] leading to possible adverse cardiovascular effects such as myocardial ischemia/infarction, arrhythmias, cerebral and subarachnoid hemorrhage, stroke, gastrointestinal ischemia, and peripheral vasospastic reactions. In addition, chest/throat/neck/jaw pain, tightness, and/or pressure has been reported, along with the possibility of medication overuse headaches and serotonin syndrome. Patients with phenylketonuria should be advised that ZOMIG-ZMT contains phenylalanine.[L12978]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27261, 'Solu-medrol 500mg vial', 'سوليو-ميدرول 500مجم فيال', '180', '98', 'Glucocorticoid', 'Methylprednisolone sodium succinate', 'Pfizer', 'Vial', 'فيال', '500mg', '1', 'كورتيزون مضاد التهاب ومضاد حساسية', NULL, NULL, NULL, 2823, '2024-11-07', 0, 'Oral and intramuscular methylprednisolone are indicated for a number of endocrine,  rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27262, 'Solupen 1000 000 iu vial', 'سوليوبن 1000000 وحدة دولية فيال', '6', NULL, 'Antibiotic.pencillin', 'Penicillin g', 'El nile.', 'Vial', 'فيال', '000 iu', '1', NULL, 'about penicillin g natural -lactamase sensitive pencillin a narrow spectrum antibiotic. mechanism of action of penicillin g it is a bactericidal drug. penicillin is a beta lactum antibiotic. it binds to the penicillin binding protein in the cell wall of b', NULL, NULL, 777, '2022-07-12', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27264, 'Solupred oro 5mg 30 orodispersible tab.', 'سوليوبريد اورو 5مجم 30 قرص ذائب بالفم', '84', '65', 'Glucocorticoid', 'Prednisolone', 'Sanofi winthrop > sanofi', 'Tab', 'أقراص', '5mg', '3', 'علاج الحساسية الشديدة -- علاج الامراض التي تحتاج الي كورتيزون', NULL, '3664798012231', NULL, 4245, '2025-06-23', 0, 'Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisolone has a short duration of action as the half life is 2.1-3.5 hours.[A187394] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27266, 'Solvadol adults throat spray 30 ml', 'سولفادول سبراي للحلق 30 مل', '345', '325', 'Oral care', NULL, 'Vitro-bio > al ansar for marketing', 'Sol', 'محلول', '30 ml', '1', 'علاج التهاب الحلق -- علاج تقرحات الفم', 'for throat infections', '6224011120036', NULL, 2800, '2025-03-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27267, 'Solvadol kids throat spray 20 ml', 'سولفادول اطفال بخاخ للحلق 20 مل', '345', '325', 'Oral care', NULL, 'Vitro-bio > al ansar for marketing', 'Sol', 'محلول', '20 ml', '1', NULL, 'for throat infections', NULL, NULL, 2588, '2025-03-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27269, 'Solvazinc 50 mg 30 caps.', 'سولفازنك 50مجم 30 كبسولة', '45', '18', 'Zinc supplement', 'Zinc', 'Al esraa pharmaceutical optima', 'Cap', 'كبسولة', '50 mg', '3', NULL, 'about zinc trance metal dietary mineral nutritional supplement treatment of zinc deficiency in wound healing. mechanism of action of zinc zinc acts as a cofactor for more than 70 different enzymes. zinc dependent enzymes are involved in the metabolism of', '6223004160394', NULL, 6045, '2025-10-16', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27271, 'Solvex 250mg/5ml syrup 120ml', 'سولفكس 250مجم/5مل شراب 120مل', '7', NULL, 'Mucolytic', 'Carboxymethylcysteine', 'Sedico', 'Syrup', 'شراب', '250mg', '1', NULL, 'abstract prescription of mucoactive drugs for chronic obstructive pulmonary disease (copd) is increasing. this development in clinical practice arises at least in part from a growing understanding of the important role that exacerbation frequency systemic', '6221042252019', NULL, 889, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27272, 'Solvex 375mg 20 caps.', 'سولفكس 375 مجم 20 كبسولة', '7', NULL, 'Mucolytic', 'Carboxymethylcysteine', 'Sedico', 'Cap', 'كبسولة', '375mg', '2', 'علاج الكحة المصحوبة بالبلغم -- طارد ومذيب للبلغم', 'abstract prescription of mucoactive drugs for chronic obstructive pulmonary disease (copd) is increasing. this development in clinical practice arises at least in part from a growing understanding of the important role that exacerbation frequency systemic', '6221042152029', NULL, 1383, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27273, 'Solvimyst 100mg/5ml syrup 120ml', 'سولفيميست شراب 120مل', '44', '30', 'Mucolytic', 'Acetylcysteine', 'Mash premiere', 'Syrup', 'شراب', '100mg', '1', 'مذيب للبلغم', 'description acetylcysteine (also known as n-acetylcysteine or n-acetyl-l-cysteine or nac) is primarily used as a mucolytic agent and in the management of acetaminophen poisoning. it is a derivative of cysteine with an acetyl group attached to the amino gr', '6222001401677', NULL, 2707, '2025-08-16', 0, 'Acetylcysteine is indicated for mucolytic therapy and in the management of [acetaminophen] overdose.[L31378,L31383,L31388,L31478]', 'A number of possible mechanisms for the mucolytic activity of acetylcysteine have been proposed. Acetylcysteine''s sulfhydryl groups may hydrolize disulfide bonds within mucin, breaking down the oligomers, and making the mucin less viscous.[A228173,L31388] Acetylcysteine has also been shown to reduce mucin secretion in rat models.[A228173] It is an antioxidant in its own right but is also deacetylated to cysteine, which participates in the synthesis of the antioxidant glutathione.[A228173] The antioxidant activity may also alter intracellular redox reactions, decreasing phosphorylation of EGFR and MAPK, which decrease transcription of the gene MUC5AC which produces mucin.[A228173]



In the case of acetaminophen overdoses, a portion of the drug is metabolized by CYP2E1 to form the potentially toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).[L31388] The amount of NAPQI produced in an overdose saturates and depletes glutathione stores.[L31388] The free NAPQI promiscuously binds to proteins in hepatocytes, leading to cellular necrosis.[L31388] Acetylcysteine can directly conjugate NAPQI or provide cysteine for glutathione production and NAPQI conjugation.[L31388]', 'Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.[L31378,L31383,L31388,L31478] It has a short duration of action as it is given every 1-8 hours depending on route of administration, and has a wide therapeutic window.[L31378,L31383,L31388,L31478] Patients should be counselled regarding diluting oral solutions in cola for taste masking,[A228153] the risk of hypersensitivity, and the risk of upper gastrointestinal hemorrhage.[L31378,L31383,L31388,L31478]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27276, 'Solvin 8 mg 20 tab.', 'سولفين 8 مجم 20 قرص', '7', NULL, 'Mucolytic', 'Bromhexine', 'Arab drug company.', 'Tab', 'أقراص', '8 mg', '2', 'مذيب وطارد للبلغم -- مهدئ للسعال -- علاج الكحة المصحوبة بالبلغم', 'about bromhexine mucolytic (secretolytic) mechanism of action of bromhexine bromhexine hydrochloride acts as a mucokinetic and mucolytic agent. it decreases mucus viscosity by altering its structure. it depolymerises mucopolysaccharides directly as well a', '6221060000197', NULL, 1499, '2022-12-08', 0, 'Bromohexine is used alone or with other ingredients such as [diphenhydramine], [dextromethorphan], and [guaifenesin] to reduce mucus viscosity and clear mucus in conditions associated with mucus hypersecretion, including the common cold, influenza, respiratory tract infections, or other conditions.[L29975,L24819,L33060]', 'Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium[L33060], allowing secretions to be expelled from the respiratory tract.[A233240]



Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.[A233345,A233350] In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.[A233365 ,A233370]', 'Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.[A233240,L26346,L33060]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27277, 'Solvin n 4mg/5ml syrup 60ml', 'سولفين ان 4مجم/5مل شراب 60مل', '5', NULL, 'Mucolytic', 'Bromhexine', 'Arab drug company.', 'Syrup', 'شراب', '4mg', '1', NULL, 'about bromhexine mucolytic (secretolytic) mechanism of action of bromhexine bromhexine hydrochloride acts as a mucokinetic and mucolytic agent. it decreases mucus viscosity by altering its structure. it depolymerises mucopolysaccharides directly as well a', '6221060004775', NULL, 876, '2023-01-05', 0, 'Bromohexine is used alone or with other ingredients such as [diphenhydramine], [dextromethorphan], and [guaifenesin] to reduce mucus viscosity and clear mucus in conditions associated with mucus hypersecretion, including the common cold, influenza, respiratory tract infections, or other conditions.[L29975,L24819,L33060]', 'Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium[L33060], allowing secretions to be expelled from the respiratory tract.[A233240]



Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.[A233345,A233350] In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.[A233365 ,A233370]', 'Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.[A233240,L26346,L33060]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27279, 'Solvolytic 8mg/5ml syrup 115ml', 'سولفوليتك 8مجم/5مل شراب 115 مل', '13', NULL, 'Mucolytic', 'Bromhexine', 'Cid', 'Syrup', 'شراب', '8mg', '1', 'شراب مذيب البلغم __ يساعد علي تحسين التنفس __ يقلل الالتهابات التنفسية الناتجة عن الكحة', 'about bromhexine mucolytic (secretolytic) mechanism of action of bromhexine bromhexine hydrochloride acts as a mucokinetic and mucolytic agent. it decreases mucus viscosity by altering its structure. it depolymerises mucopolysaccharides directly as well a', NULL, NULL, 1071, '2022-10-24', 0, 'Bromohexine is used alone or with other ingredients such as [diphenhydramine], [dextromethorphan], and [guaifenesin] to reduce mucus viscosity and clear mucus in conditions associated with mucus hypersecretion, including the common cold, influenza, respiratory tract infections, or other conditions.[L29975,L24819,L33060]', 'Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium[L33060], allowing secretions to be expelled from the respiratory tract.[A233240]



Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.[A233345,A233350] In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.[A233365 ,A233370]', 'Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.[A233240,L26346,L33060]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27280, 'Somadril compound 20 tab.', 'سومادريل مركب 20 اقراص', '9', NULL, NULL, 'Carisoprodol+caffeine+paracetamol(acetaminophen)', 'Mina pharm', 'Tab', 'أقراص', NULL, '2', NULL, NULL, '6222003700365', NULL, 1551, '2022-12-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27281, 'Somatostatin lyomark 3mg/3ml amp.', 'سوماتوستاتين ليومارك 3مجم/3مل امبول', '130', NULL, 'Growth inhibitor', 'Somatostatin', 'Lyomark-pharma > eimc', 'Amp', 'أمبول', '3mg', '1', NULL, 'about somatostatin pituitary hormone growth inhibitor. mechanism of action of somatostatin the drug exerts it`s action by inhibiting the secretion of growth hormone (gh) thyroid stimulating hormone (tsh) prolactin in pituitary; insulin and glucagons in pa', NULL, NULL, 915, '2022-07-14', 0, 'For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established.', 'Somatostatin binds to 5 subtypes of somatostatin receptors (SSTRs), which are all Gi-protein-coupled transmembrane receptors that inhibits adenylyl cyclase upon activation [A20384]. By inhibiting intracellular cyclic AMP and Ca2+ and by a receptor-linked distal effect on exocytosis, SSTRs block cell secretion [A27323]. The common pathway shared by the receptors involve the activation of phosphotyrosine phosphatase (PTP), and modulation of mitogen-activated protein kinase (MAPK) [A27323]. With the exception of SSTR3, activation of SSTRs lead to activation of voltage-gated potassium channels accompanied by increased K+ currents. This result in membrane hyperpolarization and inhibits depolarization-induced Ca2+ influx through voltage-sensitive Ca2+ channels [A20384]. Depending on the receptor subtype, signalling cascades involve activation of other downstream targets such as Na+/H+ exchanger, Rho GTPase, and nitric oxide synthase (NOS) [A20384]. SSTRs 1 to 4 bind both somatostatin isoforms with equal nanomolar binding affinity whereas SSTR5 exhibits a 5- to 10-fold higher binding affinity for SST-28 [A20384]. 



**Effects of SSTR1:** Upon biding of somatostatin and activation, SSTR1 mediates an antisecretory effect on growth hormone, prolactin and calcitonin [A20384]. 



**Effects of SSTR2:** SSTR2 subtype dominates in endocrine tissues. By binding to SST2 receptors, somatostatin exerts paracrine inhibitory actions on gastrin release from G cells, histamine release from ECL cells, and directly on parietal cell acid output [T28]. SSTR2 receptor signalling cascades also inhibit the secretion of growth hormone and that of adrenocorticotropin, glucagon, insulin, and interferon-γ [A20384]. 



**Effects of SSTR3:** Activation of these receptors lead to reduction in cell proliferation [A20384]. SSTR3 triggers PTP-dependent cell apoptosis accompanied by activation of p53 and the pro-apoptotic protein Bax [A27323]. A study of the matrigel sponge assay suggests that through SSTR3-mediated inhibition of both NOS and MAPK activities may lead to the antitumor effects of somatostatin in inhibiting tumor angiogenesis [A32606].



**Effects of SSTR4:** The functions of SSTR4 remain largely unknown [A20384].



**Effects of SSTR5:** Like SSTR2, SSTR5 subtype also predominates in endocrine tissues. Upon activation, SSTR5 signalling cascades exert an inhibitory action on growth hormone, adrenocorticotropin, insulin, and glucagon-like peptide-1 as well as the secretion of amylase [A20384].



The presence of somatostatin receptors has been identified in most neuroendocrine tumours, endocrine gastroenteropancreatic (GEP) tumors, paragangliomas, pheochromocytomas, medullary thyroid carcinomas (MTC) and small cell lung carcinomas [A32600]. The antitumor effects of somatostatin were also effective in various malignant lymphomas and breast tumours [A32600]. Gastrointestinal hormones, such as gastrin, secretin, and cholecystokinin (CCK), as well as growth hormones and growth factors are thought to be elevated in gastrointestinal tract and neuroendocrine tumours and are inhibited by somatostatin [A32595]. _In vitro_, somatostatin inhibited epidermal growth factor (EGF)-induced DNA synthesis and replication following  which suggest that somatostatin may have direct anti-proliferative effects via SSTR signalling [A32595]. Acromegaly is characterized as the endocrine disorder caused by a functioning tumour of cells that secrete growth hormone from the anterior pituitary [T28]. Somatostatin analogue therapies serve to normalize the elevated levels of GH and insulin-like growth factor 1 (IGF-1) and attenuate tumour growth.  



In the vascular system this likely produces vasoconstriction by inhibiting adenylate cyclase leading to a lowering the concentration of cyclic adenosine monophosphate in the endothelial cells which ultimately blocks vasodilation through this pathway. This vasoconstriction is though the be responsible for reducing blood flow to the esophageal tissues and so reduces bleeding from esophageal varices [A27145]. 



Somatostatin mediates an analgesic activity by reducing vascular and nociceptive components of inflammation [A32599]. Studies indicate that somatostatin may be present in nociceptive DRG neurons with C-fibers and primary afferent neurons to inhibit the release of transmitters at the presynaptic junctions of the sensory-efferent nerve terminals [A20384]. Exogenous somatostatin has shown to inhibit the release of Substance P from central and peripheral nerve ending [A20384]. ', 'Somatostatin is an endogenous peptide hormone that is secreted by the central nervous system, gastrointestinal tract, retina, peripheral neurons and pancreatic D cells of the islets of Langerhans. It exhibits several biological roles but predominantly exerts an inhibitory effect on secretion of other hormones and transmitters [A20384]. While distribution of two active isoforms of somatostatin is similar, SST-14 is more predominant in the enteric neurons and peripheral nerves whereas SST-28 is more prominent in the retina and intestinal mucosal cells [A20384].



**Anterior pituitary gland and brain:** It inhibits the release of growth hormones and thyroid-stimulating hormones, such as thyroid stimulating hormone (TSH) and thyrotrophin, from the anterior pituitary while inhibiting the release of dopamine from the midbrain, norepinephrine, TRH and corticotrophin-releasing hormone in the brain [A20384]. 



**Pancreas:** In the pancreas, somatostatin reduces the secretion of glucagon and insulin as well as bicarbonate ions and other enzymes [A20384, T28].



**Thyroid gland:** Somatosatin reduces secretion of T3, T4, and calcitonin [A20384]. Somatostatin regulates the thyroid function by reducing basal TSH release [T28].



**Gastrointestinal tract:** It attenuates the release of most gastrointestinal hormones such as gastrin, secretin, motilin, gastric acid, enteroglucagon, cholecystokinin (CCK), vasoactive intestinal peptide (VIP), gastric inhibitory polypeptide (GIP), intrinsic factor, pepsin, neurotensin, as well as bile secretion and colonic fluid secretion [A20384].



**Adrenal gland:** It inhibits angiotensin II-stimulated aldosterone secretion and acetylcholine-induced medullary catecholamine secretion [A20384].



**Eye/retina:** Somatostatin inhibits the production of vascular endothelial growth factor [A20384].



**Inflammatory cells and sensory nerves:** The expression of somatostatin has been found in inflammatory cells such as lymphocytes, monocytes, macrophages and endothelial cells to act as an autocrine or paracrine regulator in local immune responses. Findings suggest that somatostatin may play a role in exerting local and systemic anti-inflammatory and antinociceptive effects [A20384]. On primary afferent neurons, somatostatin reduces the responses to thermal stimulation in C-mechanoheat sensitive fibers in a dose-dependent fashion and reduces the responses of C-mechanoheat fibers to bradykinin-induced excitation and sensitization to heat [A32599]. Somatostatin is reported to elicit an analgesic effect when applied intrathecally; there is evidence supporting that similar effects may occur when systemically used to treat endocrine disorders [T28]. 



Somatostatin is thought to reduce bleeding from esophageal varices by causing splanchnic vasoconstriction [A27145]. Somatostatin elicits anti-neoplastic actions on various tumours via direct or indirect effects, or a combination of both [A32595]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27283, 'Somazina 100mg/ml oral drops 2*10 ml(n/a)', 'سومازينا 100مجم/مل نقط للفم 2 * 10 مل', '73', NULL, 'Cerebral circulatory inhancer', 'Citicholine', 'October pharma > ferrer international sa -spain', 'Drops', 'نقط', '100mg', '1', 'تنشيط الدورة الدموية بالمخ.', 'citicoline is a brain chemical that occurs naturally in the body. as a medicine it is taken by mouth as a supplement or given by iv or as a shot. citicoline is used for alzheimer s disease and other types of dementia head trauma cerebrovascular disease su', NULL, NULL, 1195, '2023-06-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27285, 'Somazina 500mg/4ml 5 amp for iv/im inj.', 'سومازينا 500مجم/4مل 5 امبولات', '80', NULL, 'Cerebral circulatory inhancer', 'Citicholine', 'Sigma tec > ferrer international sa -spain', 'Inj', 'حقن', '500mg', '5', 'علاج اضطرابات الوعي -- علاج الخرف والشيخوخة -- علاج الزهايمر', 'citicoline is a brain chemical that occurs naturally in the body. as a medicine it is taken by mouth as a supplement or given by iv or as a shot.ssciticoline is used for alzheimer s disease and other types of dementia head trauma cerebrovascular disease s', '6224009165049', NULL, 2434, '2023-05-21', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27286, 'Sominal 60mg 10 tab.', 'سومينال 60مجم 10 قرص', '3', NULL, 'Anti-epileptic.barbiturates', 'Phenobarbitone', 'Alexandria', 'Tab', 'أقراص', '60mg', '1', NULL, NULL, NULL, NULL, 1345, '2022-07-07', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27288, 'Sominaletta 15mg/5ml elixir 120 ml', 'سوميناليتا 15مجم/5مل 120 مل شراب', '31', '23.5', 'Anti-epileptic.barbiturates', 'Phenobarbitone', 'Alexandria', 'Unknown', 'غير محدد', '15mg', '1', 'علاج لمرض الصرع', 'about phenobarbitone barbiturate derivative sedative-hypnotic anticonvulsant. mechanism of action of phenobarbitone sedative and antiepileptic actions: phenobarbitone mainly acts on picrotoxin site of gaba -bzd receptor cl- (chloride ion) channel complex.', '6223000171233', NULL, 1595, '2025-05-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27289, 'Sominaletta 40mg/ml 10 i.m.amp.', 'سوميناليتا 40مجم/مل 10 امبولات عضل', '70', '55', 'Anti-epileptic.barbiturates', 'Phenobarbitone', 'Alexandria', 'Amp', 'أمبول', '40mg', '10', NULL, NULL, NULL, NULL, 1511, '2025-10-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27290, 'Sonakto cream 50 gm', 'سوناكتو كريم 50 جم', '89', '74.5', 'Moisturizing topicals', 'Chamomile extract+panthenol+soya protein+olive oil+vitamin e', 'Leader cosmetics > sonesta pharma', 'Cream', 'كريم', '50 gm', '1', 'علاج البواسير -- مرطب', 'moisturizing cream', '6225000146013', NULL, 2352, '2025-11-26', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27291, 'Sono acne soap 100 gm', 'سونو اكني صابون 100جم', '22', NULL, 'Soap', NULL, 'Macro group pharmaceuticals', 'Soap', 'صابون', '100 gm', '1', NULL, '*medicated soap for management of oily and acne prone skin with synergistic blend of natural ingredients. *rebalances the over-secretion of skin sebum. *has skin calming & soothing properties. use: - leave it as a mask for one minute then rinse with warm', '6224000437558', NULL, 721, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27292, 'Sonsept skin cleansing liquid 200 ml', 'سونسيبت ليكويد منظف للجلد 200 مل', '17', NULL, 'Antiseptic', 'Chlorhexidine+cocamidopropyl betaine', 'Egpi > sonesta pharmaceuticals co', 'Unknown', 'غير محدد', '200 ml', '1', NULL, 'ultra formula for skin cleansing - cleanser', NULL, NULL, 757, '2022-07-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27294, 'Sootal topical cream 50 gm', 'سوتال كريم 50جم', '25', NULL, 'Soothing topical', 'Panthenol+zinc oxide+chamomile+glycerin+almond oil+olive oil', 'Hi-care > linko pharm', 'Cream', 'كريم', '50 gm', '1', NULL, 'indications: -dermatitis -skin dryness. -napkin rash. -prophylaxis and treatment of sun burn.', NULL, NULL, 880, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27295, 'Soozy intimate wash 250 ml', 'سوزي غسول مهبلي 250 مل', '95', '49', 'Vaginal care', 'Chlorhexidine 0.1%+aloe vera+chamomile+green tea ext.+thyme+malva sylvestris+menthol+tea tree oil+rose', 'Egyptian co. for cosmetics > integra pharm', 'Unknown', 'غير محدد', '250 ml', '1', 'غسول مهبلي لتقليل فرص الاصابة بالعدوي', 'use: it can be used directly without dilution then rinse well with water.', NULL, NULL, 984, '2024-10-03', 0, 'Chlorhexidine is available over-the-counter in various formulations (e.g. solution, sponge, cloth, swab) as a topical antiseptic to sanitize prior to surgeries and/or medical procedures.[L11518,L11521,L11527,L11533] Dental formulations, available by prescription only, include an oral rinse indicated for the treatment of gingivitis[L11512] and a slow-release "chip" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth in adult patients with periodontitis as an adjunct therapy to dental scaling and root planing procedures.[L11536]', 'Chlorhexidine’s broad-spectrum antimicrobial effects are due to its ability to disrupt microbial cell membranes. The positively charged chlorhexidine molecule reacts with negatively charged phosphate groups on microbial cell surfaces - this reaction both destroys the integrity of the cell, allowing leakage of intracellular material, and allows chlorhexidine to enter the cell, causing precipitation of cytoplasmic components and ultimately cell death.[L11536,A190453] The specific means of cell death is dependent on the concentration of chlorhexidine - lower concentrations are bacteriostatic and result in leakage of intracellular substances such as potassium and phosphorous, whereas higher concentrations are bactericidal and cause cytoplasmic precipitation.[A190453]', 'Chlorhexidine is a broad-spectrum antimicrobial with demonstrated activity against both gram-positive and gram-negative bacteria, yeasts, and viruses.[A190417] Antimicrobial activity is dose-dependent - chlorhexidine is bacteriostatic at lower concentrations (0.02%-0.06%) and bactericidal at higher concentrations (>0.12%).[A190417]  Pharmacokinetic studies of oral chlorhexidine rinses indicate that approximately 30% of the active ingredient is retained in the mouth following rinsing, which is subsequently slowly released into oral fluids.[L11512] This ability to adsorb to dentine, shared with tetracycline antibiotics such as [doxycycline], is known as "substantivity" and is the result of chlorhexidine''s positive charge - it is likely that this substantivity plays at least some role in chlorhexidine''s antimicrobial activity, as its persistence on surfaces such as dentine prevent microbial colonization.[A190453]



Dental chlorhexidine rinses may result in staining of oral surfaces, such as teeth. This effect is not ubiquitous and appears to be more significant with extended therapy (i.e. up to 6 months) - nevertheless, patients for whom oral staining is unacceptable should use chlorhexidine rinse with caution and for the shortest effective interval.[L11512] Allergic reactions to chlorhexidine have been associated with the development of anaphylaxis.[A190468]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27296, 'Soplamin 160 mg 30 caps.', 'سوبلامين 160 مجم 30 كبسولة', '32', NULL, 'Prostate support', 'Saw palmetto oil', 'Technopharm > ema pharm', 'Cap', 'كبسولة', '160 mg', '3', 'علاج تضخم البروستاتاواحتباس البول', 'properties : soplamin capsules *inhibits 5 alpha - reductase enzyme which converts testosterone into dihydrotestosterone ( dht ) & antagonizes dht binding at the prostatic receptor. *alpha adrenergic receptor blocking action ( relaxation of smooth muscles', NULL, NULL, 1540, '2022-05-29', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27297, 'Soprol 10mg 30 f.c.tab', 'سوبرول 10مجم 30 اقراص', '27', NULL, 'Antihypertensive.beta blocker.selective b1', 'Bisoprolol fumarate', 'Eva pharma', 'Tab', 'أقراص', '10mg', '3', NULL, 'about bisoprolol beta1-selective adrenergic blocker antihypertensive. mechanism of action of bisoprolol bisoprolol is a cardio selective beta-1 adrenergic antagonist.it has negative chronotropic and negative inotropic effects on heart. it decreases oxygen', NULL, NULL, 856, '2022-07-13', 0, 'Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]', 'Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)[T640] are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen.  Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.[A180502,T640]



Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.[L7219]', 'Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.[T640,L7219] The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).[A180466,A180505] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27298, 'Soprol 5mg 20 f.c.tab.', 'سوبرول 5مجم 20 اقراص', '14', NULL, 'Antihypertensive.beta blocker.selective b1', 'Bisoprolol fumarate', 'Eva pharma', 'Tab', 'أقراص', '5mg', '2', NULL, 'about bisoprolol beta1-selective adrenergic blocker antihypertensive. mechanism of action of bisoprolol bisoprolol is a cardio selective beta-1 adrenergic antagonist.it has negative chronotropic and negative inotropic effects on heart. it decreases oxygen', NULL, NULL, 859, '2022-07-20', 0, 'Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]', 'Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)[T640] are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen.  Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.[A180502,T640]



Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.[L7219]', 'Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.[T640,L7219] The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).[A180466,A180505] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27299, 'Soprol plus 5/12.5mg 20 f.c.tab', 'سوبرول بلس 5/12.5مجم 20 قرص', '14', NULL, 'Antihypertensive.combined beta blocker with diuretic', 'Bisoprolol fumarate+hydrochlorothiazide', 'Eva pharma', 'Tab', 'أقراص', '12.5mg', '2', NULL, 'indications for bisoprolol + hydrochlorothiazide it is the combination of beta blocker bisoprolol and diuretic hydrochlorothiazide. hypertention typical dosage for bisoprolol + hydrochlorothiazide 1 tablet / day pregnancy related information contraindicat', '6223002453283', NULL, 900, '2022-07-08', 0, 'Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]', 'Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)[T640] are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen.  Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.[A180502,T640]



Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.[L7219]', 'Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.[T640,L7219] The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).[A180466,A180505] ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27300, 'Soral 20 mg 30 caps.', 'سورال 20مجم 30 كبسولة', '129', '88.5', 'Nsaid.oxicam', 'Tenoxicam', 'Global napi pharmaceuticals', 'Cap', 'كبسولة', '20 mg', '3', NULL, 'mechanism of action of tenoxicam the anti-inflammatory effects of tenoxicam may result from the inhibition of the enzyme cyclooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis (prostaglandins sensitize pain receptors their inhi', '6223002145188', NULL, 1104, '2024-08-28', 0, 'For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.', 'The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.', 'Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27303, 'Sorana oint 20 gm', 'سورانا مرهم 20جم', '8', NULL, 'Antiseptic', 'Jojoba oil', 'Sedico', 'Oint', 'مرهم', '20 gm', '1', NULL, NULL, NULL, NULL, 733, '2022-07-20', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27304, 'Soranib 200mg 120 f.c. tabs. (illegal import)', 'سورانيب 200مجم 120 قرص - استيراد', '0', NULL, 'Antineoplastic', 'Sorafenib', 'Cipla ltd. - india >', 'Tab', 'أقراص', '200mg', '1', 'مضاد للاورام', 'sorafenib indication sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. mechanism of action sorafenib interacts with multiple intracellular (craf braf and mutant braf) and cell surface kina', NULL, NULL, 4101, '2023-02-05', 0, 'Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.[L9341,L44577]



In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.[L9341]', 'Kinases are involved in tumour cell signalling, proliferation, angiogenesis, and apoptosis.[A14794,L9341] Sorafenib inhibits multiple intracellular serine/threonine kinases in the Ras/mitogen-activated protein kinase (MAPK) signal transduction pathway. Intracellular Raf serine/threonine kinase isoforms inhibited by sorafenib include Raf-1 (or C-Raf), wild-type B-Raf, and mutant B-Raf. Sorafenib inhibits cell surface tyrosine kinase receptors such as KIT, FMS-like tyrosine kinase 3 (FLT-3), RET, RET/PTC, vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor-β (PDGFR-β).[A255852,A255857,A14794,L9341] 



Sorafenib is thought to exhibit a dual mechanism of action: it blocks tumour proliferation and growth by inhibiting the RAF/MEK/extracellular signal-regulated kinase (ERK) pathway on tumour cells, and reduces tumour angiogenesis by inhibiting VEGFR and PDGFR signalling in tumour vasculature.[A255852,A10489]', 'Sorafenib decreases tumour cell proliferation _in vitro_. It attenuated tumour growth of human tumour xenografts in immunocompromised mice, reduced tumour angiogenesis, and increased tumour apoptosis in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.[A255852,L9341] Some studies suggest that sorafenib induces apoptosis in several tumour cell lines, although this effect is inconsistent across cell lines.[A255852] Antiviral effects of sorafenib have been documented, as it was shown to inhibit hepatitis C viral replication _in vitro_.[A255852]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27305, 'Soranib 200mg 30 f.c. tabs.(illegal import)', 'سورانيب 200مجم 30 اقراص', '0', NULL, 'Antineoplastic', 'Sorafenib', 'Cipla ltd. - india >', 'Tab', 'أقراص', '200mg', '1', NULL, 'sorafenib indication sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. mechanism of action sorafenib interacts with multiple intracellular (craf braf and mutant braf) and cell surface kina', NULL, NULL, 1105, '2022-07-09', 0, 'Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.[L9341,L44577]



In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.[L9341]', 'Kinases are involved in tumour cell signalling, proliferation, angiogenesis, and apoptosis.[A14794,L9341] Sorafenib inhibits multiple intracellular serine/threonine kinases in the Ras/mitogen-activated protein kinase (MAPK) signal transduction pathway. Intracellular Raf serine/threonine kinase isoforms inhibited by sorafenib include Raf-1 (or C-Raf), wild-type B-Raf, and mutant B-Raf. Sorafenib inhibits cell surface tyrosine kinase receptors such as KIT, FMS-like tyrosine kinase 3 (FLT-3), RET, RET/PTC, vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor-β (PDGFR-β).[A255852,A255857,A14794,L9341] 



Sorafenib is thought to exhibit a dual mechanism of action: it blocks tumour proliferation and growth by inhibiting the RAF/MEK/extracellular signal-regulated kinase (ERK) pathway on tumour cells, and reduces tumour angiogenesis by inhibiting VEGFR and PDGFR signalling in tumour vasculature.[A255852,A10489]', 'Sorafenib decreases tumour cell proliferation _in vitro_. It attenuated tumour growth of human tumour xenografts in immunocompromised mice, reduced tumour angiogenesis, and increased tumour apoptosis in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.[A255852,L9341] Some studies suggest that sorafenib induces apoptosis in several tumour cell lines, although this effect is inconsistent across cell lines.[A255852] Antiviral effects of sorafenib have been documented, as it was shown to inhibit hepatitis C viral replication _in vitro_.[A255852]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27306, 'Sorbisterit powder 500 gm', 'سوربيستريت باودر 500 جم', '867', '502.2', 'Potassium binders', 'Calcium polystyrene sulphonate', 'Fresenius kabi > egyptian group for import and export', 'Powder', 'بودرة', '500 gm', '1', 'مصدر البوتاسيوم للحفاظ علي مستوي الأملاح والمعادن في الجسم', '*potassium binders are medications that bind potassium ions in the gastrointestinal tract thereby preventing its intestinal absorption. they consist of polystyrene sulfonate resins attached to a cation and are administered either orally or by retention en', NULL, NULL, 2171, '2024-08-20', 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27308, 'Sorbitol irrigation solution 2.5%', 'سوربيتول محلول 2.5%', '10', NULL, 'Sterile solution', 'Sorbitol', 'Otsuka', 'Solution', 'محلول', '2.5%', '1', NULL, 'about sorbitol a sugar alcohol sweetener non-stimulant laxative osmotic diuretic genitourinary irrigant. mechanism of action of sorbitol sorbitol is hydrolysed in the colon to short chain fatty acids. this fatty acid stimulates colonic propulsive motility', NULL, NULL, 795, '2022-08-01', 0, 'Used as a non-stimulant laxative via an oral suspension or enema.', 'Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements.', NULL, 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27309, 'Sordevan 160 mg 7 f.c. tab.', 'سورديفان 160 مجم 7 اقراص', '22', NULL, 'Antihypertensive.angiotensin blocker', 'Valsartan', 'Hikma pharma > atos pharma', 'Tab', 'أقراص', '160 mg', '1', NULL, 'about valsartansangiotensin ii receptor antagonist antihypertensive.smechanism of action of valsartansit is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive individuals. it blocks', NULL, NULL, 804, '2022-07-09', 0, 'Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate.[F4703, L11305]



It is also used in combination with [sacubitril].[L36445]', 'Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which selectively bind to angiotensin receptor 1 (AT1) and prevent angiotensin II from binding and exerting its hypertensive effects. These include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium among others. Overall, valsartan''s physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. 



Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via  AT1 receptor blockade inhibits negative regulatory feedback within RAAS which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and prevent ventricular hypertrophy.[A174154]



The angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibits the conversion of angiotensin I to angiotensin II by inhibiting the ACE enzyme but does not prevent the formation of all angiotensin II. ARB activity is unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. 



Valsartan is commonly used for the management of hypertension, heart failure, and type 2 diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. ARBs such as valsartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.[A174124,A178153,A173869,A185324,A185327,A185333,A185342,A185345] Valsartan also slows the progression of diabetic nephropathy due to its renoprotective effects.[A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed with type 2 diabetes and in nondiabetic patients diagnosed with chronic kidney disease.[A174124,A173869]



Valsartan also binds to the AT2 receptor, however AT2 is not known to be associated with cardiovascular homeostasis like AT1. Valsartan has about 20,000-fold higher affinity for the AT1 receptor than for the AT2 receptor. The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor.[L11305]', 'Valsartan inhibits the pressor effects of angiotensin II with oral doses of 80 mg inhibiting the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan.



In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid.[L11305]



**Hypotension** 



Excessive hypotension was rarely seen (0.1%) in patients with uncomplicated hypertension treated with valsartan alone. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. This condition should be corrected prior to administration of valsartan, or the treatment should start under close medical supervision. 



Caution should be observed when initiating therapy in patients with heart failure. Patients with heart failure given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension usually is not necessary when dosing instructions are followed. In controlled trials in heart failure patients, the incidence of hypotension in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. 



If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.[L11305]





**Impaired Renal Function**



Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on valsartan. Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on valsartan.[L11305]





**Hyperkalemia**



Some patients with heart failure have developed increases in potassium. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of valsartan may be required.[L11305]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27310, 'Sordevan 320 mg 7 f.c. tabs.', 'سورديفان 320مجم 7 اقراص', '34', NULL, 'Antihypertensive.angiotensin blocker', 'Valsartan', 'Hikma pharma > atos pharma', 'Tab', 'أقراص', '320 mg', '1', NULL, 'about valsartansangiotensin ii receptor antagonist antihypertensive.smechanism of action of valsartansit is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive individuals. it blocks', NULL, NULL, 693, '2022-07-15', 0, 'Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate.[F4703, L11305]



It is also used in combination with [sacubitril].[L36445]', 'Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which selectively bind to angiotensin receptor 1 (AT1) and prevent angiotensin II from binding and exerting its hypertensive effects. These include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium among others. Overall, valsartan''s physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. 



Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via  AT1 receptor blockade inhibits negative regulatory feedback within RAAS which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and prevent ventricular hypertrophy.[A174154]



The angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibits the conversion of angiotensin I to angiotensin II by inhibiting the ACE enzyme but does not prevent the formation of all angiotensin II. ARB activity is unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. 



Valsartan is commonly used for the management of hypertension, heart failure, and type 2 diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. ARBs such as valsartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.[A174124,A178153,A173869,A185324,A185327,A185333,A185342,A185345] Valsartan also slows the progression of diabetic nephropathy due to its renoprotective effects.[A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed with type 2 diabetes and in nondiabetic patients diagnosed with chronic kidney disease.[A174124,A173869]



Valsartan also binds to the AT2 receptor, however AT2 is not known to be associated with cardiovascular homeostasis like AT1. Valsartan has about 20,000-fold higher affinity for the AT1 receptor than for the AT2 receptor. The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor.[L11305]', 'Valsartan inhibits the pressor effects of angiotensin II with oral doses of 80 mg inhibiting the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan.



In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid.[L11305]



**Hypotension** 



Excessive hypotension was rarely seen (0.1%) in patients with uncomplicated hypertension treated with valsartan alone. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. This condition should be corrected prior to administration of valsartan, or the treatment should start under close medical supervision. 



Caution should be observed when initiating therapy in patients with heart failure. Patients with heart failure given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension usually is not necessary when dosing instructions are followed. In controlled trials in heart failure patients, the incidence of hypotension in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. 



If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.[L11305]





**Impaired Renal Function**



Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on valsartan. Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on valsartan.[L11305]





**Hyperkalemia**



Some patients with heart failure have developed increases in potassium. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of valsartan may be required.[L11305]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27311, 'Sorti 20 tabs.', 'سورتي 20 قرص', '59', '49', 'Multiviamins', 'Iron+folic acid+vitamin b12+zinc+copper+vitamin c', 'Nutrixia > linkopharm', 'Tab', 'أقراص', NULL, '2', 'حديد وحمض فوليك وفيتامين ب12', 'dose: once daily.', '6224008585664', NULL, 3546, '2024-03-17', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27312, 'Sotaloc 160mg tabs.', 'سوتالوك 160مجم أقراص', '10', NULL, 'Antiarrhythmias.class iii', 'Sotalol', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '160mg', '1', NULL, 'about sotalol beta (nonselective) adneregic blocking agent a potassium channel blocker anti-hypertensive class iii anti-arrhythmic. mechanism of action of sotalol sotalol is a non selective beta receptor antagonist. it has negative chronotropic effect on', NULL, NULL, 1393, '2022-07-09', 0, 'Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.[Label] There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.[Label,L6373,L6376]', 'Sotalol inhibits beta-1 adrenoceptors in the myocardium as well as rapid potassium channels to slow repolarization, lengthen the QT interval, and slow and shorten conduction of action potentials through the atria.[A178522,A178540,A178561,A34177] The action of sotalol on beta adrenergic receptors lengthens the sinus node cycle, conduction time through the atrioventricular node, refractory period, and duration of action potentials.[A178579]', 'Sotalol is a competitive inhibitor of the rapid potassium channel.[A178522] This inhibition lengthens the duration of action potentials and the refractory period in the atria and ventricles.[A178540,A178561] The inhibition of rapid potassium channels is increases as heart rate decreases, which is why adverse effects like torsades de points is more likely to be seen at lower heart rates.[A178579] L-sotalol also has beta adrenergic receptor blocking activity seen above plasma concentrations of 800ng/L.[A178579] The beta blocking ability of sotalol further prolongs action potentials.[A178579] D-sotalol does not have beta blocking activity but also reduces a patient''s heart rate while standing or exercising.[A178579] These actions combine to produce a negative inotropic effect that reduces the strength of contractility of muscle cells in the heart.[A178522] Extension of the QT interval is also adversely associated with the induction of arrhythmia in patients.[A178561]



Hyperglycemia is a greater risk for non insulin dependant diabetics than insulin dependant diabetics.[A33725] Beta blockers inhibit insulin secretion which may cause hyperglycemia in type II diabetes mellitus.[A33725] The risk of hypoglycemia is higher in insulin dependant diabetes than non insulin dependant diabetics.[A33725] Beta blockers decrease secretion of insulin, which may mask hypoglycemia in an insulin dependant patient.[A33725] Beta blockers also increase glucose uptake into cells which may prolong or potentiate hypoglycemia.[A33725]



Further information regarding adverse reactions can be found here.[L6379]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27313, 'Souvana topical lotion 120 ml', 'سوفانا لوشن 120 مل', '60', '50', 'Soothing topical', 'Zinc oxide+menthol crystals+thymol+chamomile+dimethicone+glycerol', 'Hi-care > api pharma', 'Lotion', 'لوشن', '120 ml', '1', 'مرطب للجلد.', 'skin soothing lotion', NULL, NULL, 1974, '2024-08-13', 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27315, 'Sovelpak 400/100mg 28 tablets', 'سوفيلباك 400/100مجم 28 قرص', '1,270', NULL, 'Antiviral', 'Sofosbuvir+velpatasvir', 'Marcyrl', 'Tablet', 'أقراص', '100mg', '4', 'مضاد فيروسات', NULL, NULL, NULL, 5515, '2022-04-07', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27316, 'Soy lecithin 1200 mg 100 softgels (illegal import)', 'سوي ليسيثين 1200مجم 100 سوفت جل', '0', NULL, NULL, 'Soy lecithin', 'Puritans pride', 'Gel', 'جل', '1200 mg', '1', NULL, 'lecithin is an important natural source of choline and inositol two nutrients important for the proper functioning of the body.** since levels of phospholipids in the brain can decline as you get older it may be especially important to supplement with a h', NULL, NULL, 562, '2022-07-29', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27317, 'Spaniela mr 35mg 30 f.c. tab.', 'سبانيلا ام ار 35مجم 30 قرص', '54', '39', 'Anti-ischemic', 'Trimetazidine', 'Marcyrl co.', 'Tab', 'أقراص', '35mg', '3', 'علاج قصور الدورة الدموية — تنشيط الدورة الدموية للمخ — علاج مساعد في حالات الذبحة الصدرية', 'about trimetazidine cytoprotective vasodilator anti-ischemic (anti-anginal) agent. mechanism of action of trimetazidine it is a cytoprotective drug which reduces anginal attacks and improves exercise tolerance by nonhaemodynamic mechanisms. it improves ce', '6223003579418', NULL, 10537, '2025-05-27', 0, 'Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.[L33015]', 'During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid.[A233215] The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility.[A233215]



This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma.[A233215] When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury.[A233215]



The mechanism of action of trimetazidine is not fully understood.[A233215] Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium.[A7688,L33020] The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility.[A7688,L33020] However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine''s target, and that this mechanism may be incorrect.[A233215]', 'Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.[L33015] Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.[L33020]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27318, 'Spanomep syrup 120 ml', 'سبانوميب شراب 120 مل', '25', '16.5', 'Anti-cough.antitussive and expectorant', 'Ivy leaves', 'Mepaco', 'Syrup', 'شراب', '120 ml', '1', 'مكمل غذائى مضاد للسعال ومذيب للبلغم يدعم الجهاز التنفسي ويخفف من اعراض البرد', 'due to their broncholytic and secretolic properties ivy leaf dried extract has long provided its worth in practice. their efficacy has been demonstrated in numerous scientific studies. according to a pharmacological investigation its constituent appears t', NULL, NULL, 2211, '2023-09-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27320, 'Sparatec 200mg 12 tab.', 'سباراتيك 200مجم 12قرص', '36', NULL, 'Antibiotic.quinolone', 'Sparfloxacin', 'Unipharma co.', 'Tab', 'أقراص', '200mg', '2', NULL, 'about sparfloxacin a third generation fluoroquinolone a synthetic broad-spectrum antibiotic. mechanism of action of sparfloxacin sparfloxacin is a bacteriostatic at low concentration and bactericidal at high concentration. it acts by inhibiting the enzyme', NULL, NULL, 588, '2023-01-14', 0, 'For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by <i>Chlamydia pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>Moraxella catarrhalis</i>, <i>Mycoplasma pneumoniae</i>, or <i>Streptococcus pneumoniae</i>) and acute bacterial exacerbations of chronic bronchitis (caused by <i>Chlamydia pneumoniae</i>, <i>Enterobacter cloacae</i>, <i>Haemophilus influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Moraxella catarrhalis</i>, <i>Staphylococcus aureus</i>, or <i>Streptococcus pneumoniae</i>).', 'The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.', 'Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27324, 'Spascolon 50mg 30 f.c.tab.', 'سباسكولون 50 مجم 30 قرص', '84', '55.5', 'Smooth muscle relaxant', 'Pinaverium bromide', 'Chemipharm', 'Tab', 'أقراص', '50mg', '3', NULL, 'about pinaverium bromide a calcium channel blocker for functional gastrointestinal disorder. mechanism of action of pinaverium bromide pinaverium is a calcium channel blocker. it inhibits the calcium influx through voltage-dependent calcium channel in the', '6222006502225', NULL, 1919, '2024-09-08', 0, 'Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.', 'Pinaverium interacts with the 1,4-dihydropyridine binding sites on voltage dependent L-type calcium channels located on GI smooth muscle cells in a competitve manner [A19698]. The binding site is located in the alpha 1S subunit and pinaverium most likely antagonizes the action of calcium ions by stabilizing a non-conducting channel state [A19705]. Pinaverium inhibits smooth muscle contractions of the GI tract by inhibiting inward calcium current and calcium influx. It is suggested that pinaverium may be able to bind to both closed or inactivates states of the calcium channel with similar affinity [T37, A19697]. ', 'Pinaverium is a selective and specific voltage-dependent calcium channel blocker located on intestinal smooth muscle cells to inhibit calcium influx. It mediates various effects on the GI tract: it causes oesophageal, gastric and duodenal relaxation, relaxes the colon and intestines, inhibits colonic motility in response to food, hormonal or pharmacological stimuli, accelerates gastric emptying, and reduces contractions of the gallbladder and phasic contractions of sphincter of Oddi [L873, A19702]. At higher concentrations, pinaverium also exhibits very weak anticholinergic effects [L873] but is not shown to display vasodilatory or anti-arrythmic actions [T37]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27326, 'Spasmex 30 mg 50 f.c. tabs.', 'سبازمكس 30مجم 50قرص', '170', NULL, 'Urge incontinence', 'Trospium chloride', 'Ferring pharmaceuticals > multipharma', 'Tab', 'أقراص', '30 mg', '5', NULL, 'trospium chloride is used for the treatment of overactive bladder with symptoms of urge incontinence and frequent urination. it shouldn t be used with people who retain urine who have severe digestive conditions myasthenia gravis narrow-angle glaucoma or', '4028305000934', NULL, 1450, '2022-12-09', 0, 'Trospium is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.[L36823] It is also indicated in combination with [xanomeline] for the treatment of adult patients with schizophrenia.[L51629]', 'Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.', 'Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. According to receptor assays, it displays higher affinity towards muscarininc receptors compared to nicotinic receptors at therapeutic concentrations. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27329, 'Spasmo amrase 30 e.c. tab', 'سبازمو امريز 30 قرص', '27', NULL, 'Colon.antispasmodic.digestive enzymes', 'Pancreatin+papain+ox-bile extract+dimethicone+mebeverine', 'Amriya', 'Tab', 'أقراص', NULL, '3', 'انزيمات هاضمة لعلاج مشاكل وعسر الهضم', NULL, NULL, NULL, 3871, '2023-06-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27330, 'Spasmo rowatinex 5 supp.', 'سبازمو رواتينكس 5 اقماع', '9', NULL, 'Urinary.analgesic.antiseptic', 'Anethol+borneol+camphene+cineole+ethaverine+fenchone+pinene', 'Amoun', 'Supp', 'لبوس', NULL, '1', NULL, 'properties rowatinex promotes diuresis and relaxes urinary tract spasm. thus assisting the passage of stones. the therapeutic effect of the balanced combination of terpenes reduces urinary tract inflammation stimulating renal blood flow through the kidney', '6221025005588', NULL, 1226, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27333, 'Spasmocin 100mg/100ml syrup 120ml', 'سبازموسين 100مجم/100مل شراب 120 مل', '4', NULL, 'Antimuscarinic.antispasmodic', 'Hyoscin-n-butylbromid', 'Memphis', 'Syrup', 'شراب', '100mg', '1', NULL, 'hyoscine-n-butylbromide is an antispasmodic drug used to treat conditions associated with spasms of the gastrointestinal tract such as cramping. how does it work? this medication relieves gastrointestinal cramping by relieving smooth muscle contractions.', NULL, NULL, 800, '2022-09-07', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27335, 'Spasmocin 15mg 6 supp.', 'سبازموسين 15مجم 6 اقماع لبوس', '3', NULL, 'Antimuscarinic.antispasmodic', 'Hyoscin-n-butylbromid', 'Memphis', 'Supp', 'لبوس', '15mg', '1', NULL, 'hyoscine-n-butylbromide is an antispasmodic drug used to treat conditions associated with spasms of the gastrointestinal tract such as cramping. how does it work? this medication relieves gastrointestinal cramping by relieving smooth muscle contractions.', NULL, NULL, 848, '2023-01-11', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27336, 'Spasmocin 20mg/ml 6 amp.', 'سبازموسين 20مجم/مل 6 امبول', '15', NULL, 'Antimuscarinic.antispasmodic', 'Hyoscin-n-butylbromid', 'Memphis', 'Amp', 'أمبول', '20mg', '6', NULL, 'hyoscine-n-butylbromide is an antispasmodic drug used to treat conditions associated with spasms of the gastrointestinal tract such as cramping. how does it work? this medication relieves gastrointestinal cramping by relieving smooth muscle contractions.', '6221050010366', NULL, 972, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27337, 'Spasmocure 40mg/2ml i.m. i.v. s.c. 5 amp.', 'سبازموكيور 40مجم/2مل 5 امبول', '24', NULL, 'Antispasmodic', 'Drotaverine', 'Alfacure pharmaceuticals', 'Amp', 'أمبول', '40mg', '5', NULL, 'about drotaverine drotaverine is an effective spasmolytic drug. mechanism of action of drotaverine drotaverine has spasmolytic and vasodilating action. it exerts its action by inhibiting phosphodiesterase enzyme iv. this will leads to a decrease in cyclic', NULL, NULL, 892, '2022-09-14', 0, 'Drotaverine is used to alleviate gastrointestinal and genitourinary smooth muscle spasms, such as cholecystitis and gallbladder disorders.[L22689]', 'Drotaverine is a selective inhibitor of phosphodiesterase 4 (PDE4), which is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 leads to elevated levels of cAMP, leading to smooth muscle relaxation. Recent research showed that low levels of cAMP have been associated with brain tumorigenesis, leading to the investigation of PDE4 inhibitors as potential anticancer agents.[A231619]', 'Drotaverine is an e spasmolytic agent with a relaxing effect on smooth muscles. It works to relieve visceral spasms and improve cervical dilation. _In vitro_, drotaverine mediated cytostatic effects on several human tumor cell lines and nonmalignant mouse fibroblasts.[A231619] Drotaverine may have minor allosteric calcium channel blocking properties: _in vitro_, drotaverine behaves like voltage-dependent L-type calcium channel blockers.[A231624]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27346, 'Spasmopinaver 100mg 30 f.c. tab', 'سبازموبينافير 100مجم 30 قرص', '48', NULL, 'Antispasmodic', 'Pinaverium bromide', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '100mg', '3', 'للمغص والتقلصات', NULL, '6223002144211', NULL, 1582, '2022-10-04', 0, 'Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.', 'Pinaverium interacts with the 1,4-dihydropyridine binding sites on voltage dependent L-type calcium channels located on GI smooth muscle cells in a competitve manner [A19698]. The binding site is located in the alpha 1S subunit and pinaverium most likely antagonizes the action of calcium ions by stabilizing a non-conducting channel state [A19705]. Pinaverium inhibits smooth muscle contractions of the GI tract by inhibiting inward calcium current and calcium influx. It is suggested that pinaverium may be able to bind to both closed or inactivates states of the calcium channel with similar affinity [T37, A19697]. ', 'Pinaverium is a selective and specific voltage-dependent calcium channel blocker located on intestinal smooth muscle cells to inhibit calcium influx. It mediates various effects on the GI tract: it causes oesophageal, gastric and duodenal relaxation, relaxes the colon and intestines, inhibits colonic motility in response to food, hormonal or pharmacological stimuli, accelerates gastric emptying, and reduces contractions of the gallbladder and phasic contractions of sphincter of Oddi [L873, A19702]. At higher concentrations, pinaverium also exhibits very weak anticholinergic effects [L873] but is not shown to display vasodilatory or anti-arrythmic actions [T37]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27347, 'Spasmopinaver 50mg 30 f.c. tabs', 'سبازموبينافير 50 مجم 30 قرص', '38', NULL, 'Smooth muscle relaxant', 'Pinaverium bromide', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '50mg', '3', 'يعمل علي استرخاء العضلات -- تقليل الالام العضلات -- مسكن لالام', NULL, '6223002142804', NULL, 1080, '2022-12-09', 0, 'Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.', 'Pinaverium interacts with the 1,4-dihydropyridine binding sites on voltage dependent L-type calcium channels located on GI smooth muscle cells in a competitve manner [A19698]. The binding site is located in the alpha 1S subunit and pinaverium most likely antagonizes the action of calcium ions by stabilizing a non-conducting channel state [A19705]. Pinaverium inhibits smooth muscle contractions of the GI tract by inhibiting inward calcium current and calcium influx. It is suggested that pinaverium may be able to bind to both closed or inactivates states of the calcium channel with similar affinity [T37, A19697]. ', 'Pinaverium is a selective and specific voltage-dependent calcium channel blocker located on intestinal smooth muscle cells to inhibit calcium influx. It mediates various effects on the GI tract: it causes oesophageal, gastric and duodenal relaxation, relaxes the colon and intestines, inhibits colonic motility in response to food, hormonal or pharmacological stimuli, accelerates gastric emptying, and reduces contractions of the gallbladder and phasic contractions of sphincter of Oddi [L873, A19702]. At higher concentrations, pinaverium also exhibits very weak anticholinergic effects [L873] but is not shown to display vasodilatory or anti-arrythmic actions [T37]. ', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27349, 'Spasmopyralgin-m 25*10 tablets', 'سبازموبيرالجين-ام 25*10 اقراص', '525', '362.5', 'Antispasmodic', 'Camylofin+dipyrone(metamizole)', 'Kahira', 'Tablet', 'أقراص', NULL, '25', NULL, NULL, '6221068000335', NULL, 1760, '2024-12-07', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27350, 'Spasmorest 0.2% syrup 125ml', 'سبازمورست 0.2% شراب 125 مل', '9', NULL, 'Antimuscarinic.irritable bowel syndrome', 'Dicyclomine', 'Misr', 'Syrup', 'شراب', '0.2%', '1', NULL, 'about dicyclomine anticholinergic antimuscarinic antispasmodic and in urinary incontinence. mechanism of action of dicyclomine dicyclomine is an anticholinergic drug. it exerts its action by inhibiting muscarinic (((cholinergic))) receptors on smooth musc', NULL, NULL, 812, '2023-04-27', 0, 'Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]', 'Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.[A6556,A182555,A234659,L7967] Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.[A182555]', 'Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.[L7967] It''s duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.[L7967] Dicyclomine should not be administered intravenously.[L7967]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27353, 'Spasmorest 20mg 20 tab.', 'سبازمورست 20مجم 20 قرص', '32', '19', 'Antimuscarinic.irritable bowel syndrome', 'Dicyclomine', 'Misr', 'Tab', 'أقراص', '20mg', '2', NULL, NULL, '6221035009446', NULL, 1658, '2024-11-04', 0, 'Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]', 'Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.[A6556,A182555,A234659,L7967] Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.[A182555]', 'Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.[L7967] It''s duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.[L7967] Dicyclomine should not be administered intravenously.[L7967]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27354, 'Spasmotalin 100mg 20 f.c. tabs.', 'سبازموتالين 100مجم 20 اقراص', '9', NULL, 'Antimuscarinic.irritable bowel syndrome', 'Mebeverine', 'Amriya', 'Tab', 'أقراص', '100mg', '2', NULL, 'about mebeverine reserpine derivative antimuscarinic a musculotropic antispasmodic motility stimulant. mechanism of action of mebeverine mebeverine has a direct relaxant effect on smooth muscle. this will inhibits gastrointestinal propulsive motility and', '6221075010358', NULL, 1239, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27356, 'Spasmo-urgenin 40 tab.', 'سبازمو ارجنين 40 اقراص', '21', NULL, 'Urinary antispasmodic', 'Echinaceae angustifolia ext.+sabal extract+trospium chloride', 'Cid > madaus ag', 'Tab', 'أقراص', NULL, '4', NULL, 'echinacea is widely used to fight infections especially the common cold and other upper respiratory infections. some people take echinacea at the first sign of a cold hoping they will be able to keep the cold from developing. other people take echinacea a', '6221043040073', NULL, 852, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27358, 'Specpro 14 sachets', 'سبيكبرو 14 كيس', '155', '135', 'Immune enhancer', 'High concentration bovine colostrum+casecidins+oligosaccharide', 'Medcare > medicina medical ltd.', 'Sachet', 'أكياس', NULL, '1', NULL, 'indications: -in recurrent infections. -three or more recurrent upper & lower respiratory infections. -for treating diarrhea & lactose intolerance. -as an immunostimulant. -for low birth body weight & malnutrition. -to enhance mental & physical activities', '6225000535886', NULL, 2175, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27359, 'Specpro 7 sachets', 'سبيكبرو 7 اكياس', '75', '70', 'Immune enhancer', 'High concentration bovine colostrum+casecidins+oligosaccharide', 'Medcare > medicina medical ltd.', 'Sachet', 'أكياس', NULL, '1', NULL, 'indications: -in recurrent infections. -three or more recurrent upper & lower respiratory infections. -for treating diarrhea & lactose intolerance. -as an immunostimulant. -for low birth body weight & malnutrition. -to enhance mental & physical activities', NULL, NULL, 913, '2024-05-26', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27360, 'Specsafon 330 mg 30 caps.', 'سبكسافون 330 مجم 30 كبسولة', '59', NULL, 'Antioxidant', 'L-carnitine', 'Debeiky > zad', 'Cap', 'كبسولة', '330 mg', '3', 'مضاد للاكسدة -- مصدر للطاقة --يتخلص من الشوارد احلرة بالجسم -- يحسن اداء اعضاء الجسم', 'about l-carnitine dietary supplement amino acid derivative antioxidant. mechanism of action of l-carnitine carnitine is an essential co-factor of fatty acid metabolism in the heart liver and skeletal muscle. it is normally synthesised in the liver brain a', NULL, NULL, 1351, '2022-04-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27361, 'Spectavit 10 sachets', 'سبيكتافيت 10 كيس', '76', NULL, 'Dietary supplement', 'Colostrum powder+vitamin(b1+b6+c+d)+iron+calcium', 'Copad pharma', 'Sachet', 'أكياس', NULL, '1', NULL, 'banana & vanilla flavour use: 1 sachet to be diluted in milk or yogurt. once daily.', NULL, NULL, 922, '2022-07-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27364, 'Spectraban 55 spf cream 70 gm', 'سبيكترابان 55 كريم 70جم', '90', NULL, 'Sun block', 'Octyl methoxycinnamate+benzophenone-3+benzophenone-4+titanium dioxide', 'Stiefel mexico > modern office for import', 'Cream', 'كريم', '70 gm', '1', NULL, 'solar protection uva / uvb', NULL, NULL, 991, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27365, 'Spectracef 0.5 gm i.m/i.v vial', 'سبيكتراسيف 0.5جم عضل.وريد فيال', '36', '24', 'Antibiotic.cephalosporin.fourth-generation', 'Cefepime', 'Mup', 'Vial', 'فيال', '0.5 gm', '1', NULL, 'about cefepime fourth generation cephalosporin antibiotic. mechanism of action of cefepime cefepime is a 3rd generation cephalosporin which exerts its bactericidal action by inhibiting bacterial cell wall synthesis. cefepime inhibits transpeptidase & thus', NULL, NULL, 811, '2024-11-23', 0, 'Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (cUTI) including pyelonephritis, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (used in combination with [metronidazole]) in adults caused by susceptible bacteria.[L42095,L42100]



Cefepime is also used in combination with [enmetazobactam] to treat cUTI.[L50117]', 'Cefepime is a bactericidal cephalosporin with a mode of action similar to other beta-lactam antibiotics.[L42095,L42100] Cefepime disrupts bacterial cell walls by binding and inhibiting transpeptidases known as penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of peptidoglycan layer synthesis. This results in the lysis and death of susceptible microorganisms.[A249050] Cefepime has a broad spectrum of _in vitro_ activity that includes both Gram-positive and Gram-negative bacteria.[L42095,L42100] Cefepime has affinity for PBP-3 and PBP-1 in _Escherichia coli_ and _Pseudomonas aeruginosa_, as well as PBP-2 in _E. coli_ and _Enterobacter cloacae_.[A249050]', 'Cefepime is a fourth-generation cephalosporin antibiotic.[L42095,L42100] It is active against Gram-negative bacteria such as _Enterobacter_ spp., _Escherichia coli_, _Klebsiella pneumoniae_, _Proteus mirabilis_ and _Pseudomonas aeruginosa_, and Gram-positive bacteria such as _Staphylococcus aureus_ (methicillin-susceptible isolates only), _Streptococcus pneumoniae_, _Streptococcus pyogenes_ and Viridans group streptococci.[L42095,L42100] Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes.[A2457,A249050] Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.[A2457] 



In animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy.[L42095,L42100] It has been suggested that cefepime can cross the inflamed blood-brain barrier.[L42095,L42100] This, along with its ability to inhibit γ-aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.[A249045,A249050]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27366, 'Spectracef 1 gm i.m/i.v vial', 'سبكتراسيف 1 جم حقن عضل/وريد فيال', '76', '53', 'Antibiotic.cephalosporin.fourth-generation', 'Cefepime', 'Mup', 'Vial', 'فيال', '1 gm', '1', 'مضاد حيوي', 'about cefepime fourth generation cephalosporin antibiotic. mechanism of action of cefepime cefepime is a 3rd generation cephalosporin which exerts its bactericidal action by inhibiting bacterial cell wall synthesis. cefepime inhibits transpeptidase & thus', '6221508162517', NULL, 2157, '2024-11-23', 0, 'Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (cUTI) including pyelonephritis, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (used in combination with [metronidazole]) in adults caused by susceptible bacteria.[L42095,L42100]



Cefepime is also used in combination with [enmetazobactam] to treat cUTI.[L50117]', 'Cefepime is a bactericidal cephalosporin with a mode of action similar to other beta-lactam antibiotics.[L42095,L42100] Cefepime disrupts bacterial cell walls by binding and inhibiting transpeptidases known as penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of peptidoglycan layer synthesis. This results in the lysis and death of susceptible microorganisms.[A249050] Cefepime has a broad spectrum of _in vitro_ activity that includes both Gram-positive and Gram-negative bacteria.[L42095,L42100] Cefepime has affinity for PBP-3 and PBP-1 in _Escherichia coli_ and _Pseudomonas aeruginosa_, as well as PBP-2 in _E. coli_ and _Enterobacter cloacae_.[A249050]', 'Cefepime is a fourth-generation cephalosporin antibiotic.[L42095,L42100] It is active against Gram-negative bacteria such as _Enterobacter_ spp., _Escherichia coli_, _Klebsiella pneumoniae_, _Proteus mirabilis_ and _Pseudomonas aeruginosa_, and Gram-positive bacteria such as _Staphylococcus aureus_ (methicillin-susceptible isolates only), _Streptococcus pneumoniae_, _Streptococcus pyogenes_ and Viridans group streptococci.[L42095,L42100] Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes.[A2457,A249050] Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.[A2457] 



In animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy.[L42095,L42100] It has been suggested that cefepime can cross the inflamed blood-brain barrier.[L42095,L42100] This, along with its ability to inhibit γ-aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.[A249045,A249050]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27367, 'Spectracef 2 gm i.m/i.v vial', 'سبيكتراسيف 2جم عضل.وريد فيال', '91', '48', 'Antibiotic.cephalosporin.fourth-generation', 'Cefepime', 'Mup', 'Vial', 'فيال', '2 gm', '1', NULL, 'about cefepime fourth generation cephalosporin antibiotic. mechanism of action of cefepime cefepime is a 3rd generation cephalosporin which exerts its bactericidal action by inhibiting bacterial cell wall synthesis. cefepime inhibits transpeptidase & thus', '6221508162616', NULL, 842, '2025-02-09', 0, 'Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (cUTI) including pyelonephritis, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (used in combination with [metronidazole]) in adults caused by susceptible bacteria.[L42095,L42100]



Cefepime is also used in combination with [enmetazobactam] to treat cUTI.[L50117]', 'Cefepime is a bactericidal cephalosporin with a mode of action similar to other beta-lactam antibiotics.[L42095,L42100] Cefepime disrupts bacterial cell walls by binding and inhibiting transpeptidases known as penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of peptidoglycan layer synthesis. This results in the lysis and death of susceptible microorganisms.[A249050] Cefepime has a broad spectrum of _in vitro_ activity that includes both Gram-positive and Gram-negative bacteria.[L42095,L42100] Cefepime has affinity for PBP-3 and PBP-1 in _Escherichia coli_ and _Pseudomonas aeruginosa_, as well as PBP-2 in _E. coli_ and _Enterobacter cloacae_.[A249050]', 'Cefepime is a fourth-generation cephalosporin antibiotic.[L42095,L42100] It is active against Gram-negative bacteria such as _Enterobacter_ spp., _Escherichia coli_, _Klebsiella pneumoniae_, _Proteus mirabilis_ and _Pseudomonas aeruginosa_, and Gram-positive bacteria such as _Staphylococcus aureus_ (methicillin-susceptible isolates only), _Streptococcus pneumoniae_, _Streptococcus pyogenes_ and Viridans group streptococci.[L42095,L42100] Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes.[A2457,A249050] Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.[A2457] 



In animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy.[L42095,L42100] It has been suggested that cefepime can cross the inflamed blood-brain barrier.[L42095,L42100] This, along with its ability to inhibit γ-aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.[A249045,A249050]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27368, 'Spectracefocure 250 mg/5 ml pd. for oral susp. 60ml', 'سبيكتراسيفوكيور 25مجم/5مل شراب معلق 60مل', '32', NULL, 'Antibiotic.cephalosporin.third-generation', 'Cefdinir', 'Kahira > evercure company-egypt', 'Susp', 'معلق', '250 mg', '1', NULL, 'about cefdinir semisynthetic (third generation ) cephalosporin antibiotic oral broad-spectrum antibiotic. mechanism of action cefdinir is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & aerobic gram negativ', NULL, NULL, 1017, '2022-07-25', 0, 'Cefdinir is indicated to treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (CA) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.[L7330,A180739]



The organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinir.[L7330] Various beta-lactamase producing organisms may be treated, as indicated in certain sections below.



**Respiratory**

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



Community-acquired pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



**Ear, nose, and throat** 

Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae (penicillin-susceptible only)



Tonsillitis caused by Streptococcus pyogenes



Pharyngitis caused by Streptococcus pyogenes



Acute maxillary sinusitis caused by Haemophilus pneumoniae and Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



**Skin and skin structure infections**



Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes', 'Five-member thiazolidine rings that make up penicillins are replaced in cephalosporins by a six-member dihydrothiazine ring, conferring greater bactericidal activity. This This 6-member ring enables cefdinir and other cephalosporins to resist inactivation by certain bacterial enzymes.[A180772]



With a mechanism similar to other beta-lactam antibiotics, the bactericidal activity of cefdinir is caused by the inhibition of cell wall synthesis via binding to penicillin-binding proteins (PBPs). Cefdinir, like other cephalosporins, penetrates the bacterial cell wall, combats inactivation by beta-lactamase enzymes, and inactivates penicillin-binding proteins.[A180772] This interferes with the final step of transpeptidation in cell walls, eventually leading to cell lysis, which eventually leads to the death of bacteria that are susceptible to this drug.[A180724] Cefdinir has shown affinity to penicillin protein binding proteins 2 and 3. [A15746,A180760,A15747] It has also been shown to inhibit transpeptidase enzymes of various bacteria, which may play a role in its bactericidal action.[A180766,A180769] One in vitro study suggests that cefdinir inhibits myeloperoxidase release extracellularly.[A11897] The impact of this potential drug target in relation to its mechanism of action is unknown.', 'Cefdinir is a bactericidal agent that treats bacterial infections by interfering with cell wall synthesis.[L7330]

Cefdinir exerts broad-spectrum activity against a variety of gram-positive and gram-negative bacterial infections. It is effective against several beta-lactamase enzyme producing bacteria. As a result, many organisms that are resistant to other cephalosporins may be susceptible to cefdinir.[A180727,A180733,L7351]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27369, 'Spectracefocure 300 mg 10 caps.', 'سبيكتراسيفوكيور 300مجم 10 كبسول', '45', NULL, 'Antibiotic.cephalosporin.third-generation', 'Cefdinir', 'Kahira > evercure company-egypt', 'Cap', 'كبسولة', '300 mg', '1', NULL, 'about cefdinir semisynthetic (third generation ) cephalosporin antibiotic oral broad-spectrum antibiotic. mechanism of action cefdinir is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & aerobic gram negativ', NULL, NULL, 1043, '2022-07-23', 0, 'Cefdinir is indicated to treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (CA) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.[L7330,A180739]



The organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinir.[L7330] Various beta-lactamase producing organisms may be treated, as indicated in certain sections below.



**Respiratory**

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



Community-acquired pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



**Ear, nose, and throat** 

Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae (penicillin-susceptible only)



Tonsillitis caused by Streptococcus pyogenes



Pharyngitis caused by Streptococcus pyogenes



Acute maxillary sinusitis caused by Haemophilus pneumoniae and Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis



**Skin and skin structure infections**



Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes', 'Five-member thiazolidine rings that make up penicillins are replaced in cephalosporins by a six-member dihydrothiazine ring, conferring greater bactericidal activity. This This 6-member ring enables cefdinir and other cephalosporins to resist inactivation by certain bacterial enzymes.[A180772]



With a mechanism similar to other beta-lactam antibiotics, the bactericidal activity of cefdinir is caused by the inhibition of cell wall synthesis via binding to penicillin-binding proteins (PBPs). Cefdinir, like other cephalosporins, penetrates the bacterial cell wall, combats inactivation by beta-lactamase enzymes, and inactivates penicillin-binding proteins.[A180772] This interferes with the final step of transpeptidation in cell walls, eventually leading to cell lysis, which eventually leads to the death of bacteria that are susceptible to this drug.[A180724] Cefdinir has shown affinity to penicillin protein binding proteins 2 and 3. [A15746,A180760,A15747] It has also been shown to inhibit transpeptidase enzymes of various bacteria, which may play a role in its bactericidal action.[A180766,A180769] One in vitro study suggests that cefdinir inhibits myeloperoxidase release extracellularly.[A11897] The impact of this potential drug target in relation to its mechanism of action is unknown.', 'Cefdinir is a bactericidal agent that treats bacterial infections by interfering with cell wall synthesis.[L7330]

Cefdinir exerts broad-spectrum activity against a variety of gram-positive and gram-negative bacterial infections. It is effective against several beta-lactamase enzyme producing bacteria. As a result, many organisms that are resistant to other cephalosporins may be susceptible to cefdinir.[A180727,A180733,L7351]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27371, 'Spectrafilm 3.5*30 cm sheet', 'سبيكترافيلم 3.5*30سم لزقة', '800', NULL, 'Scar therapy', 'Polysiloxane', 'Spectrum designs medical > p.r.t.', 'Film', 'فيلم', NULL, '1', NULL, 'spectrafilm is a highly comfortable clear self adherent silicone gel sheet with the same properties as a silicone scar gel such as spectragel. spectrafilm is made with 100% healthcare grade silicone. this product is designed for scar sites covered by clot', NULL, NULL, 1157, '2022-07-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27372, 'Spectragel 10 gm gel', 'سبكتراجيل 10 جرام جل', '299', NULL, 'Scar therapy', 'Polysiloxane', 'Spectrum designs medical > p.r.t.', 'Gel', 'جل', '10 gm', '1', NULL, 'spectragel is a topical silicone gel designed for the management of keloid and hypertrophic scars which are the normal outcome of skin tissue repair. scars can cause unpleasant symptoms and be aesthetically distressing disfiguring and psychosocially and f', NULL, NULL, 1343, '2022-06-17', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27373, 'Spectragel 2q gel 10 gm', 'سبكترا جل تو كيو جل 10جم', '800', NULL, 'Scar therapy', 'Polysiloxane', 'Spectrum designs medical > p.r.t.', 'Gel', 'جل', '10 gm', '1', NULL, 'spectragel2q is a topical silicone gel designed for sensitive skin post laser chemical peeling and dermabrasion. spectragel2q is air permeable odorless and invisible in just 5 minutes. once dry spectragel2q may be worn under makeup. a great advantage of u', NULL, NULL, 942, '2023-01-19', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27374, 'Spectragel gel 28.4 gm', 'سبكتراجل جل 28.4جم', '1,300', NULL, 'Scar therapy', 'Polysiloxane', 'Spectrum designs medical > p.r.t.', 'Gel', 'جل', '28.4 gm', '1', NULL, 'spectragel is a topical silicone gel designed for the management of keloid and hypertrophic scars which are the normal outcome of skin tissue repair. scars can cause unpleasant symptoms and be aesthetically distressing disfiguring and psychosocially and f', NULL, NULL, 2806, '2023-01-19', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27375, 'Spectragyn 10 vaginal supp.', 'سبيكتراجين 10 لبوس مهبلي', '10', NULL, NULL, 'Hydrocortisone+metronidazole+neomycin+nystatin', 'Pharopharma', 'Supp', 'لبوس', NULL, '2', NULL, 'about hydrocortisone systemic synthetic glucocorticoid anti-inflammatory mechanism of action of hydrocortisone the drug exerts it`s pharmacological action by penetrating and binding to cytoplasmic receptor protein and causes a structural change in steroid', NULL, NULL, 815, '2022-07-26', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27376, 'Spectral.csf hair stimulating solution for women 60 ml', 'سبيكترال محلول للنساء 60مل', '690', NULL, 'Hair care', NULL, 'Ds laboratories > multitrade', 'Solution', 'محلول', '60 ml', '1', NULL, 'spectral.csf is indicated for women who notice hair getting thinner breaking shorter or looking older because this high-performance formula addresses the unique biology of female pattern thinning. apply 10 sprays or 1 ml twice per day twice per day apply', NULL, NULL, 616, '2022-08-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27377, 'Spectral.dnc-n hair stimulating solutlon 60 ml', 'سبيكترال محلول 60مل', '780', NULL, 'Hair care', NULL, 'Ds laboratories > multitrade', 'Sol', 'محلول', '60 ml', '1', NULL, 'spectral dnc-n topical is an original solution for the beginning/early stages of thinning hair and features an advanced formulation including our proprietary nanoxidil complex. within the complex biology of the scalp spectral.dnc-n establishes the highest', NULL, NULL, 698, '2022-07-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27378, 'Spectral.dnc-s hair stimulating serum 60 ml', 'سبيكترال سيروم 60مل', '1,125', NULL, 'Hair care', NULL, 'Ds laboratories > multitrade', 'Serum', 'سيروم', '60 ml', '1', NULL, 'spectral.dnc-s is indicated for men and women in advanced stages of hair thinning because it delivers numerous compounds performing through complementary pathways. apply six sprays twice per day shake well before use. apply six sprays twice per day direct', NULL, NULL, 666, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27379, 'Spectral.lash eye lash stimulator solutlon 2.4 ml', 'سبيكترال محلول للعين 2.4مل', '500', NULL, NULL, NULL, 'Ds laboratories > multitrade', 'Sol', 'محلول', '2.4 ml', '1', NULL, 'spectral.lash a cutting-edge treatment from ds laboratories is demonstrated through clinical research to result in eyelashes 25 percent longer in just four weeks. many users also enjoy greater thickness and density. for best results apply spectral.lashï-', NULL, NULL, 679, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27380, 'Spectral.rs anti-aging serum 60 ml', 'سبيكترال سيروم ضد الشيخوخة والتجاعيد 60مل', '493', NULL, 'Skin care', NULL, 'Ds laboratories > multitrade', 'Serum', 'سيروم', '60 ml', '1', NULL, 'spectral.rs is indicated for women and men who prefer a natural formula because it makes hair look thicker and feel stronger without using minoxidil. apply 10 sprays twice per day shake well before use. apply 10 or more sprays in the thinning area twice p', NULL, NULL, 692, '2022-08-03', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27381, 'Spectrodoxime 200mg 10 f.c. tab.', 'سبيكترودوكسيم 200مجم 10 اقراص', '55', NULL, 'Antibiotic.cephalosporin.third-generation', 'Cefpodoxime', 'Kahira > international trading office', 'Tab', 'أقراص', '200mg', '2', NULL, 'about cefpodoxime third generation cephalosporin antibiotic oral antibiotic. mechanism of action of cefpodoxime cefpodoxime is a 3rd generation cephalosporin which exerts its bactericidal action mainly against gram positive organisms by inhibiting bacteri', NULL, NULL, 723, '2022-07-30', 0, 'Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.', 'Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.', 'Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except <i>Pseudomonas aeruginosa</i>, <i>Enterococcus</i>, and <i>Bacteroides fragilis</i>.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27382, 'Speczil 250mg/5ml susp. 60 ml', 'سبيكزيل 250مجم/5مل شراب معلق 60مل', '21', NULL, 'Antibiotic.cephalosporin.second-generation', 'Cefprozil', 'Adwia', 'Susp', 'معلق', '250mg', '1', NULL, 'about cefprozil second generation cephalosporin antibiotic oral antibiotic. mechanism of action of cefprozil cefprozil is a short acting 2nd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms', NULL, NULL, 976, '2022-07-23', 0, 'For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph', 'Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.', 'Cefprozil, a semisynthetic, second-generation cephalosporin, is used to treat otitis media, soft-tissue infections, and respiratory tract infections.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27383, 'Speda soap 100 gm', 'سبيدا صابونة 100جم', '18', NULL, 'Anti-acne', 'Glutathione+titanium dioxide+olive oil+back seed extract+bht', 'Egyptian company for cosmetics > speda pharma', 'Soap', 'صابون', '100 gm', '1', NULL, 'anti-bacterial soap - acne care', NULL, NULL, 784, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27384, 'Spego 10 sachets', 'سبيجو 10 اكياس', '175', '115', 'Dietary supplement', 'Whey protein+skimmed milk+selenium+zinc+magnesium+vitamins(c+b1+b2+b6+b12)+maltodextrin+omega-3 fish oil', 'Pharmazad > tedavi pharm', 'Sachet', 'أكياس', NULL, '1', 'مكمل غذائي -- فيتامينات متعددة -- مصدر للطاقة -- مصدر للزنك وفيتامين ب و الاوميجا 3', 'with banana flavor. combination of amino acids omega-3 vitamins & minerals. indicatyions: it is supportive treatment in chronic illness liver disorders brain performance malnutrition and general weakness. use: dissolve 1 sachets into 100 ml of water milk', '6225000383913', NULL, 3425, '2024-08-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27385, 'Sperience 10 sachets 10 gm', 'سبيريانس 10 اكياس 10 جرام', '130', '79', 'Iron supplement', 'Lactoferrin+iron+vitamin b-complex+vitamin c+calcium+folic acid', 'Med care > rony trade', 'Sachet', 'أكياس', '10 gm', '1', NULL, '** usage: add 1 sachet to a cup of water & stir well ** serving unit: 1 sachet once daily', NULL, NULL, 1988, '2025-11-29', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27386, 'Sperience 7 sachets 10 gm', 'سبيريانس 7 اكياس 10 جرام', '79', NULL, 'Iron supplement', 'Lactoferrin+iron+vitamin b-complex+vitamin c+calcium+folic acid', 'Med care > rony trade', 'Sachet', 'أكياس', '10 gm', '1', NULL, NULL, NULL, NULL, 836, '2022-06-27', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27387, 'Spersadex comp eye drops', 'سبيرسادكس كومب قطرة للعين', '12', NULL, 'Antibiotic with glucocorticoid', 'Chloramphenicol+dexamethasone', 'Excelvision ag switzerland > novartis', 'Drops', 'نقط', NULL, '1', NULL, 'about chloramphenicol bacteriostatic antibiotic a systemic broad ? spectrum antibacterial agent. mechanism of action of chloramphenicol chloramphenicol is a broad spectrum antibiotic which is primarily bacteriostatic & exerts some bactericidal action at h', '7680305140170', NULL, 776, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27388, 'Spididol 400 mg 12 eff. gr. in sachets', 'سبيديدول 400مجم 12 حبيبيات فوارة', '25', NULL, 'Nsaid.propionic acid derivatives', 'Ibuprofen', 'Zambon > pharmacon', 'Sachet', 'أكياس', '400 mg', '1', NULL, 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', NULL, NULL, 754, '2022-07-25', 0, 'Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]



The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]



Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.[A39092]



As ibuprofen is a widely used medication, the main therapeutic indications are:



* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]



* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]



* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]



* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]



* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]



* Pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] It is also used to manage mild to moderate pain and moderate to severe pain as an adjunct to opioid analgesics.[L40208]



* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer''s disease, Parkinson disease, and breast cancer.[A39092]', 'The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and thus it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway.[L4614]



Ibuprofen is a non-selective COX inhibitor and hence, it inhibits the activity of both COX-1 and COX-2. The inhibition of COX-2 activity decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever, and swelling while the inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration.[A39195]', 'Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic inflammation. The main effects reported in ibuprofen are related to the control of pain, fever and acute inflammation by the inhibition of the synthesis of prostanoids by COX-1 and COX-2. Pain relief is attributed to peripheral affected regions and central nervous system effects in the pain transmission mediated by the dorsal horn and higher spinothalamic tract. Some reports have tried to link the pain regulation with a possible enhancement on the synthesis of endogenous cannabinoids and action on the NMDA receptors. The effect on pain has been shown to be related to the cortically evoked potentials.[A39190]



The antipyretic effect is reported to be linked to the effect on the prostanoid synthesis due to the fact that the prostanoids are the main signaling mediator of pyresis in the hypothalamic-preoptic region.[A39190]



The use of ibuprofen in dental procedures is attributed to the local inhibition of prostanoid production as well as to anti-oedemic activity and an increase of plasma beta-endorphins. Some reports have suggested a rapid local reduction of the expression of COX-2 in dental pulp derived by the administration of ibuprofen.[A39190]



The administration of ibuprofen in patients with rheumatic diseases has shown to control joint symptoms.[A39092] 



Ibuprofen is largely used in OTC products such as an agent for the management of dysmenorrhea which has been proven to reduce the amount of menstrual prostanoids and to produce a reduction in the uterine hypercontractility.[A39181] As well, it has been reported to reduce significantly the fever and the pain caused by migraines.[A39182, A39183] This effect is thought to be related to the effect on platelet activation and thromboxane A2 production which produces local vascular effects in the affected regions. This effect is viable as ibuprofen can enter in the central nervous system.[A39190]



In the investigational uses of ibuprofen, it has been reported to reduce neurodegeneration when given in low doses over a long time.[A39184] On the other hand, its use in Parkinson disease is related to the importance of inflammation and oxidative stress in the pathology of this condition.[A39185] The use of ibuprofen for breast cancer is related to a study that shows a decrease of 50% in the rate of breast cancer.[A39186]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27389, 'Spididol 600 mg 12 eff. gr. in sachets', 'سبيديدول 600 مجم 12 كيس به حبيبات فوارة', '132', '36', 'Nsaid.propionic acid derivatives', 'Ibuprofen', 'Zambon > pharmacon', 'Sachet', 'أكياس', '600 mg', '1', 'مسكن عام -- تقليل الالتهابات -- تقليل الالام -- خافض للحرارة', 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', NULL, NULL, 1776, '2025-01-11', 0, 'Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]



The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]



Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.[A39092]



As ibuprofen is a widely used medication, the main therapeutic indications are:



* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]



* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]



* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]



* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]



* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]



* Pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] It is also used to manage mild to moderate pain and moderate to severe pain as an adjunct to opioid analgesics.[L40208]



* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer''s disease, Parkinson disease, and breast cancer.[A39092]', 'The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and thus it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway.[L4614]



Ibuprofen is a non-selective COX inhibitor and hence, it inhibits the activity of both COX-1 and COX-2. The inhibition of COX-2 activity decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever, and swelling while the inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration.[A39195]', 'Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic inflammation. The main effects reported in ibuprofen are related to the control of pain, fever and acute inflammation by the inhibition of the synthesis of prostanoids by COX-1 and COX-2. Pain relief is attributed to peripheral affected regions and central nervous system effects in the pain transmission mediated by the dorsal horn and higher spinothalamic tract. Some reports have tried to link the pain regulation with a possible enhancement on the synthesis of endogenous cannabinoids and action on the NMDA receptors. The effect on pain has been shown to be related to the cortically evoked potentials.[A39190]



The antipyretic effect is reported to be linked to the effect on the prostanoid synthesis due to the fact that the prostanoids are the main signaling mediator of pyresis in the hypothalamic-preoptic region.[A39190]



The use of ibuprofen in dental procedures is attributed to the local inhibition of prostanoid production as well as to anti-oedemic activity and an increase of plasma beta-endorphins. Some reports have suggested a rapid local reduction of the expression of COX-2 in dental pulp derived by the administration of ibuprofen.[A39190]



The administration of ibuprofen in patients with rheumatic diseases has shown to control joint symptoms.[A39092] 



Ibuprofen is largely used in OTC products such as an agent for the management of dysmenorrhea which has been proven to reduce the amount of menstrual prostanoids and to produce a reduction in the uterine hypercontractility.[A39181] As well, it has been reported to reduce significantly the fever and the pain caused by migraines.[A39182, A39183] This effect is thought to be related to the effect on platelet activation and thromboxane A2 production which produces local vascular effects in the affected regions. This effect is viable as ibuprofen can enter in the central nervous system.[A39190]



In the investigational uses of ibuprofen, it has been reported to reduce neurodegeneration when given in low doses over a long time.[A39184] On the other hand, its use in Parkinson disease is related to the importance of inflammation and oxidative stress in the pathology of this condition.[A39185] The use of ibuprofen for breast cancer is related to a study that shows a decrease of 50% in the rate of breast cancer.[A39186]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27391, 'Spin cream 120 gm', 'سبين كريم 120 جرام', '105', NULL, 'Scar therapy', 'Cyclopentasiloxane+dimethicone+onion+zno+tio2+salicylic acid+lactic acid+arbutin+olive oil+panthenol', 'El-helou perfumes & cosmetics > beauty & beyond international', 'Cream', 'كريم', '120 gm', '1', NULL, 'anti scar cream for keloids scars hyper trophic scar burn scar traumatic scar and plastic surgery scars', NULL, NULL, 1288, '2022-06-18', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27392, 'Spinax topical gel 30 gm', 'اسبيناكس جل موضعي 30 جم', '60', NULL, 'Soothing topical', NULL, 'Hi-care > novell pharma', 'Gel', 'جل', '30 gm', '1', 'جل موضعي للترطيب الجلد و تنعيمه -- تلطيف الجلد -- علاج التشقق الجلدي', 'soothing gel for nipples', NULL, NULL, 1199, NULL, 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27393, 'Spiolto respimat 2.5/2.5 mcg 60 puffs inhaler', 'سبيولتو ريسبيمات 2.5/2.5 ميكروجرام 60 بخه استنشاق', '495', NULL, 'Bronchodilator with anticholinergic', 'Tiotropium bromide+olodaterol hcl', 'Boehringer ingelheim', 'Inhaler', 'جهاز استنشاق', '2.5 mcg', '1', NULL, 'sptiolto respimat containes a combination of olodaterol and tiotropium. olodaterol is a long-acting bronchodilator. tiotropium is an anticholinergic. these medications work by relaxing muscles in the airways to improve breathing. indications and usage mai', NULL, NULL, 1038, '2022-07-07', 0, 'Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD.[L7084] A combination tiotropium and [olodaterol] metered inhalation spray is indicated for maintenance of COPD.[L7087] A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old.[L7090] A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.[L7093]', 'Tiotropium is an antagonist of muscarinic receptors M<sub>1</sub> to M<sub>5</sub>.[A180163,L7084,L7087,L7090,L7093] Inhibition of the M<sub>3</sub> receptor in the smooth muscle of the lungs leads to relaxation of smooth muscle and bronchodilation.[A180163,L7084,L7087,L7090,L7093]', 'Tiotropium is a long acting antimuscarinic that causes bronchodilation.[A180163,L7084,L7087,L7090,L7093] The effects of tiotropium last over 24 hours and there is a wide therapeutic index as overdoses are uncommon even at doses well above the recommended maximum.[L7084,L7087,L7090,L7093]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27396, 'Spiraquet 100mg 20 f.c. tab.', 'سبيراكيت 100مجم 20 قرص', '70', NULL, 'Psychiatric.antipsychotics', 'Quetiapine', 'Medizen pharmaceutical industries', 'Tab', 'أقراص', '100mg', '2', 'يستخدم لعلاج انفصام الشخصية.', NULL, NULL, NULL, 1877, '2022-05-13', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27397, 'Spiraquet 200 mg 20 f.c.tabs.', 'سبيراكويت 200مجم 20 اقراص', '148', '110', 'Psychiatric.antipsychotics', 'Quetiapine', 'Medizen pharmaceutical industries', 'Tab', 'أقراص', '200 mg', '2', 'مضاد للاكتئاب والذهان والانفصام', 'indication for the treatment of schizophrenia and related psychotic disorders. pharmacodynamics quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. quetiapine', NULL, NULL, 2733, '2025-10-07', 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27398, 'Varipan cream 60 gm', 'فاريبان كريم 60 جم', '35', NULL, 'Treatment of varicose veins', NULL, 'Awaa', 'Cream', 'كريم', '60 gm', '2', NULL, 'treatment of varicose veins', '6224008851110', NULL, 697, '2022-10-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27399, 'Bonixir 30 f.c. tabs.', 'بونيكسير 30 قرص', '110', NULL, 'Calcium supplement', 'Calcium+vitamin d3+magnesium+zinc+boron+manganese+copper+selenium', 'Averroes pharma', 'Tab', 'أقراص', NULL, '3', 'مكمل غذائى يساعد على نمو العظام ومنع هشاشة ولين العظام', NULL, '6224008179627', NULL, 4735, '2022-10-15', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27401, 'Spirex 1.5 m.i.u. 16 tab.', 'سبيريكس 1.5 مليون وحدة دولية 16 قرص', '108', '32', 'Antibiotic.macrolide', 'Spiramycin', 'Mup', 'Tab', 'أقراص', NULL, '2', NULL, 'about spiramycin macrolide antibiotic antibacterial (systemic antiprotozoal in toxoplasmosis cryptosporidiosis. mechanism of action of spiramycin spiramycin is a member of macrolide antibiotic. it binds to the 50s sub unit of bacterial ribosome and inhibi', '6221508016810', NULL, 1083, '2025-11-19', 0, 'Macrolide antibiotic for treatment of various infections.', 'The mechanism of action of macrolides has been a matter of controversy for some time. Spiramycin, a 16-membered macrolide, inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1 : 1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. The primary mechanism of action is done by stimulation of dissociation of peptidyl-tRNA from ribosomes during translocation.I ', 'The absolute bioavailability of oral spiramycin is generally within the range of 30 to 40%. After a 1 g oral dose, the maximum serum drug concentration was found to be within the range 0.4 to 1.4 mg/L.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27402, 'Spirex 3 m.i.u. 10 tab', 'سبيركس 3 مليون وحدة دولية 10 اقراص', '108', '42', 'Antibiotic.macrolide', 'Spiramycin', 'Mup', 'Tab', 'أقراص', NULL, '1', 'مضاد حيوي', NULL, '6221508016919', NULL, 2626, '2025-05-06', 0, 'Macrolide antibiotic for treatment of various infections.', 'The mechanism of action of macrolides has been a matter of controversy for some time. Spiramycin, a 16-membered macrolide, inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1 : 1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. The primary mechanism of action is done by stimulation of dissociation of peptidyl-tRNA from ribosomes during translocation.I ', 'The absolute bioavailability of oral spiramycin is generally within the range of 30 to 40%. After a 1 g oral dose, the maximum serum drug concentration was found to be within the range 0.4 to 1.4 mg/L.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27403, 'Spirex plus 20 f.c. tabs.', 'سبيركس بلس 20 قرص', '142', '48', 'Antibiotic.macrolide.combined with nitroimidazoles', 'Metronidazole+spiramycin', 'Mup', 'Tab', 'أقراص', NULL, '2', 'يستخدم كعلاج لخراج الأسنان--الالتهاب الخلوي بالفك--التهاب اللثة.', 'pregnancy related information use with caution. breast feeding related information contraindicated indications for metronidazole + spiramycin 1.dental abscess 2.cellulites of the jaw 3.pericoronitis 4.gingivitis 5.stomatitis 6.parotitis 7.submaxillaritis', '6221508513210', NULL, 4694, '2025-05-14', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27406, 'Spiriva handihaler device', 'سبيريفا جهاز استنشاق بمفرده', '9', NULL, NULL, NULL, 'Boehringer ingelheim', 'Unknown', 'غير محدد', NULL, '1', NULL, 'for use with spiriva 18 mcg capsules', NULL, NULL, 847, '2022-07-21', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27407, 'Spiriva respimat 2.5mcg 60 puffs inhaler', 'سبيريفا ريسبيمات 2.5مكجم 60 وحدة استنشاق', '416', NULL, 'Bronchodilator', 'Tiotropium bromide', 'Boehringer ingelheim', 'Inhaler', 'جهاز استنشاق', '2.5mcg', '1', 'موسع للشعب الهوائية', 'about tiotropium anticholinergic(muscarinic antagonist) bronchodilator thiophene antiasthma in copd.smechanism of action stiotropium selectively acts on bronchial muscle by binding very tightly to bronchial m1/m3 muscarinic receptors and produces long las', NULL, NULL, 4298, '2023-02-05', 0, 'Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD.[L7084] A combination tiotropium and [olodaterol] metered inhalation spray is indicated for maintenance of COPD.[L7087] A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old.[L7090] A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.[L7093]', 'Tiotropium is an antagonist of muscarinic receptors M<sub>1</sub> to M<sub>5</sub>.[A180163,L7084,L7087,L7090,L7093] Inhibition of the M<sub>3</sub> receptor in the smooth muscle of the lungs leads to relaxation of smooth muscle and bronchodilation.[A180163,L7084,L7087,L7090,L7093]', 'Tiotropium is a long acting antimuscarinic that causes bronchodilation.[A180163,L7084,L7087,L7090,L7093] The effects of tiotropium last over 24 hours and there is a wide therapeutic index as overdoses are uncommon even at doses well above the recommended maximum.[L7084,L7087,L7090,L7093]', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27408, 'Spirometro 30 f.c. tabs.', 'سبيروميترو 30 اقراص', '44', '24', 'Antibiotic.macrolide.combined with nitroimidazoles', 'Metronidazole+spiramycin', 'El-obour', 'Tab', 'أقراص', NULL, '3', NULL, 'pregnancy related information use with caution. breast feeding related information contraindicated indications for metronidazole + spiramycin 1.dental abscess 2.cellulites of the jaw 3.pericoronitis 4.gingivitis 5.stomatitis 6.parotitis 7.submaxillaritis', NULL, NULL, 958, '2024-12-13', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27409, 'Spiromide 100/20mg 10 f.c.tab.', 'سبيروميد 100/20مجم 10 اقراص', '18', '11.5', 'Combination diuretics', 'Furosemide+spironolactone', 'Sedico', 'Tab', 'أقراص', '20mg', '1', NULL, 'description a benzoic-sulfonamide-furan. it is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. mechanism of action furosemide a loop diuretic inhibits water reabsorption in the nephron by blocking the', '6221042083019', NULL, 906, '2025-08-16', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27410, 'Spiromide 50/20mg 10 f.c.tab.', 'سبيروميد 50/20مجم 10 قرص', '12', '8.5', 'Combination diuretics', 'Furosemide+spironolactone', 'Sedico', 'Tab', 'أقراص', '20mg', '1', NULL, 'description a benzoic-sulfonamide-furan. it is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. mechanism of action furosemide a loop diuretic inhibits water reabsorption in the nephron by blocking the', '6221042082012', NULL, 1169, '2024-11-22', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27411, 'Zimas 125 ml massage spray', 'زيماس 125 مل مساج سبراي', '130', NULL, 'Massage spray', 'Methyl salicylate-menthol crystals - camphor oil - eucalyptus - clove oil-ginger - chamomile', 'Skills care pharma', 'Spray', 'بخاخ', '125 ml', '1', NULL, NULL, NULL, NULL, 751, '2022-10-18', 0, 'For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).', 'Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.', 'After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27414, 'Spirozide 25/25mg 20 tab.', 'سبيروزايد 25/25مجم 20 قرص', '18', '8.5', 'Diuretic.combined thiazide with potassium-sparing', 'Hydrochlorothiazide+spironolactone', 'Sedico', 'Tab', 'أقراص', '25mg', '2', NULL, 'about hydrochlorothiazide thiazide derivative diuretic. mechanism of action of hydrochlorothiazide it is thiazide diuretic which exerts its action by acting at site-3(central dilating segment of early distal tubule). it binds to na+cl- symporter and inhib', '6221042088021', NULL, 1048, '2024-11-22', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27415, 'Spirulina 500 mg 100 tablets (puritans pride)', 'سبيرولينا 500مجم 100 قرص', '825', NULL, NULL, 'Spirulina', 'Puritans pride', 'Tablet', 'أقراص', '500 mg', '1', NULL, 'spirulina is a blue/green algae that can be found in the worlds oceans and lakes. it is an important source of plant enzymes which are protein molecules that are an integral part of many important systems within the body. spirulina contains trace amounts', '6192421100439', NULL, 1245, '2022-07-08', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27416, 'Spleet exfoliating cream 40 gm', 'سبليت كريم تقشير 40 جرام', '80', '60', 'Skin care', 'Salicylic acid+urea', 'Hi-care > interpharma egycare', 'Cream', 'كريم', '40 gm', '1', 'تقليل الالتهابات الجلدية -- تقليل الاحمرار و الحكة -- تفتيح الجلد -- ترطيب الجلد', 'body exfoliating cream', NULL, NULL, 2125, '2024-04-01', 0, 'Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.', 'Salicylic acid directly irreversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes. Salicylate''s use in rheumatic diseases is due to it''s analgesic and anti-inflammatory activity. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. Salicylic acid allows cells of the epidermis to more readily slough off. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid competitively inhibits oxidation of uridine-5-diphosphoglucose (UDPG) with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of the glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to a phenolic acceptor. Inhibition of mucopoly saccharide synthesis is likely responsible for the slowing of wound healing with salicylates.', 'Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27417, 'Splendo vag.douche 250 ml', 'سبليندو غسول مهبلي 250 مل', '40', NULL, 'Vaginal wash', 'Thyme extract+calendula extract+triclosan+tea tree oil', 'Hi-care > pharma cure pharmaceuticals', 'Unknown', 'غير محدد', '250 ml', '1', NULL, NULL, '6224000651220', NULL, 1432, '2022-12-09', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27418, 'Authentic 50 gm cream', 'اوثنتيك كريم 50 جم', '50', NULL, 'Massage cream', 'Menthol + eucalyptus + camphor', 'Flare pharma', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 1023, '2022-08-02', 0, NULL, NULL, NULL, NULL, 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27420, 'Ventamor anti-aging serum 50 ml', 'فينتامور سيروم مضاد للتجاعيد 50 مل', '360', '320', 'Skin care', 'Vitamin c 10% + hyaluronic acid + marine collagen + ginseng + caviar', 'Prime pharma', 'Serum', 'سيروم', '50 ml', '1', NULL, NULL, NULL, NULL, 965, '2025-02-24', 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank', 0, 0, 0);
INSERT OR IGNORE INTO drugs (id, trade_name, arabic_name, price, old_price, category, active, company, dosage_form, dosage_form_ar, concentration, unit, usage, pharmacology, barcode, qr_code, visits, last_price_update, updated_at, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology, has_drug_interaction, has_food_interaction, has_disease_interaction) VALUES (27421, 'Sporanox 100mg 4 caps.', 'سبورانوكس 100مجم 4 كبسول', '42', NULL, 'Antifungals.triazoles', 'Itraconazole', 'Janssen cilag > soficopharm', 'Cap', 'كبسولة', '100mg', '1', NULL, 'about itraconazole a synthetic triazole derivative systemic antifungal. mechanism of action of itraconazole itraconazole is a fungicidal or fungistatic depending on the drug concentrations. it inhibits the conversion of lanosterol to 14 demethyl lanostero', NULL, NULL, 1174, '2022-07-22', 0, 'Itraconazole is indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients:[L50051, L50056]



- Blastomycosis, pulmonary and extrapulmonary

- Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis, and

- Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy



It is also indicated for the treatment of the following fungal infections in non-immunocompromised patients:[L50051]



- Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium)

- Onychomycosis of the fingernail due to dermatophytes (tinea unguium).



Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis.[L50061]', 'Itraconazole mediates its antifungal activity by inhibiting 14α-demethylase, a fungal cytochrome P450 enzyme that converts lanosterol to ergosterol, a vital component of fungal cell membranes.[L50051] The azole nitrogen atoms in the chemical structure of itraconazole form a complex with the active site, or the haem iron, of the fungal enzyme to impede its function.[A34257, A263232] The accumulation of lanosterol and 14-methylated sterols results in increased permeability of the fungal cell membrane, and modified membrane-bound enzyme activity, and dysregulated chitin synthesis.[A34257, A263222, A263227] Other proposed mechanisms of action of itraconazole include the inhibition of fungal cytochrome c oxidative and peroxidative enzymes that also lead to the disruption of fungal cell membranes.[A34257]', 'Itraconazole is an antifungal agent that inhibits cell growth and promotes cell death of fungi.[A34257] It exhibits in vitro activity against _Blastomyces dermatitidis_, _Histoplasma capsulatum_, _Histoplasma duboisii_, _Aspergillus flavus_, _Aspergillus fumigatus_, and _Trichophyton_ species.[L50051]', 'DrugBank', 0, 0, 0);
